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ABSTRACT 
 
This thesis describes biochemical and biophysical studies of two protein domains that are 
believed to be involved in the interaction between the merozoites of Plasmodium 
falciparum and human red blood cells. The parasite protein fragment derives from the 
erythrocyte binding antigen 181 (EBA-181) invasion protein, and the human protein 
fragment comes from the 4.1R erythrocyte skeletal protein. The initial goal of the PhD 
project was to derive structural information on the nature of this complex, with a 
perspective towards generating new therapeutic approaches.  
 
Extensive biochemical and biophysical characterisation of the complex was carried out 
and is described in detail in Chapter 3 of the thesis: the results confirm the interaction, 
add insights to the stability of the complex and suggest the presence of significant disorder 
in both the individual proteins and the complex. Structural studies were carried out using 
small-angle neutron and X-ray scattering, used in conjunction with selective deuteration. 
These studies, which are described in Chapter 4, provide low resolution images of the 
individual proteins and of the complex; these have been compared to structure predictions 
using bioinformatics. In Chapter 5, solution state NMR studies were carried out, 
principally on the EBA-181 protein, but with preliminary results from titration work 
designed to further probe the nature of the interaction between the two proteins. Chapter 6 
concludes the thesis with a summary of the work placed in context of the host-pathogen 
interaction, and proposes directions for future work. 
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GLOSSARY 
 
His-EBA181945-1097: tagged domain of EBA-181 encompassing the residues 945 to 1097 
EBA181945-1097: untagged domain of EBA-181 encompassing the residues 945 to 1097 
GST-4.1R10kDa: GST-tagged 4.1R 10 kDa domain encompassing the residues 405 to 471 
4.1R10kDa: untagged 4.1R 10 kDa domain encompassing the residues 405 to 471 
 
 
Amp: Ampicillin 
 
Cam: Chloramphenicol 
 
CD: Circular dichroism  
 
C-terminus / N-terminus: Carboxy-terminal / amino-terminal part of a protein  
 
Da / kDa: Dalton / kilo Dalton  
 
ddH2O: Double distilled H2O  
 
DLS: Dynamic light scattering 
 
Dmax: Maximum distance of a particle from the distance 
distribution function P(r) 
 
DTT: Dithiothreitol 
 
E.coli: Escherichia coli  
 
EDTA: Ethylenediaminetetraacetic acid 
 
FPLC: Fast protein liquid chromatography 
 
GSH: Reduced glutathione 
 
GST: Glutathione S-transferase  
 
HSQC: Heteronuclear single quantum coherence (NMR 
spectroscopy) 
 
viii 
 
IDP(s): 
 
Intrinsically disordered protein(s) 
IMAC: Immobilised metal affinity chromatography 
 
IPTG: Isopropyl-β-D-thiogalactopyranoside 
 
ITC: Isothermal titration calorimetry 
 
Kan: Kanamycin 
 
LB: Luria-Bertani broth medium 
 
MM: Molar mass 
 
MW: Molecular weight 
 
MST: Micro-scale thermophoresis 
 
NaP: 
 
nOe: 
Sodium phosphate buffer (NaH2PO4 / Na2HPO4) 
 
Nuclear Overhauser effect (transfer of nuclear spin 
polarisation from one nuclear spin population to 
another) 
 
NMR: 
 
Nuclear magnetic resonance  
 
OD: Optical density  
 
PBS: Phosphate buffered saline 
 
pI: Iso-electric point 
 
PDB: 
 
p.p.m.: 
Protein Data Bank 
 
Parts-per-million 
 
P(r): Distance distribution function 
 
Rg: Radius of gyration 
 
Rh: Hydrodynamic radius 
 
rpm: Rotations per minute  
 
RT: 
 
 
Room temperature (25°C) 
 
 
ix 
 
RT-PCR: 
 
Reverse transcription polymerase chain reaction 
SA: Sialic acid 
 
SANS: Small-angle neutron scattering  
 
SAXS: Small-angle X-ray scattering 
 
SDS-PAGE: Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
 
SEC-MALLS-RI:  
 
Multi-angle laser light scattering coupled to size 
exclusion chromatography and refractive index 
 
SOC: Super optimal broth medium with catabolite repression 
 
SP: 
 
Sulphadoxinepyrimethamine 
Tag: Peptide sequence genetically fused to a recombinant 
protein (6x histidines or GST) 
 
Tris: 2-amino-2-hydroxymethyl-1,3-propanediol  
 
TSA: Thermal shift assay  
 
 
 
 
 
Remark: amino-acids and DNA/RNA bases are described using the international codes. 
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1. INTRODUCTION 
 
1.1 Malaria: an emerging world disease 
 
Malaria is a devastating parasitic disease that affects approximately one third of the human 
population. Every year up to five hundred million people contract the disease and several 
hundred thousand die, mainly African children under the age of five (World Health 
Organization: The World Health Report, 2005). This enormous mortality/morbidity burden 
has dramatic social and economic implications. Attempts to eradicate malaria have failed 
and current prevention and treatment programmes are compromised by the emergence of 
drug resistant parasites and the resistance of mosquitoes to insecticides. In addition, our 
lack of knowledge of the structural biology underlying vital aspects of the parasite-host 
interaction hinders effective drug and vaccine development. 
 
Malaria is widespread in tropical and subtropical regions, including much of sub-Saharan 
Africa, the Americas and Asia (Figure 1.1). Malaria is also often a problem in co-infection 
with the human immunodeficiency virus (HIV). Compared with HIV-negative non-
immune patients, more severe malaria is observed in HIV-infected non-immune and 
severely immune-compromised HIV-infected patients, where higher parasite densities are 
found (Chirenda et al., 2000; Grimwade et al., 2003). The World Health Organisation 
(WHO) has estimated that the number of cases of malaria rose from 233 million in 2000 to 
244 million in 2005, but decreased to 225 million in 2009 and 198 million in 2013 (with, 
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according to WHO, high uncertainties). The number of deaths due to malaria is estimated 
to have decreased from 985 000 in 2000 to 781 000 in 2009, and more recently, in 2013, to 
584 000 (uncertainty range 367 000 – 755 000). These numbers are howerver controversial 
and, according to Robert W. Snow seem to be underestimated (Snow et al., 2005). A 
combination of epidemiological, geographical and demographic data has allowed Snow 
and colleagues to estimate the number of clinical events around the world. As a result, it 
was estimated that there were 515 million episodes of clinical malaria in 2002 (range 300–
660), which is up to 50 % higher than those reported by the WHO and 200 % higher for 
areas outside Africa. This reflects the reliance of the WHO upon weak national reporting in 
these countries.  
 
 
 
 
Figure 1.1: Malaria endemic worldwide distribution (map built from WHO data, World 
Malaria report, 2014) 
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1.2 Life cycle of the parasite 
 
It has been over 100 years since the discovery that malaria is caused by infection with the 
protozoan parasite Plasmodium, a member of the Apicomplexan phylum that also includes 
parasites responsible for important human and animal diseases such as toxoplasmosis or 
coccidiosis. Evolution from ancient evolutionary host-vertebrate lineage specialisations has 
given rise to some 200 Plasmodium species transmitted by different mosquitoes of 
divergent genera (Levine et al., 1988; Bruce-Chwatt et al., 1993). Various animals such as 
reptiles, amphibians, birds, rodents and primates are susceptible to infection from these 
species, whereas other vertebrates are mysteriously free of Plasmodium, even if they can 
be hosts of other apicomplexan parasites. Malaria parasites infecting humans are 
Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and 
Plasmodium knowlesi. Of these parasites, P. falciparum and P. vivax cause the greatest 
morbidity (disability-adjusted life years) and P. falciparum causes the most mortality, 
mainly amongst young African children (World Health Organization: The World Health 
Report, 2005).  
 
The infection starts when a Plasmodium-infected mosquito injects sporozoite forms into 
the human host (Figure 1.2). They migrate to the liver, where they can pass through 
Kupffer cells, invade hepatocytes and thus develop into liver merozoites. After being 
released into the bloodstream where all clinical symptoms arise, they invade erythrocytes 
and develop through the ring, trophozoite and schizont stages (Figure 1.3). They replicate 
to produce from 16 to 32 daughter merozoites which are released during egress. To 
continue the asexual blood-stage life cycle, the free merozoites are then able to invade 
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other erythrocytes. Once in the blood, the sexual form of the parasite starts with the 
development of some intra-erythrocytic stages into male or female gametocytes. They are 
then taken up by the mosquito during feeding to develop into gametes in the insect gut. 
They then fuse to form zygotes and finally develop to form an invasive ookinete, which 
can traverse the midgut to transform into an oocyst. From these midgut cells, sporozoites 
are released and migrate to the salivary glands for injection into a human host during the 
next blood meal. 
 
 
 
Figure 1.2: The life cycle of P. falciparum in the human host and the female Anopheles 
mosquito vector (from Xinzhuan et al., 2007). 
 
 
The disease itself results from the multiplication of malaria parasites within red blood cells 
(Figure 1.3), causing flu-like symptoms that typically include fever, headache, nausea and 
vomiting. Moreover, cerebral malaria is the most important complication of P. falciparum 
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malaria, inducing changes in mental status and coma, with a mortality rate between 
25-50 %. If a patient is not treated, cerebral malaria can be fatal in 24-72 hours because of 
the sequestration within cerebral capillaries and venules of parasitised red blood cells. 
 
 
 
   
 
 
Figure 1.3: Merozoites differentiation in red blood cells. Top: Blood stage infection by 
P. falciparum (modified from Cowman et al., 2006). Bottom: Optical microscopy pictures 
from red blood cell cultures that were infected with P. falciparum (M. Blanc, unpublished). 
 
 
After rupture of an erythrocyte, each released merozoite can follow two developmental 
pathways (Figure 1.4). It can either follow another round of schizogony, or it can be 
Ring Trophozoite Schizont 
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converted to a single male or female gametocyte (Diebner et al., 2000). Recently, it has 
been demonstrated that expression levels of the DNA-binding protein PfAP2-G correlate 
strongly with levels of gametocyte formation, proving therefore that PfAP2-G would be 
essential for parasite sexual differentiation (Kafsack et al., 2014). To increase its own 
chance of survival, Plasmodium is one of the few Apicomplexa to exhibit asexual 
schizogony, probably as a means of extending the period of its transmissibility (Dyer and 
Day, 2000), but this implies an elaborate balance between the asexual and sexual cycles. 
Prolonging the asexual cycle (and so reducing the exposure of the antigenic gametocytes) 
must be balanced with ensuring the availability of gametocytes when a mosquito bites 
(Dyer and Day, 2000). Presently the life cycle parasite switch mechanisms have not been 
fully elucidated, but an understanding of sexual development is the key in the development 
of transmission blocking new drugs and vaccines. 
 
 
 
Figure 1.4: The processes from asexual merozoites to sexual gametocytes. a: asexual 
cycle within red blood cells followed by the production of male and female gametocytes, b: 
Transmission to a mosquito during a blood meal, where they fuse to form oocysts and 
divide to create sporozoites. These migrate to the salivary glands, where the cycle of 
infection starts again (modified from Michalakis & Renaud, 2009). 
b 
a 
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A coordinated expression of sexual stage-specific genes leads to the development of 
gametocytes, in addition to the up or down regulation of the expression of many genes 
(Janse and Waters, 2004). By using a high density microarray it is possible to identify 
genes showing elevated levels of expression in gametocytes, and genes expressed uniquely 
in sexual stages (Le Roch et al., 2003). 
 
In addition, proteomic analysis of this stage has confirmed the existence of stage-specific 
gene expression, with many proteins found to be over-represented in the gametocyte 
(Florens et al., 2002). It includes proteins required to respond immediately to the stimuli 
(so involved in cell cycle/DNA processing) in order to initiate gametogenesis. It can be 
noticed that proteins involved in protection against oxidative stress are up-regulated in the 
sexual stages to compensate for the elevated levels of oxidative agents associated with the 
erythrocytic stages (Lasonder et al., 2002). The number of proteins expressed uniquely in 
sexual stages, and the diversity of their functions, reflects the fundamental changes and 
adaptations that the parasite must make to ensure its survival in a new environment. 
 
 
1.3 Treatment and resistance 
 
The emergence of drug resistance, mostly in P. falciparum, has been a major cause of the 
global reappearance of malaria in the last three decades (Marsh et al., 1998). Resistance to 
malaria treatment is the most probable explanation for a doubling of child mortality from 
malaria in eastern and southern Africa (Korenromp et al., 2003). The overall toll caused by 
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malaria has changed little since the 1950s (WHO data), when the first big programmes 
based on elimination of the mosquito vector and anti-malarial prophylaxis were performed. 
So whilst there have been large reductions in mortality and morbidity in some regions (for 
example South Asia), malaria continues to be a major paediatric killer in many parts of 
sub-Saharan Africa.  
 
Control has traditionally relied on two approaches: 1) control of the mosquito through 
removal of reproduction sites, use of insecticides (such as DDT) and prevention of contact 
with humans (particularly by using screens and bed nets impregnated with insecticides); 
and 2) effective case management. A third approach, a fully effective malaria vaccine, is 
not expected for a least five to ten years.  
 
Case management has been mainly through the use of inexpensive anti-malarial 
compounds, primarily chloroquine and more recently sulphadoxinepyrimethamine (SP) 
which are widely available. Together with antipyretics to decrease fever, anti-malarial 
compounds are among the most commonly used drugs in tropical areas. But overuse is 
widespread and as a consequence, detectable concentrations of chloroquine are found in 
the blood of a majority of the tropical population. The wide deployment of these anti-
malarial drugs has in fact provided a tremendous selection pressure on human malaria 
parasites, and so selects for resistance mechanisms. Unfortunately Plasmodium falciparum 
is now highly resistant to chloroquine in most malarial zones. Resistance to SP is also 
widespread and has developed much more quickly. Resistance to mefloquine is confined to 
where it has been used extensively (Vietnam, Cambodia and Thailand) but arose within six 
years of systematic deployment (Nosten et al., 2000). For now and according to the WHO, 
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the most effective strategy is the use of artemisinins, in combination with other anti-
malarial drugs (like quinine sulphate, hydroxychloroquine, mefloquine) to avoid the 
development of drug resistance against artemisinin based therapies.  
 
In contrast to many other pathogens, Plasmodium subspecies can efficiently infect their 
host cells by using their own invasion machinery to penetrate and establish themselves. 
Host cell entry by Plasmodium represents a parasite-specific process, an Achilles’ heel 
which can and will be exploited for development of new treatments. It is increasingly clear 
that a better understanding of the host-parasite interaction is essential for the development 
of new treatments and, hopefully and most importantly, a vaccine for long-term sustainable 
decrease in the global burden of malaria. 
 
 
1.4 The process of parasitic invasion and the role of erythrocyte 
binding-like (EBL) proteins 
 
The process of Plasmodium falciparum parasites invading erythrocytes involves a highly 
specific receptor–ligand recognition requiring multiple steps and complex interactions: 
binding, reorientation, apical junction, apical organelle content release, and erythrocyte 
entry. Different erythrocyte receptors facilitate parasite penetration during this process 
(Chitnis et al., 2000; Chitnis et al., 2001; Miller et al., 2002; Cowman et al., 2006), which 
takes only about one minute to occur (Gilson et al., 2009). It is supposed that components 
of the initial attachment include antigens on the surface of the merozoite, such as 
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merozoite surface protein 1 (MSP1) (Goel et al., 2003; Gilson et al., 2006), which is 
probably the most abundant merozoite protein (O’Donnell et al., 2001; Goel et al., 2003). 
After attachment to an erythrocyte, the merozoite undergoes apical re-orientation involving 
the integral membrane protein called apical membrane antigen 1 (AMA1) (Mitchell et al., 
2004). It is also known that actin-based motility is used by the parasite to enter the 
erythrocyte (Baum et al., 2008). Moreover, secondary interactions are required to complete 
the invasion process, with the participation of two families of invasion ligands: the 
erythrocyte binding-like (EBL) and reticulocyte binding-like (RBL) homologues which 
have been shown to play a central role (Sim et al., 1990; Triglia et al., 2001; Rayner et al., 
2001; Duraisingh et al., 2003; Maier et al., 2003; Stubbs et al., 2005; Triglia et al., 2005; 
Gaur et al., 2006; Gao et al., 2008; DeSimone et al., 2009; Tham et al., 2009; Triglia et 
al., 2009). 
 
Five genes that would encode EBL proteins have been identified. The three principal 
proteins encoded (see the sequence alignment and comparison in Appendix B) are the 
erythrocyte binding antigen 175 (EBA-175, Orlandi et al., 1990; Sim et al., 1990), 
EBA-181 (also called JESEBL, Gilberger et al, 2003; Mayer et al, 2004), and EBA-140 
(also identified as BAEBL, Mayer et al., 2001; Maier et al., 2003). The remaining two 
genes code for EBL-1 and EBA-165. EBL-1 is not expressed in some parasite lines 
because of the presence of missense mutations within its coding region. It is nevertheless 
functional in some lines and thus could play an important role in P. falciparum invasion 
(Mayer et al., 2009). The gene encoding EBA-165 (PFD1155w) carries also missense 
mutations, probably suggesting that it is a pseudogene. Its expression has not yet been 
detected in any parasite line (Triglia et al., 2001).  
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Invasion phenotypes can be generally classified into two main groups of sialic acid (SA)-
dependent invasion and sialic acid-independent invasion. SA-dependent invasion involves 
the EBA proteins and PfRh1. EBA175 and EBA140 bind to the erythrocyte surface 
molecules glycophorin A (Orlandi et al., 1992; Sim et al, 1994) and glycophorin C 
(Duraisingh et al, 2003; Maier et al., 2003) respectively, whilst EBA181 binds to SA and 
probably to an unknown second receptor on the erythrocyte surface as well as to the 4.1R 
protein (Figure 1.5) which is a critical protein in the erythrocyte cell membrane skeleton 
(Gilberger et al., 2003; Lanzilotti et al., 2005). 
 
 
 
 
Figure 1.5: Plasmodium falciparum adhesion process to erythrocytes initiating the 
pathogenic phase essential for parasite survival and progression of clinical malaria 
(modified from Kappe et al., 2010). 
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On the other hand, PfRh2b and PfRh4 which have been shown to bind to erythrocytes, are 
important in SA-independent invasion (Duraisingh et al., 2003; Stubbs et al., 2005; Gaur 
et al, 2006 and 2007), although their specific binding ligands are not known. EBL and 
PfRh proteins are found in the apical organelles of the merozoite and are released onto the 
surface prior to the erythrocyte invasion (Duraisingh et al., 2003; Singh et al., 2005; 
Triglia et al. 2009). Whilst the DBL and PfRh proteins are important in merozoite 
invasion, they are likely not to be essential. PfRh5 would be the only member of either 
family demonstrated to be necessary for erythrocyte invasion, through its interaction with 
the erythrocyte surface protein basigin (Baum et al., 2008; Crosnier et al., 2011). 
Moreover, antibodies against this epitope also elicit high anti-invasion activity, suggesting 
this epitope could form the basis of an effective vaccine against malaria (Crosnier et al., 
2011; Douglas et al., 2011; Williams et al., 2011; Bustamante et al., 2013; Douglas et al., 
2014; Reddy et al., 2014) . In contrary, the genes expressing the other invasion proteins 
can be independently disrupted in different P. falciparum lines without an obvious effect 
on blood-stage growth rates (Duraisingh et al., 2003 and 2003; Maier et al., 2003; Stubbs 
et al., 2005; Triglia et al., 2005). However, they each clearly mediate specific routes of 
invasion through independent receptors and termed invasion pathways, providing the 
merozoite with a broad array of ligands.  
 
In summary, mediators of invasion have been identified on the merozoite but the precise 
functioning of these proteins and mechanisms governing the entry process remain poorly 
understood.  
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1.5 Structural information: the state-of-the-art 
 
1.5.1 Protein complex between P. falciparum EBA-181 and erythrocyte 4.1R 
The invasion of erythrocytes by Plasmodium falciparum initiates the pathogenic phase of 
the parasite’s life cycle (Miller et al., 2002). This complex process is essential for its 
survival and the progression of clinical malaria, and involves a series of molecular 
interactions between P. falciparum merozoites and erythrocyte membrane receptors. As 
mentioned above, one of them is the erythrocyte binding antigen-181 of P. falciparum, an 
important invasion protein mediating a unique host cell entry pathway by interacting with 
the human erythrocyte protein 4.1R (Lanzillotti et al., 2006 and Figure 1.6). 
 
 
 
Figure 1.6: Interaction and schematic domains of EBA-181 and 4.1R (redrawn, original 
diagram from Lanzillotti et al., 2006. See Appendix B.2 for more details). The EBA-181 
protein interacts with the 10 kDa domain of 4.1R. 
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1.5.1.1 Protein EBA-181 (Uniprot sequence accession number Q812B4) 
The structure of full length EBA-181 is as yet unknown, but the structure of two domains 
(the RII and RVI domains, Figure 1.7 A) has been determined by X-ray crystallography for 
the homologue EBA-175 (Tolia et al., 2005). These structures may be of value in building 
homology models for EBA-181 and EBA-140 (RII domains, Figure 1.7 B). The protein 
sequence comparison of EBA-175 and EBA-181 reveals 25% identity for the whole 
sequence (see Appendix B.2), 25% identity in the RII domain, and 20% identity in the 
945-1097 region in EBA-181. The previous structural study of the erythrocyte-binding 
domain of EBA175 revealed an all-helical domain, forming dimers in a handshake 
arrangement. Each monomer consists of two Duffy-binding-like (DBL) domains (Tolia et 
al., 2006). This region is referred to as the ‘F region’ or ‘region II’ and is composed of two 
related domains (domains F1 and F2) involved in receptor binding (Orlandi et al., 1990; 
Sim et al., 1990 and 1994) and appears to be polymorphic (Baum et al., 2003). In contrast, 
EBA-140 and EBA-181 have only a few polymorphisms in the equivalent RII domain 
(Mayer et al., 2001). This low polymorphism in the binding regions of EBA-140 and EBA-
181 has been shown to decrease the binding affinity to their receptor but without any 
changes in their specificity (Maier et al., 2009). Maier and colleagues have demonstrated a 
correlation between decreased EBA-140 binding and its functional contribution in 
merozoite invasion (Maier et al., 2003 and 2009), suggesting that the sequence variability 
in the EBL proteins is driven by immune selection and not by receptor selectivity. Changes 
in expression and/or use of EBA and PfRh proteins can result in utilisation of different 
erythrocyte invasion pathways (Dolan et al., 1990; Reed et al., 2000; Baum et al., 2003; 
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Duraisingh et al., 2003; Stubbs et al., 2005; Nery et al., 2006; Bei et al., 2007) allowing 
the parasites to escape antibody-mediated host immune responses. 
 
Like the other EBL proteins, EBA-181 consists mainly of the N-terminal F region, (the 
region II with the two DBL domains F1 and F2), a C-terminal cysteine-rich domain (RVI) 
and a transmembrane domain. The central section between RII and RVI is composed of the 
RIII to RV regions. 
 
 
1.5.1.2  Protein 4.1R (Uniprot sequence accession number P11171) 
The human erythrocyte membrane is a complex protein network consisting of a membrane 
skeleton underlying a lipid bilayer, which contains transmembrane proteins. Erythrocyte 
protein 4.1 (4.1R) is a critical component of the membrane skeleton. It enhances the 
interaction of spectrin tetramers with F-actin thereby stabilising horizontal membrane 
protein connections (Figure 1.8 lower rectangle). It also links the underlying skeleton to 
the lipid bilayer through vertical interactions with glycophorin C (Figure 1.8 top rectangle). 
 
Limited proteolysis of 4.1R generates four structural domains with distinct functions. 
Amongst them, a crystal structure is only available for the 30 kDa domain (Figure 1.9). Of 
particular relevance to this study is the 10 kDa domain that binds to spectrin and actin 
(Schischmanoff et al., 1995) and stabilises this ternary complex, which is crucial for 
membrane integrity. In addition, this domain interacts with myosin and regulates its 
activity.  
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Figure 1.7: A) EBA-175 X-ray crystal structures of domains RII and RVI (pdb files 1ZRL 
at 2.3 Å resolution and 2RJI at 1.8 Å resolution respectively) and B) RII domain X-ray 
crystal structure of EBA-175 and homology models for EBA-140 and EBA-181. The 
polymorphic residues are shown in red, and the putative glycan contact residues with 
glycophorin A on EBA-175 are shown in orange. The polymorphism is highlighted on the 
structures of EBA-140 and EBA-181 with the circles (modified from Maier et al., 2009). 
EBL protein 
A) 
B) 
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Figure 1.8: Model of the erythrocyte membrane, with the protein 4.1R (T. Coetzer 
personal communication). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Crystal structure of the 30 kDa core domain of 4.1R (pdb file 1GG3) and the 
four different structural domains of 4.1R. 
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2. EXPERIMENTAL TECHNIQUES 
 
The work described in this thesis employed a variety of methods including sample 
preparation techniques, biochemical and biophysical characterisation techniques as well as 
several multi-lengthscale light, neutron and X-ray scattering approaches for structural 
studies (Figure 2.1) available at the ‘European Photon and Neutron’ (EPN) science campus 
(Grenoble, France). This chapter describes these techniques in general terms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Sizes of different biological structures and examples of techniques used to 
probe them at different resolutions. From left to right: an alanine molecule, a micelle, the 
ribosome, the human immunodeficiency virus and the E.coli bacterium (images from 
Wikipedia).  
X-ray crystallography 
NMR 
SAXS / SANS 
1 Ǻ 1 nm 1 μm 10 nm 100 nm 
19 
 
2.1 Molecular biology methods 
 
Molecular biology methods are day-to-day tools to isolate, characterise and manipulate the 
molecular components of cells and organisms, from DNA and RNA to proteins and their 
functional complexes. A range of these tools were used during the work of this thesis and 
are summarised below. 
 
2.1.1 Plasmid DNA preparation 
Plasmid preparation was used to extract and purify the DNA (plasmids are small and 
circular self-replicating DNA molecules) containing the genes (cDNA) for the various 
proteins of interest. It involves three steps, starting with the growth of the bacterial culture 
transformed beforehand with the desired plasmid, then the harvesting and lysis of the 
bacteria cells, finishing with the purification of the plasmid DNA. This was performed 
using a mini-prep kit from SIGMA-ALDRICH
TM
 (GenElute
TM
 Plasmid Miniprep Kit). 
 
2.1.2 In-vitro transposition 
Transposition is found in nature in prokaryotes and eukaryotes as a mutation where a DNA 
segment is transferred to a new position in the genome using transposable elements, also 
called transposons (McClintock et al., 1950). In molecular biology, transposition can be 
used in vitro as an alternative method to the traditional re-cloning technique for changing 
the antibiotic resistance carried by a plasmid (Goryshin et al., 1998). To perform the 
change of the antibiotic resistance from ampicillin to kanamycin, the kit EZ-Tn5™ 
<KAN> Insertion Kit from Epicentre Technologies Corporation® was used (Figure 2.2). 
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This system uses a transposase enzyme and a transposon element containing the 
kanamycin resistance gene to be randomly inserted into the target DNA (the plasmid). The 
crucial step is to select positive kanamycin resistant clones and screen for clones where the 
transposon element has been successfully inserted into the ampicillin resistance gene in 
order to inactivate it (see Section 3.2.2 for further technical details). Finally, the clone 
DNAs were sequenced to insure their quality. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Transposon insertion protocol (modified from Epicentre®). 
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inactivation) and kan
R
 clones 
Plasmid DNA extraction 
5. Positive clones 
DNA sequencing Bacterial transformation 
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2.1.3 Polyacrylamide gel electrophoresis 
 
2.1.3.1  Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein expression and purity levels by size characterisation was performed using sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), with Tris-glycine 
conditions (Laemmli, 1970) or Tris-tricine conditions, which increases the resolving power 
of the gel for lower (5-20 kDa) molecular weight proteins (Schaegger et al., 1987). For the 
work of this thesis, the gels were run at 165 V and stained with Coomassie blue (unspecific 
staining of the proteins, mainly arginine residues) and then destained with deionised water 
containing 5% v/v acetic acid and 7.5% v/v ethanol.  
 
2.1.3.2  Native polyacrylamide gels 
One-dimensional electrophoresis using non-denaturing (or ‘native’) conditions is an 
electrophoresis performed in the absence of denaturants such as detergents (for example 
SDS). Because mobility depends on the size, shape and intrinsic charge of a protein, non-
denaturing electrophoresis provides a set of separation parameters distinctly different from 
mainly size-dependent denaturing sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Separation of proteins by non-denaturing electrophoresis 
requires the same type of equipment used for denaturing slab gels. In a continuous system, 
the same buffer is used to prepare the acrylamide solution and filling electrophoresis 
chambers, and separation is governed by pH (four different types of buffers in function of 
the chosen pH, from pH 3.7 to pH 10.6). This choice of pH and thus the buffer system 
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depends on the protein being studied (its isoelectric point). See Appendix A.2 for further 
details. 
 
2.1.3.3  Peptide gels 
In order to increase the resolution and separation of very small proteins (< 10 kDa) and 
peptides, commercially pre-prepared polyacrylamide gels were used (Bio-rad 16.5% 
Criterion™ Tris-Tricine Gel). 
 
2.1.4 Affinity purification 
Affinity chromatography is a technique used to separate biochemical components using 
highly specific interactions. Here, immobilised metal ion chromatography (IMAC) was 
used to purify the proteins of interest from the bacterial crude extract. IMAC is based on 
the specific binding affinity of histidine side-chains to metal ions (nickel or cobalt) 
covalently immobilised to the resin beads. This allows tagged proteins to be retained by the 
column and thus to be physically separated from the other proteins.  
 
In this thesis two different IMAC were used: nickel NiNTA resin to retain the proteins 
expressed with a histidine tag, and glutathione-agarose resin to bind the GST tagged 
proteins. 
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2.1.5 Size-exclusion chromatography  
For all proteins the final purification stage was a size-exclusion chromatography, also 
called gel filtration. This method allows the proteins to be separated as a function of their 
size by the use of a chromatography column packed with beads with pores of different 
sizes. The columns used were the Superdex S200 10/300 GL and the Superdex S75 10/300 
GL, GE Healthcare. 
 
2.1.6 Protein concentration measurements 
To measure protein concentrations, four different techniques were used. Two direct UV 
measurements: near UV (280 nm) and far UV (190 nm) absorbance; and two colorimetric 
methods using dyes: Bradford (595 nm) and bicinchoninic acid (562 nm) assays. 
 
2.1.6.1  Near UV absorbance (280 nm) 
UV absorption spectroscopy is a direct measurement using natural UV absorption by 
proteins. The near UV absorption at 280 nm is mainly due to tyrosine and tryptophan side 
chains with a small contribution of phenylalanine and disulphide bonds. This method is 
simple, direct, and the sample can be recovered. It has also some disadvantages, including 
possible interference with the protein buffer components or with any chromophore and 
nucleic acid contaminants. Moreover the specific absorption value must be calculated 
theoretically for each protein.  
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2.1.6.2  Far UV absorbance (190 nm) 
Another characteristic UV absorption is due to the peptide bond and occurs in the far UV 
(maximum at about 190 nm). Due to the difficulties caused by the low output of 
conventional spectrophotometers at 190 nm, measurements are usually made at 205 nm 
with various side chains making contributions, including tryptophan, phenylalanine, 
tyrosine, histidine, cysteine, methionine and arginine. Also for this method the extinction 
coefficients are needed. The advantages include simplicity and sensitivity, and the sample 
can be recovered. The principle disadvantage is the necessity for accurate calibration of the 
spectrophotometer in the far UV. 
 
2.1.6.3  Bradford assay (595 nm) 
The Bradford protein assay is a spectroscopic analytical procedure commonly used to 
measure the concentration of protein and developed by Marion M. Bradford (Bradford, 
1976). The Bradford method is a colorimetric protein assay based on an absorbance shift of 
the dye Coomassie Brilliant Blue G-250. Under the acid conditions the dye is normally 
brownish/red colour but on binding to the protein the blue form of the dye is produced 
(binding mainly to arginine residues). The bound form of the dye has an absorption 
spectrum maximum historically held to be at 595 nm.  
 
When used in this thesis, a standard reference was measured from bovine serum albumin. 
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2.1.6.4  Bicinchoninic acid assay (562 nm) 
The principle of the bicinchoninic acid (BCA) assay (also called Smith assay) was 
developed by Paul K. Smith (Smith et al., 1985) and is similar to the well-known Lowry 
method. It relies on the formation of a Cu
2+
 / protein complex under alkaline conditions 
followed by reduction of the Cu
2+
 to Cu
+
 proportionally to concentration of protein 
(tyrosine, tryptophan, cystine, cysteine and the peptide bond are able to reduce Cu
2+
 to 
Cu
+
). The BCA forms a purple-blue complex with Cu
+
 in alkaline environments, thus 
providing a basis to monitor the reduction of alkaline Cu
2+
 at the absorbance maximum of 
562 nm, and thus monitor protein concentration. The BCA assay is more sensitive than the 
Lowry method and less variable than the Bradford assay. Moreover, since EBA181945-1097 
does not contain any aromatic residues, it is therefore the only available method to quantify 
the concentration of EBA181945-1097 samples. 
  
2.1.7 Pull-down assays for purification and characterisation of the complex 
The complex formed by His-EBA181945-1097 and GST-4.1R10kDa was purified using 
pull-down assay. This is an in vitro method used to establish the existence of an interaction 
between two or more proteins. It can therefore be used to confirm the existence of a 
protein-protein interaction after being firstly predicted by other techniques (for example 
co-immunoprecipitation) or as an initial screening assay to identify unknown protein-
protein interactions.  
 
In a pull-down assay, a tagged protein is captured on an immobilised affinity ligand, 
specific to the protein tag. This allows generation of a ‘secondary affinity support’ which is 
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then incubated with a protein source (for example a bacterial crude extract) that contains 
the putative ‘prey’ proteins. 
 
 
2.2 Biochemical and biophysical characterisation techniques 
 
In order to improve the expression and purification conditions of the different proteins and 
to study their intrinsic characteristics and properties, a combination of biophysical and 
biochemical techniques were used. Their principles are described below. 
 
2.2.1 Time-of-flight mass spectrometry (TOF-MS) 
Mass spectrometry (MS) allows the calculation of the mass of a protein by ionising it and 
measuring its time of flight. MS measurements were carried out at the Institut de Biologie 
Structurale in collaboration with Lucas Signore. 
 
2.2.2 N-terminal sequencing 
This technique uses a chemical process based on Pehr Edman degradation (Edman et al., 
1950) in order to sequence the first amino-acids in the N-terminus of a protein. N-terminal 
sequencing was carried out at the Institut de Biologie Structurale in collaboration with 
Jean-Pierre ANDRIEU. 
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2.2.3 Dynamic light scattering (DLS) 
Dynamic light scattering (DLS), also called quasi-elastic light scattering (QELS) or photon 
correlation spectroscopy (PCS), allows the size of the protein of interest to be estimated 
and the homogeneity of a protein solution to be assessed. This technique is based on the 
interference generated by particles in solution when illuminated by a coherent light source 
(laser). A detector measures the intensity of the light scattered by the particles in the 
sample. The Brownian motion (Brown, 1827) of particles in solution makes the scattered 
intensity vary as a function of time and, using an autocorrelation function, allows the 
diffusion coefficient to be measured. The relation between this coefficient and the size of 
particles is based on the theory of Einstein concerning the Brownian motion of spherical 
particles (an example of a DLS result is presented in Figure 2.3). The Stokes-Einstein 
equation (see below) allows the hydrodynamic radius of the observed particles to be 
measured. With assumption of the protein as a sphere it is possible to estimate the 
molecular mass via a predefined calibration. However, proteins are not always comparable 
to spheres and can adopt various shapes so the calculated hydrodynamic radius can differ 
from the real size of the protein and the calculation of the molecular mass may remain 
approximate. 
 
 
 
Stokes-Einstein equation: D is the diffusion coefficient for a particle in a free volume and depends on the 
Boltzmann constant (k) (k= 1.3806503 × 10
-23
 m
2
 kg s
-2
, relates energy at the individual particle level with 
temperature), the absolute temperature (T), the viscosity of the solution (ƞ), and the hydrodynamic radius (R) 
of the particle. 
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Figure 2.3: Example of a DLS result for a mono-disperse (meaning a single population) 
protein. 
 
 
 
2.2.4 Multi-angle laser light scattering coupled to size exclusion 
chromatography and refractive index (SEC-MALLS-RI) 
This method allows the molecular mass of a particle to be determined as well as its 
hydrodynamic radius using a combination of several techniques (Figure 2.4): size 
exclusion chromatography (SEC), multi-angle laser light scattering (MALLS) as well as 
the measurement of the refractive index (RI). The homogeneity and the polydispersity of a 
sample can also be estimated by this technique. Specifically for the work presented here, a 
size exclusion chromatography column Superdex
TM
 75 (Amersham) was used with a 
refractometer RI2000b (Schambeck SFD) and a DAWN-EOS (Wyatt Technology Corp.) 
MALLS instrument using a laser emitting at 690 nm. 
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Figure 2.4: Representation of a SEC-MALLS-RI device. 
 
 
The molecular mass is calculated from the intensity of light scattered in different angles 
and from the calculation of the concentration obtained from the refractive index. An 
average molecular mass is calculated on all the width of the elution peak. For every point 
on the chromatogram, the scattering light intensity is directly proportional to the 
concentration of proteins and to the molecular mass, in agreement with the Zimm formula 
for diluted solutions of polymers: 
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Rθ: measured Rayleigh ratio; C: protein concentration (g/ml); M: molar mass (g/mol); K*: optical constant 
given by the following equation: 
 
 
 
 
Na: Avogadro constant; no is the refractive index of the solvent at the wavelength of the incident wave (1.33 
for the diluted aqueous buffers); dn/dc: refractive index of the solute (ml/g); λ: wavelength of the incident 
wave. 
 
 
In addition, the homogeneity and polydispersity of samples can be estimated by this 
technique. The key advantages lies in the use of the size exclusion chromatography which 
allows possible aggregates and other protein species to be separated, and the possibility to 
determine the molecular mass without making any hypothesis for the shape as is the case 
for DLS. 
 
2.2.5 Circular dichroism (CD) 
Circular dichroism (CD) measures the differences of absorption of left- and right-handed 
circularly polarised light. These differences result from structural asymmetries of proteins 
which are chiral molecules and which absorb differently both components of the polarised 
light. CD is particularly used to study the folding state of a protein and to characterise its 
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global secondary structure. The study is made by measuring the difference in left- and 
right-handed polarised light absorption in the far UV, from 190 to 260 nm. Each type of 
secondary structure (α-helix, ß-sheet, turn or random coil) results in a characteristic 
spectrum (Figure 2.5). The average composition of the sample in terms of secondary 
structure elements can be deduced from the resulting curve.  
 
For this thesis work, each experiment was repeated three times and at a temperature of 4°C 
or 20°C. For each protein sample, a blank sample which contains only the dialysis buffer 
of each protein (see Appendix A.2 for buffer compositions) was also measured to be 
subtracted from the final measurement. 
 
 
 
Figure 2.5: Circular dichroism spectra of ‘pure’ secondary structures (adapted from 
Brahms and Brahms, 1980). 
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When circularly polarised light passes through an optically active medium (chiral 
molecules like proteins), the speeds between right and left polarisations differ (cL ≠ cR), as 
well as their wavelength (λL ≠ λR) and the extent to which they are absorbed (εL ≠ εR). By 
definition delta absorbance is the difference between absorbance of left and right circularly 
polarised light (LCP/RCP) as a function of the wavelength: 
 
ΔA = AL – AR 
 
It can also be expressed as the molar circular dichroism, by applying Beer's law, as:  
 
ΔA = (εL - εR)×C ×l  
 
Where εL and εR are the molar extinction coefficients for LCP and RCP lights, C is the 
molar concentration and l is the path length in centimetres. 
 
With the molar circular dichroism of the substance defined by: 
 
 Δε = εL – εR 
 
Although ΔA is usually measured, for historical reasons most measurements are reported 
in degrees of ellipticity. Fortunately it is very easy to inter-convert between θ and ΔA: 
 
ΔA = 
𝛉
𝟑𝟐.𝟗𝟖𝟐
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The final CD curve in mean residue ellipticity is obtained using the measured rotation in 
mdeg applied to the following equation:  
 
[𝛩] =  
𝛩𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑
10∗𝑛∗𝑐∗𝑙
  (deg.cm
2
.decimol
-1
.residue
-1
) 
Where Θmeasured is the experimental rotation in mdeg, n the number of amino-acid residues 
in the protein, c the concentration in molarity and l the path length in cm. 
 
 
2.2.6 Fluorescence thermal shift assay (TSA) 
Fluorescence thermal shift assay technique (TSA, also called Thermofluor
TM
) allows the 
thermal stability of a protein to be measured using a fluorescent marker interacting with the 
hydrophobic core of proteins. The probe used (Sypro Orange
®
, Invitrogen) is sensitive to 
the surrounding medium and its fluorescence signal is limited when it is in aqueous 
solution due to the phenomenon of ‘quenching’. TSA is based on two principles. The first 
one is that a folded protein does not interact with the fluorescent agent. The second 
principle comes directly from the nature of the sample. Upon increasing temperature the 
protein unfolds and becomes denatured, so exposing its hydrophobic core to which the 
fluorescent probes can then bind and emit a fluorescent signal proportional to the protein 
denaturing. In effect, TSA gives an optical readout of protein melting making it possible to 
determine the melting temperature (Tm) of a protein (Figure 2.7). After emission of a 
maximum signal, the signal decreases because the intrinsic fluorescence of the probe 
quenches with increasing temperature.  
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As the melting point is linked to protein stability, applications of TSA are very broad: 
 Optimisation of solution conditions (pH, salt concentration, cofactors, metals,) for 
protein stabilisation (protein preparation and biochemistry and optimisation of 
crystallisation conditions).  
 Measurement of ligand binding affinity (drug screening, analysis of binding 
cooperativity between multiple ligands, inhibitors or cofactors). 
 Use of libraries to find proteins of unknown function.  
 Use of structural analogue libraries to determine detailed energetics of cofactor 
binding. 
 
The assays are realised on a reverse transcription polymerase chain reaction (RT-PCR) 
device (specifically in the work here an Mx3005P Q-PCR
®
, Stratagene) with protein 
sample concentration always included between 20 nM and 100 nM. The wavelengths of 
excitement and emission are respectively 470 nm and 570 nm.  
 
 
 
Figure 2.6: Principle of thermofluor (image from Imiplex, www.imiplex.com). 
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Figure 2.7: Graphical representation of a TSA measurement. The fluorescent signal 
increases as a function of the temperature which leads to the unfolding of the protein. The 
experimental Tm is calculated at the inflexion point of the curve. 
 
 
2.2.7 1D NMR spectroscopy 
One dimensional liquid state proton NMR spectroscopy (1D 
1
H NMR) can be used to 
quickly characterise biological macromolecules in solution (Silverstein, 1991). In 
particular the degree of folding of a protein can be determined by observing the presence 
or not of proton NMR peaks in specific regions of chemical shifts (an example of a 
spectrum is given in Figure 2.8). 1D NMR was carried out at the Institut de Biologie 
Structurale with the ‘Characterisation of Proteins’ platform. 
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Figure 2.8: Example of a 1D-NMR measurement of a folded and an unfolded protein 
(taken as example from an IBS experimental NMR report). 
 
 
2.2.8 Heteronuclear single quantum coherence NMR spectroscopy 
The heteronuclear single quantum coherence (HSQC) or heteronuclear single quantum 
correlation experiment is used in NMR spectroscopy and particularly in protein NMR 
(Bodenhausen et al., 1980). The result is a two dimensional spectrum with one axis for 
1
H 
and the other for a heteronucleus (an atomic nucleus other than a proton), most often 
13
C or 
15
N. The spectrum contains a peak for each unique proton attached to the heteronucleus 
being considered (see Chapter 5 for more details). 
 
 
Folded protein Unfolded protein 
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2.3 Small-angle X-ray and neutron solution scattering (SAXS and 
SANS) 
 
The concepts and mathematical framework underlying the small-angle scattering of X-rays 
and neutrons, known as SAXS and SANS respectively, have been described in a number of 
classical texts and reviews (non-exhaustive list: Baruchel et al., 1993 ; Fanchon et al., 
2002 ; Jacques et al., 2010 ; Kokhanovsky et al., 2014 ; Serdyuk et al., 2007) and full 
details will not be repeated here. However the studies carried out for this thesis work have 
made extensive use of X-ray and neutron scattering techniques, therefore it is appropriate 
to summarise the associated principles. 
 
The added value for this work was to combine the strength of both X-ray and neutron 
scattering techniques in order to obtain a consensus on the structural properties of the 
proteins. The high X-ray flux of the ESRF allowed a wide set of buffer conditions to be 
screened to find the most suitable one for each of the protein samples to be studied and an 
overall molecular envelope to be determined, allowing even low protein concentration to 
be used. Small-angle neutron scattering was used to distinguish and discriminate between 
the two proteins involved in the complex, with contrast variation being used in conjunction 
with protein deuteration to visualise individual proteins whilst in complex.  
 
2.3.1 Small-angle scattering: X-rays and neutrons as complementary probes 
Light scattering is one of a few methods that allow the determination of the radius of 
gyration and molecular mass. The principles behind both neutron and X-ray techniques are 
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similar except for how the incident radiation interacts with the sample: X-rays interact with 
the electrons of each atom whilst neutrons interact with the nucleus. X-ray scattering 
depends upon the number of electrons present – and thus increases with increasing atomic 
weight. The interaction of neutrons with matter however, depends on a completely 
different interaction between the incident neutron and the nuclei of the atoms in the 
sample. The scattering powers for neutrons and X-rays for the atoms of a biological system 
are very different (Figure 2.9) and this leads to a strong complementarity of X-ray and 
neutron scattering, particularly in the case of using the strong difference in hydrogen and 
deuterium scattering for application in neutron scattering experiments. In the case of 
solution scattering, it is convenient to calculate a scattering length density (SLD) which 
quantifies the scattering power of particular parts of the structure. 
 
 
   
 
 
Figure 2.9: Representation of scattering lengths for X-rays (blue, proportional to Z) and 
neutrons (green). 
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2.3.2 Deuteration for SANS 
The large difference in the scattering lengths of hydrogen and its isotope deuterium means 
that it is possible to label molecules in such a way that their scattering length densities 
(SLDs) are significantly different. Sample preparation using deuteration is well known for 
biological systems; and while perdeuteration (100 % deuteration) is commonly used to 
improve the signal-to-noise ratio in neutron crystallography, selective labelling (for 
example where only one particular subunit of a protein complex is labelled) can provide 
information about a specific part of a protein complex in neutron solution scattering studies 
(Figure 2.10). Moreover, combining the use of selective deuterium labelling of proteins 
with different ratios of D2O/H2O in the buffer means that it is possible to create different 
contrasts such that specific protein components can be matched in or out (Stegmann et al., 
1998). Indeed, the interesting features of the curves shown in Figure 2.10 are the points 
where the lines intersect. At these points, the molecules involved are matched out and the 
point at which this occurs (in terms of % D2O/H2O) is known as the match point. Hence 
contrast variation can be used to highlight the individual components of a complex. 
 
In the case of a two protein complex, by random fractional deuteration of one component 
to a global level of 75% (in D2O) and keeping the other partner unlabelled, and by using 
three different concentrations of D2O in the protein buffers, it is possible to alternatively 
match out one or the other protein, and also to observe the full complex. Briefly: in 0 % 
D2O the whole complex will stay visible, and the unlabelled protein and the 75 % 
deuterated protein will be individually matched out in respectively 40 % and 100 % D2O 
(Figure 2.11). 
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Figure 2.10: Plot of the variation of neutron scattering density with the percentage of D2O 
in an aqueous solution of biological molecules (such as H or D proteins, phospholipids 
and nucleic acids). Match points for a 75 % deuterated protein and an unlabelled protein 
are shown at 40% and 100% respectively. 
 
 
   
     
Figure 2.11: Principle of a contrast variation experiment, example of a two-protein 
complex involving an unlabelled protein and a 75 % deuterated protein. 
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2.3.3 The ESRF synchrotron radiation source 
The European Radiation Synchrotron Facility (ESRF, Grenoble, France) operates the most 
intense synchrotron X-ray source in the world (Figure 2.12). The linear accelerator (linac) 
accelerates the electrons previously emitted by an electron gun which are then transferred 
to a booster synchrotron. After reaching the energy of 6 GeV, they are transferred to the 
storage ring. Bending magnets direct the beam from one straight section of the storage ring 
to the next. Synchrotron radiation, emitted from insertion devices (ID) or from the bending 
magnets (BM) (Figure 2.13), is captured and tailored (energy selection, focussing) for use 
in experiments on the beamlines. 
 
 
 
 
Figure 2.12: Aerial picture of the ESRF located on the EPN campus in Grenoble. 
Photograph from www.esrf.eu. 
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Figure 2.13: Schematic of the inside of a synchrotron showing the linac and booster 
synchrotron as well as bending magnets, insertion devices and the beamlines of the main 
storage ring. Picture from www.esrf.eu. 
 
 
Small-angle X-ray scattering measurements were performed at the bioSAXS beamlines of 
the ESRF (Grenoble, France, Pernot et al., 2013), dedicated to measuring biological 
macromolecules in solution. During this work beamline ID14-3 was transferred to BM29. 
Both the ID14-3 beamline and now the BM29 beamline are equipped with an optimised 
optical layout for bioSAXS experiments with a multilayer monochromator for maximising 
the available flux, and a toroidal focusing mirror for the generation of a 100 µm
2
 beam. 
The working energies are between 7 to 15 keV with an achievable q-range of 0.01 to 
5 nm
-1
. The bioSAXS facility is equipped with a Pilatus 1M detector and a liquid handling 
robot (Figures 2.14 and 2.16). The minimum sample size is 5 µl, but 30 µl is needed for the 
30 frame measurement. A schematic of the bioSAXS beamline is presented in Figure 2.15. 
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Figure 2.14: Left: General organisation of an ESRF beamline; right: Photo of the 
beamline experimental cabin. Pictures from http://www.esrf.eu. 
 
 
 
 
Figure 2.15: Schematic of the BioSAXS beamline. Picture from http://www.esrf.eu. 
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Figure 2.16: Left: Photo of the Sample charger robot; right: photo of the sample loaded 
in the measurement capillary. Pictures from http://www.esrf.eu. 
 
 
2.3.4 The Institut Laue Langevin neutron source 
The high-flux research reactor of the Institut Laue-Langevin (ILL, Grenoble, France) 
produces neutrons through fission to be then directed at a suite of instruments and used to 
probe the structure and behaviour of many forms of matter by elastic and inelastic neutron 
scattering (general photo presented in Figure 2.17).  
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Figure 2.17: The Institut Laue-Langevin and its nuclear reactor (blue dome) producing the 
neutrons used for the SANS data collection. Photograph from Patrick Blanc. 
 
 
The small-angle neutron scattering measurements presented in Chapter 4 were performed 
on the D22 instrument of the Institut Laue-Langevin (ILL, Grenoble, France) as presented 
in Figure 2.18 and Figure 2.19. D22 has a resolution range varying from 10-15 Å to 
approximately 1000 Å. The maximum flux at sample is equal to 1.2x10
8
 neutrons/cm
2
/s. 
Neutrons are firstly selected in function of their speed via the velocity selector (used as a 
monochromator) in order to define the wavelength (from 4.5 to 40 Å). Then, a guide is 
used for their collimation to reduce the divergence of the flux. Samples in their quartz 
cuvettes are set in the sample holder which allows temperature control. After scattering 
through the samples, neutrons are finally detected in a surface detector which can be 
moved along a 20 metre long and 2.5 metre width evacuated tube under vacuum, providing 
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sample-to-detector distances of 1.1 m to 17.6 m. Thus, in standard conditions D22 covers a 
total q range of 4 x 10
-4
 to 0.44 Å
-1
 (no detector offset) or 0.85 Å
-1
 (with detector offset). 
The data are collected via a two dimensional 
3
He multidetector of 1 m
2
 size, before being 
integrated to get the final intensity vs diffusion angle curve.  
 
 
 
Figure 2.18: Picture of the small-angle diffractometer D22 instrument with its 20 metre 
long detector tube. Photograph from http://www.ill.eu. 
 
 
Figure 2.19: Schematic of the D22 instrument of the ILL. Picture from http://www.ill.eu. 
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2.3.5 Data treatment 
The software used for the SAXS and SANS data analysis are summarised in Table 2.1 (see 
Chapter 4 for further details). 
 
Software employed for SAXS analysis  
Primary data reduction Primus (Konarev et al., 2003) 
Data processing Gnom (Svergun, 1992) 
Ab initio modelling 
DAMMIF (Franke et al., 2009) 
DAMAVER (Volkov and Svergun, 2003) 
3D model display PyMol (Schrödinger company) 
Software employed for SANS analysis  
Primary data reduction RNILP, DETCI, RMSK (ILL / R. Ghosh) 
Data processing SPOLLY, Gnom (ILL / R. Ghosh) 
Ab initio modelling 
DAMMIF (Franke et al., 2009) 
DAMAVER (Volkov and Svergun, 2003) 
3D model display PyMol (Schrödinger company) 
Software employed for analysis of the predicted 
models 
Crysol (Svergun et al., 1995) 
 
Table 2.1: Summary of the main programs employed for SAXS and SANS data treatment.  
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2.4 Protein crystallisation 
 
2.4.1 Fundamental principles: 
The first step necessary for obtaining a structure by X-ray or neutron diffraction is the 
preparation of good quality crystals. Various methods are available to crystallise a protein 
(Figure 2.20, left), amongst which are microbatch (A) to vapour diffusion (B), dialysis (C), 
and free interface diffusion (D). 
 
In the vapour diffusion method small drops (tens of nanolitres to few microlitres) are made 
containing the target protein in buffered solution with a low concentration of precipitate 
(e.g. PEG, MPD, salts). These are set in ‘wells’ containing the same buffer, without protein 
but a high concentration of precipitant, and the whole system is then sealed. The 
equilibrium of the chemical potentials in the well is responsible for the evaporation of 
water in the drop towards the well, increasing gradually the protein concentration. If this 
balance crosses the nucleation zone, crystalline seeds will form. The concentration of 
soluble protein will then decrease, allowing crystalline growth phase. The two techniques 
used here are referred to as ‘hanging drop vapour diffusion’ and ‘sitting drop vapour 
diffusion’.  
 
In hanging drop vapour diffusion (Figure 2.20, right side), the protein solution is contained 
in a hanging drop held downward over the well containing a higher concentration of the 
precipitating agent(s). In sitting drop style, the protein solution is held in small ‘bridges’ 
above the well. 
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In this work, initial screening for crystallisation conditions was performed automatically 
using the High Throughput Crystallisation (HTX) platform of EMBL Grenoble. The 
Cartesian® (Genomics Solution) robot of the HTX platform realises nano-drops (0.1 µl) in 
the sitting drop configuration allowing automatic screening of 576 standard conditions. 
Promising conditions were then reproduced manually with the technique of hanging drop 
vapour diffusion to optimise the conditions and obtain the best possible quality and size of 
crystals. 
 
  
 
Figure 2.20: Left: simplified phase diagram for protein crystallisation. Paths for 
microbatch (A), vapour diffusion (B), dialysis (C), and free interface diffusion (D) are 
shown. Crystals only form in the zone of supersaturation (right of the solubility curve), 
where the concentration of the protein in the precipitant solution is above its solubility. In 
the zone of undersaturation (left of the solubility curve), crystals dissolve and cannot form 
(Figure modified from Chayen et al., 1998). Right: hanging drop vapour diffusion method. 
 
 Supersaturation 
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2.4.2 Preparation of crystallography experiments 
To avoid radiation damage (review Garman et al, 2002) resulting from the high intensity 
synchrotron beams, protein crystals are routinely cooled to liquid nitrogen temperatures 
(Garman and Mitchell, 1996). However, protein crystals typically contain a high 
percentage of water. To therefore avoid the formation of ice in loops during their cooling, 
crystals are usually transferred in to a solution containing the crystallisation mother liquor 
with addition of a cryo-protectant - typically glycerol, PEG or MPD, before being cryo-
cooled. 
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3. THE EBA181-4.1R PROTEIN COMPLEX: 
EXPRESSION AND CHARACTERISATION BY 
BIOCHEMICAL AND BIOPHYSICAL TECHNIQUES 
 
 
Abstract 
 
This chapter focuses on biochemical and biophysical characterisation of the interaction 
between the EBA181 and 4.1R proteins that have been associated with the Plasmodium 
falciparum infection of red blood cells. This work was essential preparation for the 
structural work carried out for the SAXS, SANS and NMR solution studies that are 
described in later chapters of this thesis. Initial work from collaborators in the group of 
Prof. Theresa Coetzer at Witwatersrand University Medical School identified the 
interaction between these proteins using phage display. The subsequent development and 
optimisation of the expression systems involved are described in detail in this chapter.  
Following this, work that characterises the interaction between the two proteins is 
described. This includes detailed pull-down assays as well as a wide ranging biochemical 
and biophysical investigation that was designed to yield information on the conformation 
and behaviour of individual proteins as well as of the complex. 
 
The pull-down assays have demonstrated the interaction in a tag- or -resin-independent 
way and allowed the characterisation of the interaction between the two proteins by testing 
complex stability in different conditions (pH variation, salt strength) as well as competition 
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assays using small peptides. Light scattering has provided the size of individual proteins 
and the complex, showing that both proteins behave as monomers in solution, and that the 
complex has a 1:1 protein stoichiometry, with a Kd estimated at 0.3 μM using micro-scale 
thermophoresis (MST). Structural characterisation by 
1
H-NMR and circular dichroism has 
shown the intrinsically disordered state of EBA-181 and the low level of compactness of 
4.1R. 
 
 
3.1 Introduction 
 
This chapter focuses on the structural and functional characterisation of the interaction 
between the 10 kDa domain of the human erythrocyte 4.1R protein (the 4.1R10kDa sequence 
is well-known in the literature and defined as from residue 405 to 471, Leto et al., 1984) 
and the PfJ fragment of the malarial Plasmodium falciparum protein EBA181 
(EBA181945-1097). The background to this work has been described in Chapters 1 and 2, and 
exploits the availability of the expression systems developed by the Coetzer Group as well 
as facilities within the Partnership for Structural Biology (PSB) in Grenoble.  
 
The overall strategy was to modify and develop the expression systems to yield suitable 
quantities of proteins to allow complementary biochemical and biophysical techniques to 
get insights and allow a consensus on key aspects of the structure, interactions and 
functional relationships of these proteins. Section 3.2 describes the expression system and 
the way in which the two proteins were produced and purified. A considerable amount of 
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time was put into this given the need for high efficiency and large quantities of protein. 
The plasmid DNA transposition, bacterial transformation and protein solubility tests are 
described. The way in which the large scale bacterial cultures were carried out is also 
described, as are the purification methods used for both proteins. Additionally, information 
on the preparation of the complex, pull-down, and inhibition assays is given in Section 3.3. 
Section 3.4 describes the biochemical characterisation carried out, mainly focused on pull-
down assays that were designed to yield information on the complex by testing its stability. 
Section 3.5 describes an extensive set of biophysical studies including one dimensional 
nuclear magnetic resonance (
1
H-NMR), circular dichroism (CD), thermal shift assays 
(TSA), size exclusion chromatography coupled to multi-angle laser light scattering and 
refractive index detection (SEC-MALLS-RI), dynamic light scattering (DLS), micro-scale 
thermophoresis (MST) and many crystallisation trials. The chapter finishes with a 
discussion/conclusion section that summarises the overall results and their implications for 
the structural studies on this interaction which are described later in this thesis. 
 
 
3.2 Production of individual EBA181945-1097 and 4.1R10kDa proteins 
 
3.2.1 Plasmid DNA: extraction and quality control 
Both plasmids, pGEX-4T-2 containing the 4.1R10kDa coding sequence, and pET15b 
containing the EBA181945-1097 coding sequence, were extracted from E.coli DH5α bacteria 
via mini-preps based on the alkaline lysis method. The quality of the mini-preps was 
checked on agarose gels, and UV spectra over the range from 220 nm to 350 nm 
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(Figure 3.1) were recorded in order to measure the concentrations. The two mini-prep 
samples with the highest concentration are shown with black and red arrows in Figure 3.1: 
pGEX-4T-2 (GST-4.1R10kDa) concentrated at 135 ng/μl and pET15b (His-EBA181945-1097) 
concentrated at 95 ng/μl. Prior to use the plasmids were stored at -20°C. 
 
 
  
 
Figure 3.1: 1.2% Agarose gel (left) and UV spectra (right) of the different plasmids after 
the mini-prep. Lanes of the agarose gel are: 
1: DNA marker used as a calibrant. 
2: pGEX-4T-2 containing the GST-4.1R10kDa coding sequence. 
3: pET15b containing the His-EBA181945-1097 coding sequence. 
 
 
2 3 
pET15b (His-EBA181945-1097) 
pGEX-4T-2 (GST-4.1R10kDa) 
1 
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3.2.2 Change of resistance marker 
In vitro transposition was used in order to change the antibiotic resistance from ampicillin 
to kanamycin for both plasmids. This was necessary because in high cell density cultures 
and/or cultures involving deuterated media the expressed beta-lactamase enzymes (from 
the bla gene carried by the plasmid), have a tendency to leak outside the cell, where they 
inactivate the ampicillin antibiotic, leading to a loss of selection pressure and overgrowth 
of plasmid-less cells. Hence recombinant plasmid expression is drastically reduced or 
eliminated. In the case of kanamycin resistant cells the expression of the protein involved 
occurs in the cytosol and hence leakage to the medium is much less likely to occur since 
the protein would have to cross two bacterial membranes. 
 
The kit used for in vitro transposition was the EZ-Tn5™ <KAN> Insertion Kit from 
Epicentre Technologies Corporation®. A total reaction volume of 10 μl was prepared with 
0.2 μg of each plasmid of interest containing one of the two sequences (pGEX-4T-2 or 
pET15b) mixed with diluted transposon at a molar equivalent concentration to the plasmid 
(in 10 mM Tris-HCl pH 7.5 with 1 mM EDTA), 1 U of transposase (in 50% glycerol 
containing 50 mM Tris-HCl pH 7.5, 0.1 M NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, and 
0.1% Triton® X-100), 1 μl of 10x reaction buffer (0.50 M Tris-acetate pH 7.5, 1.5 M 
potassium acetate, 100 mM magnesium acetate, and 40 mM spermidine) and finally 
completed with ddH2O.  
 
The reaction was incubated for 2 hours at 37°C, and spun in a centrifuge for 30 seconds in 
case of evaporation on the lid. The reaction was terminated by the addition of 1 μl of 10x 
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stop solution (1% SDS solution). After being mixed, the solution was heated for 
10 minutes at 70°C. Top10 and JM109 bacteria cells were used for transformation. 3 μl 
and 7 μl of the previous reaction were respectively used with 30 μl of Top10 and the 
JM109 bacteria cells, and maintained on ice for 15 minutes. Heat shock was performed 
at 42°C for 30 seconds and the tubes were immediately put back on ice for 5 minutes. After 
the addition of 1 ml of super-optimal broth with catabolite repression medium (SOC) 
(see composition detailed in Appendix A.1), the tubes were incubated at 37°C for 1 hour to 
facilitate cell growth before being spread on kanamycin-containing plates to select 
transformants which had the kanamycin transposon inserted into their plasmid DNA.  
 
The plates were grown overnight at 37°C. In order to screen for clones having the 
kanamycin transposon inserted into the ampicillin resistance gene, each kanamycin 
resistant colony was tested on two new plates: one plate containing kanamycin to double 
check, and one containing ampicillin to screen for insertional inactivation of the ampicillin 
gene. The clones that grew on the kanamycin plate and that did not grow on the ampicillin 
plate were picked and subsequently grown overnight in LB medium to perform mini-preps 
in order to extract DNA from each of the kanamycin resistant pGEX-4T-2 or pET15b 
plasmids. 
 
3.2.3 Bacterial transformation and long-term storage of clones 
To express the proteins, each plasmid was transformed into competent bacterial cells 
suitable for protein expression. E. coli Rosetta™ 2 (DE3) was chosen for its particularity to 
improve expression levels of gene/cDNAs containing rare codons (codons rarely used in 
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E. coli). These strains supply tRNAs for seven rare codons (AGA, AGG, AUA, CCC, 
CGG, CUA and GGA) on a compatible chloramphenicol-resistant plasmid.  
 
1 μl of each different plasmid DNA concentrated to 50 ng/μl was mixed with 50 μl of 
E. coli (DE3) Rosetta™ 2 cells and incubated on ice for 15 minutes. To increase 
transformation efficiency and allow the DNA to pass through the bacterial cell 
wall/membrane, a heat-shock was performed: 30 seconds at 42°C in a water-bath, then 
15 minutes on ice. 1 ml of SOC medium (see medium composition in Appendix A.1) was 
added to the mixture and incubated for 1 h at 37°C under rapid agitation (200 rpm). 
Finally, 200 μl of each previous culture was plated onto Petri dishes containing LB-agar 
medium and the appropriate antibiotics (Appendix A.1). 
 
E. coli Rosetta
TM
 2 cells for each of the expression constructs were stored at -80°C. A fresh 
and dense culture (having reached the stationary phase) of each individual clone was used 
to make long-term storage stocks using sterile beads in a cryo-preservative solution 
(Technical Service Consultants Ltd). 
 
3.2.4 Expression and solubility tests 
For the expression and solubility tests of GST-4.1R10kDa, separate cultures of LB medium 
supplemented with 30 µg/ml of kanamycin and with 34 µg/ml
 
of chloramphenicol 
(resistance given by the E. coli Rosetta
TM
 2 cells) were started using colonies from Petri 
dishes. These were then incubated overnight at 37°C under agitation. The overnight culture 
was used to start three different LB cultures (with appropriate antibiotics) in order to test 
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three different induction conditions: 18°C overnight, 30°C for 3 hours and 37°C for 
3 hours. The bacteria were grown at 37°C until the optical density at 600 nm reached 0.7 
and protein expression was then induced with 1 mM IPTG for the three different 
temperature tested (see Figure 3.2, top). 
 
For His-EBA181945-1097, the optimal expression conditions were known from our 
collaborators: induction with 1mM IPTG at 37°C for 3 hours (see Figure 3.2, bottom). 
Similarly to the expression of GST-4.1R10kDa, cultures of LB medium containing 30 µg/ml 
of kanamycin and 34 µg/ml
 
of chloramphenicol were started using colonies from Petri 
dishes. These were incubated overnight at 37°C under agitation and this overnight culture 
was used to start the final LB culture. The bacteria were grown at 37°C until the optical 
density at 600 nm reached 0.7 and protein expression was then induced with 1 mM IPTG 
for 3 hours at 37°C. 
 
3.2.5 Large-scale bacterial cultures 
Following the change of the antibiotic resistance, eight kanamycin resistant clones 
expressing His-EBA181945-1097 or GST-4.1R10kDa were tested in order to compare the 
solubility and expression levels of each protein (data not shown). The expression levels as 
judged by SDS-PAGE of the two kanamycin resistant clones that showed the highest 
expression yield of soluble His-EBA181945-1097 or GST-4.1R10kDa after 3 hours of induction 
at 37°C are shown in Figure 3.3. 
 
 
15 kDa 
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Figure 3.2: A: Western blot analysis after expression of GST-4.1R10kDa at three different 
temperatures. B: SDS-PAGE (12 % Tris-Tricine gel) showing the expression and solubility 
test of the His-EBA181945-1097 protein after induction at 37°C. 
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Not induced: Sample before induction with IPTG. 
Total: Insoluble and soluble protein after IPTG induction. 
Soluble: Soluble proteins after IPTG induction and centrifugation. 
GST- 
4.1R10kDa 
His-EBA181945-1097 
 
A) 
B) 
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For the large-scale protein expression, the selected medium was LB medium supplemented 
with 30 µg/ml of kanamycin and with 34 µg/ml of chloramphenicol. Firstly, 5 ml 
precultures were inoculated from Petri dish and incubated until reaching the stationary 
phase of growth (37°C, overnight under agitation). Further precultures were subsequently 
started from the 5 ml ones, in three steps with 20 ml, 100 ml to finally 500 ml. After this, 
each 1 litre culture was inoculated using the starter 500 ml precultures (1:50 dilution). The 
bacteria were grown at 37°C to an optical density of around 0.7 at 600 nm. Protein 
expression was induced with 1 mM IPTG over 3 hours as defined from the previous 
expression and solubility tests. The bacteria were lysed by sonication to release the 
proteins; the suspension was then centrifuged at 40 000 g for 1 h and at 4°C to separate the 
soluble material. 
 
It should be noted that EBA181945-1097 is very negatively charged at pH 7, which leads to 
an unusual migration pattern on SDS-PAGE (Iakoucheva et al., 2001).  Instead of having a 
migration at around 19 kDa which is its real molecular weight, the migration appears close 
to 50 kDa, due to decreased binding of the SDS which is also negatively charged. 
N-terminal sequencing and mass spectrometry experiments were performed on 
EBA181945-1097 which confirmed the molecular weight and N-terminal sequence (first eight 
amino-acids).  
 
3.2.6 Protein purification 
Both proteins were purified using two different techniques (Table 3.1). 
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A) Immobilised metal affinity chromatography (IMAC, using an Äkta Prime system or a 
peristaltic pump), following three different steps (binding, washing and elution) and 
the buffers listed in Appendix A.2, Table A.1. 
B) Size exclusion chromatography, carried out using the Äkta Purifier system and 
Superdex columns from GE Healthcare® (S75 or S200). 
 
 
 
Figure 3.3: SDS-PAGE showing expression of His-EBA181945-1097 (left) and 
GST-4.1R10kDa (right) after the change of the antibiotic resistance.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Not induced: Sample before induction with IPTG. 
Total: Insoluble and soluble protein after IPTG induction. 
Soluble: Soluble proteins after IPTG induction and centrifugation. 
His-EBA 
181945-1097 
 
GST- 
4.1R10kDa 
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Diagram 3.1: Summary and comparison of the main steps of EBA181945-1097 and 4.1R10kDa 
purification protocol. 
 
 
3.2.6.1 Purification of EBA181945-1097 
His-tagged EBA181945-1097 can be purified by affinity chromatography (Figure 3.4) on a 
nickel column (packed with NiNTA Superflow resin from Qiagen®), equilibrated in lysis 
A) 
B) 
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and binding buffer (Appendix A.2, Table A.1). Soluble proteins extracted from E. coli 
culture were loaded onto the NiNTA resin column. Washing buffer was then used to 
remove the non-specifically-bound proteins, and His-EBA181945-1097 was finally eluted 
using the elution buffer containing 150 mM imidazole (Appendix A.2, Table A.1). After 
elution, His-EBA181945-1097 was dialysed overnight at 8°C against the lysis buffer with 
thrombin protease (3U / mg of protein), in order to cleave the histidine tag. 
 
 
 
Figure 3.4: SDS-PAGE of the first NiNTA purification of EBA181945-1097.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Sol: Soluble proteins after centrifugation. 
FT: Flow through the NiNTA resin column. 
Wash: Wash of the column with the washing buffer. 
Elu: Elution of the proteins with the elution buffer. 
Dialysis: Sample after dialysis and tag cleavage. 
EBA181945-1097 
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After dialysis, EBA181945-1097 was again purified on a NiNTA column in order to retain the 
uncleaved (intact) fraction of His-EBA181945-1097 as well as the His-tag itself, leaving the 
untagged EBA181945-1097 protein in the flow-through fraction (Figure 3.5, ‘FT’). According 
to the SDS-PAGE, the tag was successfully removed from EBA181945-1097 since the whole 
sample was not retained by the NiNTA column and no His-EBA181945-1097 was detectable 
in the elution fraction (Figure 3.5, ‘Elu’). The His-tag alone resulting from the cleavage is 
too small to be seen on the gel. 
 
The untagged (FT) fraction was concentrated to a volume of approximately 1 ml (by a 
factor of 15-20) using an Amicon Ultra centricon tube with a cut-off of 10 kDa and then 
filtered (0.2 µm filter). The resulting solution was then injected onto a size exclusion 
chromatography column (Figure 3.6, column reference: Superdex S200 10/300 GL, GE 
Healthcare®) that had previously been equilibrated in filtered and degassed buffer for two 
column volumes (50 ml) at a flow of 0.5 ml/min. 500 μl of protein was injected per run in a 
1 ml loop using the same flow of 0.5 ml/min. 
 
Because of the absence of aromatic residues in EBA181945-1097, the absorbance during the 
gel filtration was monitored at 205 nm, corresponding to the peptide bond absorbance. This 
leads to a noisier spectrum, though still sufficiently good to identify the fractions 
containing the protein. The size exclusion chromatography led to good separation of 
EBA181945-1097 from the other contaminants (Figure 3.6). Approximately 5 mg of pure 
EBA181945-1097 was obtained per litre of bacterial culture. The pooled fractions containing 
EBA181945-1097 (Figure 3.6, fractions C1 to C9) were concentrated (from 5 to 90 mg/ml) 
and finally centrifuged (to eliminate any aggregates) for further analysis. The resulting 
65 
 
EBA181945-1097 was considered highly pure for subsequent biochemical and biophysical 
analysis, as judged by SDS-PAGE (Figure 3.7). 
 
      
 
Figure 3.5: SDS-PAGE of the second NiNTA purification after tag cleavage of 
EBA181945-1097.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Sample before: Sample kept after the first NiNTA purification (control). 
FT: Flow through the NiNTA resin column. 
Elu: Elution with the elution buffer. 
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3.2.6.2 Purification of 4.1R10kDa 
Due to the fused GST tag on its N-terminus, the GST-tagged 4.1R10kDa protein 
(GST-4.1R10kDa) can be purified by affinity chromatography, on a glutathione Sepharose 
column (packed with Glutathione Sepharose
TM
 High Performance resin from GE 
Healthcare®).  
 
Following E. coli cell lysis and centrifugation, the supernatant (15 ml) was loaded on the 
GST resin column (Figure 3.8, A) at a flow of 0.1 ml/min, previously equilibrated with the 
lysis buffer (Appendix A.2, Table A.1). The column was then washed using 7 to 8 column 
volumes of the washing buffer (Appendix A.2, Table A.1) in order to remove the 
contaminant proteins (Figure 3.8, top, ‘Wash 1’). During the optimisation of the large scale 
purification of GST-4.1R10kDa, a significant amount of nucleic acids was found to be co-
eluted with GST-4.1R10kDa. Therefore an extended overnight washing step with a least 75 
column volumes of washing buffer containing 1 M NaCl was used to eliminate these 
nucleic acid contaminants (Figure 3.8, ‘Wash 2’). After the overnight wash GST-4.1R10kDa 
was eluted from the column using 5 ml of the elution buffer containing reduced state 
glutathione (buffer composition in Appendix A.2, Table A.1). 
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Figure 3.6: A: Size exclusion chromatography purification of EBA181945-1097 using 
Superdex S200 10/300 GL column, GE Healthcare®. Pink curve: absorption curve (A205nm 
in mAU). B: SDS-PAGE analysis of collected fractions. The two black lines show the 
corresponding chromatography fractions on the SDS PAGE. 
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Sample before: Sample kept after the second NiNTA purification step (control). 
B2 to C11: Elution fractions. 
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Figure 3.7: SDS-PAGE of EBA181945-1097 after the final size-exclusion step of purification.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
EBA181945-1097: Purified EBA181945-1097 protein. 
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Figure 3.8: Purification of GST-4.1R10kDa on the GST resin column and tag cleavage.  
A: Chromatogram of the different steps for the GST column purification (blue curve: A280nm 
in mAU, red curve: conductivity in mS). B: SDS-PAGE of the different steps of the GST 
column purification.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
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Sol: Soluble proteins after centrifugation. 
FT: Flow through the GST resin column. 
Wash 1: Wash of the column with the washing buffer. 
Elu: Elution of the proteins with the elution buffer. 
Dia: Sample after dialysis and GST tag cleavage. 
 
 
After elution, GST-4.1R10kDa was dialysed overnight at 8°C in the same buffer as for 
EBA181945-1097, with thrombin protease (3U / mg of protein) in order to cleave the GST 
tag. After the dialysis, the solution containing 4.1R10kDa was concentrated to around 1 ml 
volume (by a factor of 15) using an Amicon Ultra centricon tube with the right weight 
cut-off (3.5 kDa for 4.1R10kDa), filtered through a 0.2 µm filter and injected in a size 
exclusion chromatography column (column reference: Superdex S75 10/300 GL, 
GE Healthcare
®
), previously equilibrated in filtered and degassed dialysis buffer for two 
column volumes (50 ml) at a flow of 0.5 ml/min. 500 μl of protein is injected per run in a 
1 ml loop using the same flow of 0.5 ml/min
 
(Figure 3.9). In this case, the absorbance of 
4.1R10kDa could be monitored as usual at 280 nm due to the presence of aromatic residues 
(Figure 3.9, A, blue curve) with the contaminant nucleic acids absorption monitored at 
254 nm (red curve). Using the size exclusion chromatography, 4.1R10kDa was successfully 
separated from contaminants (mostly nucleic acids, cleaved GST tag and uncleaved GST-
4.1R10kDa, Figure 3.9, B). Approximately 0.5 mg of pure 4.1R10kDa was obtained per litre of 
bacterial culture. The fractions containing purified 4.1R10kDa (Figure 3.9, C3 to C5 
fractions, red arrows) were centrifuged to eliminate any aggregates present and finally 
concentrated to around 5 mg/ml
 
(Figure 3.10). 
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Figure 3.9: A: Size exclusion chromatography purification of 4.1R10kDa using Superdex 
S75 10/300 GL column, GE Healthcare®. Blue curve: A280nm in mAU, red curve: A254nm in 
mAU. B: Corresponding SDS-PAGE. The two black lines show the corresponding 
chromatography fractions on the SDS PAGE and the thin red arrows show the fractions 
pulled together for concentration.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Sample before: 4.1R10kDa after dialysis and tag-cleavage (control). 
B10 to C9: Elution fractions. 
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Figure 3.10: SDS-PAGE of 4.1R10kDa after final size-exclusion step of purification.  
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
4.1R10kDa: Purified 4.1R10kDa protein. 
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3.3 Preparation and purification of the complex 
 
The complex formed by EBA181945-1097 and 4.1R10kDa was formed either by mixing both 
previously freshly purified individual proteins in a 1:1 molar ratio, or by using a pull-down 
assay to purify the complex from bacterial crude extract (this latter method is presented in 
this section).  
 
  
 
Figure 3.11: SDS-PAGE of the pull-down of the complex His-EBA181945-1097 / 
GST-4.1R10kDa using NiNTA resin. EBA181945-1097 is used as the bait for 4.1R10kDa. 
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
 FT: Flow through the NiNTA resin column. 
Wash: Washing steps. 
1 to 10: Elution fractions. 
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In the first step, bacterial crude extract from a 1 litre culture expressing His-EBA181945-1097 
was loaded onto the IMAC column (Figure 3.11, ‘His-EBA Total’ and ‘His-EBA FT’). 
Due to the His-tag and the resin used (Nickel NiNTA, as previously) the 
His-EBA181945-1097 protein bound to the column. In the second step, bacterial crude extract 
from a 1 litre culture expressing GST-4.1R10kDa was added and bound to the previously 
loaded His-EBA181945-1097 (Figure 3.11, lanes ‘GST-4.1 Total’ and ‘GST-4.1 FT’). In the 
third step, the contaminant proteins were removed by washing the column with the 
His-EBA181945-1097 washing buffer (composition in Appendix A.2, Table A.1). The 
complex was then eluted (Figure 3.11, elution fractions from 1 to 10) using the His-
EBA181945-1097 elution buffer and loaded on a size exclusion chromatography column 
(Superdex S200, GE Healthcare
®
) to further increase its purity (Figure 3.12).  
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Figure 3.12: A: Size exclusion chromatography purification using Superdex S200 
10/300 GL column, GE Healthcare® (blue curve: A280nm in mAU, red curve: A254nm in mAU) 
of the complex between His-EBA181945-1097 and GST-4.1R10kDa and B: Corresponding 
SDS-PAGE. The two black lines show the corresponding chromatography fractions on the 
SDS-PAGE. 
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3.4 Biochemical characterisation of individual EBA181945-1097 and 
4.1R10kDa proteins and the complex 
 
3.4.1 Quantification of nucleic acid contamination 
The purity of the isolated proteins was confirmed by SDS-PAGE gel. However, these 
protein samples might still be contaminated by nucleic acids through non-specific binding 
to the protein. In order to check if 4.1R10kDa preparations were largely nucleic-acid free, the 
ratio protein/nucleic acids was determined by UV spectroscopy (Figure 3.13). For 
EBA181945-1097, it was not possible to measure this ratio since there is no aromatic residue 
in its sequence. Nevertheless, since EBA181945-1097 is highly negatively charged at pH 
between 6 and 8, as DNA or RNA are, binding is therefore, in this case, very unlikely to 
occur. 
 
The ratio of absorptions at 260 nm vs. 280 nm of 4.1R10kDa (Figure 3.13) is equal to 0.61, 
which means that the sample is composed of essentially 100% protein (Table 3.2, 
Sambrook and Russell, 2001), demonstrating the effectiveness of the overnight washing 
step during the GST purification which targeted to remove any nucleic-acid contamination. 
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Table 3.2: Determination of DNA/RNA contamination in a protein sample using the 
absorbance ratio A260nm (nucleic acids) / A280nm (protein, tryptophan residues mainly). 
Source: Sambrook et al., 2001. 
 
 
 
 
        
 
Figure 3.13: UV measurements of 4.1R10kDa at 260 nm (red) and 280 nm (blue) during the 
size exclusion chromatography purification step. 
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15 85 1.98 
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3.4.2 Storage and degradation tests 
To be able to store either the tagged His-EBA181945-1097 and GST-4.1R10kDa or the 
untagged EBA181945-1097 and 4.1R10kDa proteins, anti-proteases were added after final step 
of purification and concentration (1 mM PMSF final or commercial Complete from 
ROCHE®). Storage/degradation tests were performed. Each protein was stored at 4°C and 
aliquots were taken at T=0, after 1 week, 2 weeks and finally 3 weeks. These samples were 
mixed with gel loading buffer and heated at 100°C for 5 minutes to stop any degradation 
process. In parallel, a ‘freezing test’ was performed in order to test the feasibility to store 
the proteins at -20°C. Fresh samples were put at -20°C for three weeks, then defrosted to 
be analysed and allow the comparison with the 4°C test results (Figure 3.14). 
His-EBA181945-1097 samples were intentionally overloaded on the SDS-PAGE in order to 
be able to detect even weak degradation. It was not possible to load as much for 4.1R10kDa 
because of the weak expression yield.  
 
According to the SDS-PAGE (Figure 3.14, A), EBA181945-1097 can be stored at 4°C for at 
least three weeks without significant degradation. Moreover, the freezing process does not 
induce major proteolytic cleavage of the protein. Nevertheless it is impossible to see on a 
SDS-PAGE if freezing the protein has an impact on secondary structures. 
CD measurements were done as quality checks of the secondary structure on purified 
EBA181945-1097 before and after freezing (not shown). Both spectra were identical, 
indicating no significant change in secondary structure upon freeze/thaw cycles. 
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Figure 3.14: Storage and degradation tests. 
A: SDS-PAGE of purified His-EBA181945-1097 (left) and 4.1R10kDa (right) proteins. 
B: Western blot anti GST tag on purified GST-4.1R10kDa protein. 
A) 
B) 
4.1R10kDa His-EBA181945-1097 
GST-4.1R10kDa 
80 
 
For 4.1R10kDa the SDS-PAGE from the degradation tests have shown that the protein is 
stable for approximately two weeks at 4°C, with some degradation visible in three week 
old aliquots. As for EBA181945-1097, no difference is visible on gel for 4.1R10kDa after three 
weeks at -20°C and being defrosted. Similarly to EBA181945-1097, CD measurements were 
performed on purified 4.1R10kDa before and after freezing (not shown). The two spectra 
were also identical, showing no significant structural change upon a freeze-thaw cycle. 
 
On the contrary, GST-4.1R10kDa is not stable and rapidly degraded (few days), as noticed 
during the purification steps. This result shows the crucial importance of working at low 
temperature and the usage of anti-protease to minimise the activity of trace proteases. 
 
3.4.3 Development of a ‘micro pull-down’ protocol 
To study the complex and characterise the interaction between the EBA-181 and 4.1R 
proteins, a micro pull-down protocol was developed. The use of a 96 mini column system 
and a 96 well micro-plate permits the use of only a small amount of protein whilst testing 
different conditions in parallel, as well as using the same sample and protocol to allow a 
good and reliable comparison between each tested condition.  
 
After testing different volumes of samples, resins and buffers (data not shown), the 
following optimised protocol was used for the pull-down characterisation studies 
(Figure 3.15). Firstly, 50 μl of the chosen resin (NiNTA or GST) was applied onto each 
mini column (the resin was retained by the filter, see photo of the receiver plate in 
Figure 3.15). Then, 500 μl of ddH20 was added on top of the resin and drawn down into it 
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using a pipette in order to remove the ethanol storage solution of the resin. Depending 
upon the chosen characterisation test, 500 μl of the buffer of interest (see Appendix A.2 for 
buffer composition and 3.4.3 for the results and the different characterisation performed) 
were added on top of the resin to equilibrate the resin and again drawn down to the level of 
the top of the resin to remove any excess. In the meantime, the two freshly purified 
proteins were incubated together for 30 minutes in a tube on ice to form the complex. 
Starting from this step, the study was done using gravity flow only, in order to minimise 
the flow speed. 50 μl of the protein complex (concentration between 0.1 and 0.5 mg.ml-1) 
was applied on top of the resin. Once the protein sample had passed through the resin, 
50 μl of the protein buffer was added to compensate the volume of the resin and recover 
the entire flow-through (total 100 μl). To remove the non-specifically bound proteins and 
to test the complex under different conditions and stresses (pH, salt concentration, 
competition with peptides), the resin was washed in several steps with the chosen washing 
buffer (two resin volumes, 100 μl each time) until no further protein was detected in the 
washing fractions. Finally, the proteins bound to the resin were eluted with 100 μl of 
elution buffer. All the fractions were collected to be analysed on SDS-PAGE. 
 
3.4.4 Inhibition assays 
Two 30 amino-acid peptides were used for micro pull-down experiments as competitors of 
the EBA-181945-1097 / 4.1R10kDa complex. The first peptide, called here Pf30, contains the 
amino acid sequence from EBA-181 binding to human 4.1R 10kDa domain (as found by 
phage display technique by our collaborators, Lanzilotti et al., 2005, see Figure 3.16). 
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Figure 3.15: The mini pull-down technique used to characterise the interaction between 
EBA181945-1097 and 4.1R10kDa. Left: the 96 mini column system, right: Summary of the 
main steps of the protocol. 
 
  
  Pf30: NSVVDRATDSMNLDPEKVHNENMSDPNTNT 
 
Figure 3.16: EBA-181 domains and Pf30 peptide sequence interacting with 4.1R10kDa. 
 
 
The second peptide, called Pr30, was used as a comparison. Its sequence (see below) 
originates from Plasmodium reichenowi which infects only chimpanzees and not humans, 
and therefore might not interact with human 4.1R protein. 
 
Pr30: NSVVVNKETSSKDLAHEMVDEEQDKHPNTNI 
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Each different peptide was pre-incubated with the two proteins, with a 10 or 100 fold 
molar excess of peptide (on ice for 30 minutes). The previously described micro pull-down 
protocol was then used to perform the inhibition experiment. 
 
3.4.5 Application of the micro pull-down technique 
Further characterisation of the interaction between EBA-181945-1097 and 4.1R10kDa was 
performed using the developed micro pull-down technique. The four possible constructs 
were used: tagged His-EBA181945-1097 and GST-4.1R10kDa, and untagged EBA181945-1097 
and 4.1R10kDa. The following micro pull-down experiments were performed: 
 
 Test of the complex formation in a tag-or-resin independent way, 
 Negative controls to confirm the specificity of the tag-to-resin binding and the 
absence of false positives, 
 High-salt (positive and negative charges competition), 
 pH variation, 
 Inhibition using competitor peptides. 
 
3.4.5.1  Test of the complex formation in a tag-or-resin independent way 
These first pull-down experiments involved the four different constructs, in order to 
confirm the formation of the complex independently of them being tagged/untagged and of 
the resin used (NiNTA or GST resin). When using the NiNTA resin, His-EBA181945-1097 is 
retained first. GST-4.1R10kDa or 4.1R10kDa can similarly only be retained by the column if 
held in complex with His-EBA181945-1097 (Figure 3.17, A1 & A2). In the case of the GST 
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resin, GST-4.1R10kDa is retained first and His-EBA181945-1097 or EBA181945-1097 can only be 
retained if they bind to GST-4.1R10kDa (Figure 3.17, B1 & B2). 
 
To study the interaction between His-EBA181945-1097 and 4.1R10kDa the chosen buffer was 
50 mM sodium phosphate at pH 6.0 with 50 mM NaCl and 5 mM βME. However, because 
the theoretical iso-electric point of GST-4.1R10kDa is equal to 6.57, the buffer to study the 
interaction between EBA181945-1097 and GST-4.1R10kDa has to be sufficiently different in 
pH to avoid the protein to be not charged; PBS at pH 7.4 was therefore used, with 5 mM 
βME. 
 
A1) For the pull-down experiment of 4.1R10kDa by His-EBA181945-1097 using the NiNTA 
resin, some of the His-EBA181945-1097 was visible in the flow-through (lane 2) and the first 
washing step (lane 3), meaning not 100 % of the protein was bound to the resin. No 
4.1R10kDa was detectable in either flow-through or washing fractions. After ten column 
volumes of wash, no remaining protein was detectable (lane 5), allowing a careful analysis 
of the following elution fractions. Finally, His-EBA181945-1097 and 4.1R10kDa were co-eluted 
as a complex (lanes 8, 9 and 10). 
 
A2) For the pull-down experiment of GST-4.1R10kDa by His-EBA181945-1097 with the 
NiNTA resin, some of the His-EBA181945-1097 (not bound to the resin) and GST-4.1R10kDa 
(not bound to the EBA protein) were visible in the flow-through (lane 2) and the two first 
washing steps (lanes 3 and 4). After washing with ten column volumes of washing buffer, 
no remaining protein was detectable (lane 5), allowing the analysis of the following elution 
fractions. Finally, His-EBA181945-1097 and GST-4.1R10kDa were co-eluted as a complex 
(lanes 6 to 10). 
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B1) For the pull-down experiment of His-EBA181945-1097 by GST-4.1R10kDa using the GST 
resin, some of the His-EBA181945-1097 was visible in the flow-through (lane 2) and the first 
washing step (lane 3), so as a ‘free form’ not in complex with GST-4.1R10kDa. No 
GST-4.1R10kDa was detectable in either flow-through or washing fractions. After ten 
column volumes of wash, no remaining protein was detectable (lane 5). As previously, this 
allows the analysis of the following elution fractions. Finally, GST-4.1R10kDa and 
His-EBA181945-1097 were co-eluted as a complex (lanes 6 to 9). 
 
B2) For the pull-down experiment of untagged EBA181945-1097 by GST-4.1R10kDa with the 
GST resin, EBA181945-1097 proteins were visible in the flow-through (lane 2) and the first 
washing step (lane 3) as a ‘free form’, like in the previous pull-down (B1). But no 
GST-4.1R10kDa was detectable in either flow-through or washing fractions. No remaining 
protein was detectable after ten column volumes of wash (lane 5). Finally, GST-4.1R10kDa 
and EBA181945-1097 were co-eluted as a complex (lanes 8 to 10). 
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A1) NiNTA resin: Pull-down His-EBA181945-1097 / 4.1R10kDa 
 
 
 
 
A2) NiNTA resin: Pull-down His-EBA181945-1097 / GST-4.1R10kDa 
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B1) GST resin: Pull-down GST-4.1R10kDa / His-EBA181945-1097 
 
 
 
B2) GST resin: Pull-down GST-4.1R10kDa / EBA181945-1097 
 
 
 
Figure 3.17: SDS-PAGE of the pull-down experiments with (A) NiNTA and (B) GST resins; 
using (A1) His-EBA181945-1097 and 4.1R10kDa, (A2) His-EBA181945-1097 and GST-4.1R10kDa; or (B1) 
GST-4.1R10kDa and His-EBA181945-1097, (B2) GST-4.1R10kDa and EBA181945-1097. 
MW: Molecular marker. 1: Flow-through. 2 to 4: Washes. 5 to 9: Elution fractions. 
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3.4.5.2  Negative controls 
Negative controls were also performed using both GST-4.1R10kDa and His-EBA181945-1097 with 
the NiNTA and GST resins, in order to confirm that neither His-EBA181945-1097 nor 
GST 4.1R10kDa could bind non-specifically to the GST and NiNTA resins respectively 
(Figure 3.18). 
 
  
 
Figure 3.18: Left: SDS-PAGE of negative controls with GST-4.1R10kDa on NiNTA and right: 
His-EBA181945-1097 on GST resin. 
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3.4.5.3  High salt characterisation 
The following characterisation experiment was to apply two high salt stresses in order to test if 
the interaction is sensitive to charge competition given by the Na
+
 and the Cl
-
, and mimicking the 
cell local concentrations (Figure 3.19). The three NaCl concentrations used were 250 mM (lanes 
from 2 to 4), 1 M (lanes from 5 to 7) and 2 M (lanes from 8 to 10). As shown by the SDS-PAGE 
from the three different micro pull-down experiments (Figure 3.19), the complex is stable in 
competition with 250 mM or 1 M (elution fractions 4 and 7); and when the salt concentration 
was increased to 2 M NaCl, no complex dissociation was neither noticeable in both flow-through 
and washing fractions. The complex was therefore present in the elution fraction (fraction 10).  
 
 
 
 
Figure 3.19: SDS-PAGE of pull-down experiment on His-EBA181945-1097 and 4.1R10kDa complex, 
resistance in high salt conditions. The rectangles show the eluted complex after each of the 
three different experiments. 
‘F.T.’: flow through the NiNTA resin column. 
‘Wash’: wash with the washing buffer containing: 3: 250mM NaCl, 6: 1M NaCl, 9: 2M NaCl. 
‘Elu.’: elution of the proteins with the elution buffer. 
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3.4.5.4  pH variation 
The next characterisation was a pull-down test carried out to study the complex stability against 
pH, from pH 5.0 to 9.0 (Figure 3.20). The nickel resin used (NiNTA) has a pH binding capacity 
between 5.0 and 9.0; it is therefore compatible with the range of pH targeted. The micro pull-
down protocol was used as described earlier (see 3.3.1). The complex between 
His-EBA181945-1097 and 4.1R10kDa was pre-formed on ice and incubated 30 minutes in each of the 
different pH solutions before being loaded onto the columns. Washing and elution steps were 
also performed in the corresponding pH values. 
 
The complex between His-EBA and 4.1R was detected at each pH point tested (pH 5.0, 6.0, 7.0, 
8.0 and 9.0; Figures 3.20 and 3.21), as shown on the SDS-PAGE elution lanes (rectangle). 
Nevertheless, it is noticeable that the complex seems to be slightly less stable at the extreme 
pH 9.0, since the flow-through fraction at pH 9.0 showed a slightly higher quantity of the 4.1R 
partner (compared to pH 8.0 on the same gel). These results provide insights into the robustness 
of the complex to these high negative or positive charges (given by the Na
+
 and Cl
-
 ions); and so 
upon local pH variations in cells.  
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Figure 3.20: SDS-PAGE of pull-down experiments on the His-EBA181945-1097 and 4.1R10kDa 
complex, resistance of the complex to pH variations (pH from 5.0 to 7.0). The rectangles show 
the eluted complex at each different pH. 
‘F.T.’: flow through the NiNTA resin column. 
‘Wash’: wash with the washing buffer. 
‘Elu.’: elution of the proteins with the elution buffer.  
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Figure 3.21: SDS-PAGE of pull-down experiments on the His-EBA181945-1097 and 4.1R10kDa 
complex, resistance of the complex to pH variations (pH 8.0 and 9.0). The rectangles show the 
eluted complex at each different pH. 
‘FT’: flow through the NiNTA resin column. 
‘Wash’: wash with the washing buffer. 
‘Elution’: elution of the proteins with the elution buffer.  
 
 
3.4.5.5  Binding competition assays 
The last pull-down experiment was to perform a binding competition assay by the use of two 
different 30 amino-acid peptides (Pf30 and Pr30) with the complex. Pf30 contains the EBA 
binding sequence to 4.1R, so is therefore likely to bind to 4.1R and will act as a competitor to 
EBA. On the other hand, Pr30 contains the homologue sequence of Pf30 but from Plasmodium 
4.1R10kDa 
 
His-EBA 
181945-1097 
 
pH 9.0 pH 8.0 
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reichenowi. As this parasite does not infect humans, the Pr30 peptide might not bind to 4.1R. 
Pr30 was therefore used for comparison and as a likely negative control. In order to facilitate and 
improve the protein detection on gel, only tagged proteins were used for this pull-down 
experiment (His-EBA181945-1097 and GST-4.1R10kDa, Figure 3.22).  
 
 
 
Figure 3.22: SDS-PAGE of pull-down experiments on His-EBA181945-1097 and GST-4.1R10kDa 
complex, binding competition by the two Pf30 and Pr30 peptides. 
‘F.T.’: flow through the NiNTA resin column. 
‘Wash’: final washing fraction. 
‘Elu.’: elution of the proteins with the elution buffer. 
‘+’: positive control, pull-down without any peptide. 
‘Pr30 peptide’: complex binding competition with Pr30 peptide (100 fold excess). 
‘Pf30 peptide’: complex binding competition with Pf30 peptide (100 fold excess). 
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The same competition pull-down experiment was performed twice, with 10 times (data not 
shown) or 100 times molar excess peptide (Figure 3.22). In both cases there was no inhibition of 
complex formation. Neither of the 30 amino-acid peptides disrupted the interaction between 
EBA and 4.1, even with a 100 fold excess. This suggests that the whole EBA181945-1097 sequence 
is important for binding to 4.1R. Thus, even if the 30 amino-acids are sufficient to bind to 4.1R, 
the rest of the sequence might increase the affinity and/or help to stabilise the complex. 
 
3.4.6 Native polyacrylamide gel electrophoresis 
Native polyacrylamide gels were used to analyse and demonstrate the complex formation, as 
well as to detect any charge and/or conformation changes of the two proteins upon binding. 
Native gel electrophoresis does not use a charged denaturing agent; therefore the molecules 
being separated differ not only in molecular mass and intrinsic charge, but also in their 
cross-sectional area, and thus experience different electrophoretic forces dependent on the shape 
of the overall structure. These analyses were carried out using 5 μg of each purified protein and 
gels were run during 4 hours at 15 mA and at 8°C (Figure 3.23).  
 
Native gel electrophoresis of 4.1R10kDa showed that 4.1R10kDa did not enter the gel: since the 
protein was almost uncharged at the required pH used (pH=8.9, theoretical iso-electric point of 
4.1R10kDa = 8.25, 13 residues with negatively charged side chain and 14 residues with positively 
charged side chain, see Appendix B.4 for more details on the sequence properties). This result 
was used to compare the change of overall charges when bound to EBA181. 
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                              EBA181                         4.1R       Complex  
 
 
Figure 3.23: Native polyacrylamide gel of EBA181945-1097, 4.1R10kDa and the complex. 
 
 
In contrast to 4.1R10kDa, electrophoresis of EBA181945-1097 showed that the protein entered in the 
gel (theoretical iso-electric point of EBA181945-1097 = 4.20, 37 negatively-charged side chain 
residues for only 13 positively-charged, see Appendix B.3). The migration pattern showed a 
single band, reflecting the presence of a single species. Nevertheless, probably due to the 
disordered character and its very negatively charged property, the migration pattern of the band 
was smeared. 
Complex 
EBA181945-
1097 alone 
 
Third species  
 
EBA181945-1097 
alone 
 
4.1R10kDa 
alone 
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When 4.1R10kDa and EBA181945-1097 were in complex, the electrophoresis migration pattern was 
different. The result was also another smeary migration pattern, with the appearance of two new 
bands in addition to the ‘EBA181945-1097 alone’ band: one above it, and one which migrated 
further down, close to the end of the gel. This is evidence for a change in apparent charges upon 
binding of the two proteins. A further analysis of this first native gel electrophoresis permitted 
the migration band of the complex to be identified. Thus, since 4.1R10kDa alone (not in complex) 
is not charged at the pH used here, it might decrease the average negative charges carried by 
EBA181945-1097 when both proteins are in complex, and so slowing its migration in the gel. 
Moreover, the weight of the complex is expected to be higher than the individual proteins. This 
intrinsic property will also lead to a slower migration, and so to a higher band on the gel. Based 
on these assumptions, the higher migration band was assigned to the complex (Figure 3.23, lane 
‘complex’, band ‘complex’). In addition to the migration band of EBA181945-1097 alone, the third 
band showed the presence of a third species, which is hard to interpret. The migration is further 
along the gel, reflecting the presence of a small species, or an even more negatively charged than 
the EBA alone migration band.  
 
In order to cross-check these results, a further native gel electrophoresis experiment was 
performed. In this, the complex was loaded on a native gel at different times during a 6 hour 
migration (Figure 3.24). Here, the complex was carefully pre-formed in a tube at a 1 to 1 molar 
ratio. In this case and as shown by the native gel, the ‘EBA181945-1097 alone’ and ‘4.1R10kDa 
alone’ bands are almost invisible (Figure 3.24, lanes ‘complex’), showing that almost all the 
proteins are effectively in complex. The results are similar to the first native gel, showing the 
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appearance of a higher band upon binding of the two proteins; as another evidence of the 
formation of the EBA/4.1R complex. 
  
 
Figure 3.24: Native polyacrylamide gel of: EBA181945-1097 and 4.1R10kDa alone, migrated for 6 
hours (control); and the complex migrated for 0h, 1h, 3h, 4h and 6h. 
 
 
3.4.7 Protein quantification using SDS-PAGE  
Quantification of protein bands on SDS-PAGE was made to allow an estimation of the molar 
ratio of EBA181945-1097 and 4.1R10kDa in the protein complex.  
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Firstly, the staining power of Coomassie blue was measured on each of the tagged and untagged 
proteins (Figure 3.25) to give a baseline/calibration for the further analysis of gels run on the 
complex. For this, respectively 2 μg and 5 μg of EBA181945-1097, His-EBA181945-1097, 4.1R10kDa 
and GST-4.1R10kDa were loaded onto a SDS-PAGE and the luminosity of each band was 
measured with the following protocol. After scanning the gel (1200 dpi resolution TIFF file, 
Figure 3.25), the resulting image was colour inverted with Photoshop software. A box covering 
the biggest band (in this case lane GST-4.1R10kDa, 5 μg) was drawn using the Photoshop marquee 
tool. The same sized box was then used for all the other bands. Using the Photoshop histogram 
tool, the total luminosity was measured for each individual band. The background value was 
obtained in the same way, using the same sized box but on a ‘blank’ area of the gel containing no 
protein bands.  After this, for each individual luminosity value the corresponding background 
value was subtracted. It was decided to only keep the values from the 5 μg lanes (lane 
‘Luminosity’ in Tables 3.3, 3.4 and 3.5) since those from the 2 μg samples were weaker and at 
the limit of the Coomassie binding capacity. The GST-4.1R10kDa value was set to 1 as the 
reference; therefore all other protein values were divided by the GST-4.1R10kDa value (lane 
‘Ratio of luminosity normalised to GST-4.1R10kDa’ in Tables 3.3, 3.4 and 3.5). These divided 
values were then converted according to the ratio GST-4.1R10kDa / each protein weights, in order 
to have the molar ratio.  
 
The final results from the Coomassie staining quantification are listed in Table 3.3. Figures for 
4.1R10kDa could not be extracted since the protein was poorly stained. Thus GST-4.1R10kDa was 
used and analysed afterward. 
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Figure 3.25: Original SDS-PAGE gel used to quantify the Coomassie blue staining of tagged 
and untagged 4.1R10kDa and EBA181945-1097 proteins. Left: 2 μg of each protein. Right: 5 μg of 
each protein. 
 
 
Following this first calibration step, the same method was then applied to the pull-down gels (see 
Section 3.4.3.1 for the full size gels) in order to determine the molar ratio of the complex. Since 
SDS-PAGE gels of the eluted pull-down fractions displayed several bands for each protein, the 
only difference with the protocol previously described and used for calibration was the 
calculation of the ‘mean luminosity’ coming from each single band luminosity, by averaging 
each individual band value (and subtraction of the background). Since the 4.1R10kDa staining was 
not sufficient, it was chosen to only analyse the gels with tagged GST-4.1R10kDa. Both GST 
(Table 3.4) and NiNTA (Table 3.5) resins were used to cross-check the final result.  
GST-4.1R10kDa 
 
His-EBA181945-1097 
100 
 
 Calibration gel 
 
Protein GST-4.1R10kDa His-EBA181945-1097 EBA181945-1097 
Luminosity (Photoshop) 
5 μg 
96 61 35 
Ratio of luminosity 
(luminosity normalised to 
GST-4.1R10kDa) 
1 
(=96/96) 
0.64 
(=61/96) 
0.36 
(=35/96) 
Molar ratio 
(weight corrected to 
GST-4.1R10kDa) 
1 
(36 kDa) 
0.32 
(18 kDa) 
0.18 
(17 kDa) 
 
Table 3.3: Coomassie blue staining capability of His-EBA181945-1097, EBA181945-1097 and 
GST-4.1R10kDa from the calibration gel (5 μg). 
 
 
3.4.7.1  GST resin pull-down gels 
The first stoichiometry calculation was performed on the elution fractions coming from the GST 
resin pull-downs (Section 3.4.3.1; B1 and B2). 
 
The data in Table 3.4 were extracted from the pull-down gels in Figure 3.26. After measurement 
of the mean luminosity and subtraction of the background, each mean luminosity value was 
normalised to the GST-4.1R10kDa one (as previously described).  Finally, the stoichiometry is 
defined by applying the coefficients from the calibration gel.  
 
For both tagged and untagged EBA181945-1097 the final result was similar and gave a 
stoichiometry of close to 1 to 1 when binding to GST-4.1R10kDa.  
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Figure 3.26: SDS-PAGE from elution fractions from GST resin pull-down used to 
determine the 4.1R10kDa / EBA181945-1097 protein ratio when in complex.  
Left: GST-4.1R10kDa in complex with tagged His-EBA181945-1097. Right: GST-4.1R10kDa in 
complex with untagged EBA181945-1097. 
MW: Molecular weight markers. 
5 to 9: Elution fractions. 
 
 GST resin pull-down gels 
 
Protein GST-4.1R10kDa His-EBA181945-1097 EBA181945-1097 
Mean luminosity 81 29 16 
Ratio of luminosity 
 (luminosity normalised 
to GST-4.1R10kDa) 
1 
(=81/81) 
0.36 
(=29/81) 
0.20 
(=16/81) 
Stoichiometry 
(molar ratio calculated 
from calibration gel)  
 
1 : 1.12 
(0.32/0.36) 
1 : 1.06 
(0.18/0.20) 
 
Table 3.4: Luminosity and ratio calculation on the SDS-PAGE from GST resin pull-downs 
of the GST-4.1R10kDa / His-EBA181945-1097 complex and GST-4.1R10kDa / EBA181945-1097 
complex. 
5 
 
MW 
 
6 
 
7 
 
8 
 
6 
 
7 
 
8 
 
9 
 
MW 
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3.4.7.2  NiNTA resin pull-down gel 
The second and last stoichiometry calculation was performed on the elution fractions 
coming from the NiNTA resin pull-downs (Section 3.4.3.1; A2). 
 
 
 
Figure 3.27: SDS-PAGE from elution fractions from NiNTA resin pull-down used to 
determine the 4.1R10kDa / EBA181945-1097 protein ratio when in complex. Tagged 
His-EBA181945-1097 in complex with GST-4.1R10kDa. 
MW: Molecular weight markers. 5 to 9: Elution fractions. 
 
 NiNTA resin pull-down gel 
 
Protein 
 
GST-4.1R10kDa 
 
His-EBA181945-1097 
Mean luminosity 
 
122 
 
43 
Ratio of luminosity 
(luminosity normalised to GST-4.1R10kDa) 
1 0.35 
Stoichiometry 
(molar ratio calculated from calibration gel) 
 
1 : 1.1 
 
Table 3.5: Luminosity and ratio calculation on SDS-PAGE from NiNTA resin pull-downs of 
the His-EBA181945-1097 / GST-4.1R10kDa complex. 
6 
 
MW 
 
7 
 
8 
 
9 
 
 
5 
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The data in Table 3.5 were extracted from the pull-down gels in Figure 3.27. The final 
result was similar to the previous result using GST resin and gave a close to 1 to 1 
stoichiometry for the GST-4.1R10kDa and His-EBA181945-1097 binding. 
 
In combining both GST and NiNTA resin pull-downs, it was possible to determine that the 
interaction between EBA-181 and 4.1R has a 1 to 1 stoichiometry. 
 
This relative coarse method was the first attempt to determine the binding stoichiometry of 
untagged EBA-181 and 4.1R proteins and was used to complement the set of pull-down 
characterisation. This method is indirect and requires preliminary calibration steps, which 
could lead to loss of accuracy and accumulation of errors coming from the different 
measurements (errors coming from the initial pull-down experiments, the SDS-PAGE, the 
scan of the gels, the Photoshop software for measuring each different luminosity, the 
calibration process,…). In order to confirm this 1 to 1 binding stoichiometry, SEC-
MALLS-RI experiments were performed (see Section 3.5.5). 
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3.5 Biophysical characterisation of individual EBA181945-1097 and 
4.1R10kDa proteins and the complex 
 
3.5.1 Structural bioinformatics analysis 
Bioinformatics analysis is a powerful tool for the prediction and analysis of the structure of 
proteins and nucleic acids. The specific rules of protein folding are poorly understood, and 
thus bioinformatics predictions need to be interpreted with care. Nonetheless, as part of an 
attempt to provide additional information in the context of biochemical and biophysical 
results, and to provide insight for preparing effective constructs and crystallisation 
strategies, secondary structure and disorder predictions were performed for the two entire 
4.1R and EBA-181 proteins as-well-as for both the 4.1R10kDa and EBA181945-1097 expressed 
domains. Since it is difficult to estimate with certitude the quality of the predictions, it was 
thought important to deploy different bioinformatics approaches. 
 
Secondary structure predictions were carried out using the web-based PSIPRED and 
I-TASSER servers (Ambrish et al., 2010). PSIPRED gave an overview of the protein 
secondary structure, while I-TASSER provided models with tertiary structure. The 
I-TASSER server provides a confidence score for estimating the quality of predicted 
models called the C-score. The C-score is typically in the range of [-5, 2], with a C-score 
of higher value signifying a model with a high confidence. The I-TASSER server also 
calculates a ‘TM-score’ and RMSD of the predicted models by comparison to the native 
structures based on the C-score. The TM-score weights smaller RMSD pair distances 
greater than longer ones to avoid local structural differences in a small part of the 
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prediction from overly biasing a standard RMSD calculation. A TM-score > 0.5 indicates a 
model of correct topology and a TM-score < 0.17 means a random similarity. 
 
In addition to the structural predictions, disorder predictions were carried out for the 
proteins, using the two web-based server programs DISOPRED (Ward et al., 2004) and 
IUPRED (Dosztányi et al, 2005). Linked to IUPRED, potential binding sequence in the 
disordered regions were mapped with the ANCHOR prediction server program. Since 
various disordered proteins function via binding to a structured partner and undergo a 
disorder-to-order transition, the ANCHOR server predicts disordered domains which 
cannot form enough favourable intra-chain interactions to fold on their own but can be 
stabilised to a more ordered structure by interacting with a globular protein partner. 
 
This section is divided into four parts:  
  Modelling of full-length EBA-181. 
  Modelling of the EBA181945-1097 domain. 
  Modelling of full-length 4.1R. 
  Modelling of the 4.1R10kDa domain. 
 
Each of these parts is then subdivided into (1) the results of the secondary and tertiary 
structure prediction results from PSIPRED and I-TASSER, and (2) the disorder predictions 
from DISOPRED, IUPRED and potential binding sequences from ANCHOR. 
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3.5.1.1  Secondary structure and disorder predictions of full-length EBA-181 
According to PSIPRED and I-TASSER, the EBA-181 protein seems from a structural 
point of view to be clearly divided into three well-defined domains. The secondary 
structure map of full-length EBA-181 by PSIPRED is presented in Figure 3.29 and the 
overall three-dimensional structure prediction of I-TASSER is shown in Figure 3.30. 
 
The first half of the sequence from the N-terminus to approximately residue 900 is 
predicted to be structurally folded. This prediction is largely based on the existing crystal 
structure of the homologue EBA-175 RII domain (see Section 2.1.1) which is composed of 
only alpha-helices (Figure 3.29, residues in pink colour). This domain contains the signal 
peptide required for correct microneme trafficking as well as the two F1 and F2 Duffy 
binding-like (DBL) domains (Figure 3.28), known to play a crucial role in the binding of 
merozoites to the host cell and in defining erythrocyte specificity.  
 
Following this structured domain, the second domain is predicted to be disordered, 
spanning approximately residues 900 to 1350, as shown in Figure 3.29. This part includes 
the 4.1R10kDa binding sequence (971-1001). 
 
Finally, the C-terminus is predicted to be largely folded as alpha-helices. The C-terminus 
end is known to host the cysteine-rich motif essential for correct microneme trafficking 
and a transmembrane domain (Figure 3.28); this could explain the required fold of the 
C-terminus region. 
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Figure 3.28: Schematic of the domain organisation of the full-length P.falciparum invasion 
EBA-181 protein (accession number: PFA0125c). 
 
 
Figure 3.29: Secondary structure map of full-length EBA-181 given by PSIPRED 
web-based server. 
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Figure 3.30: The highest scoring predicted 3D model of the full-length EBA-181 protein 
using the I-TASSER server. Estimated accuracy: C-score= -1.23, TM-score= 0.56 ± 0.15 
and RMSD= 13.0 ± 4.2Å. The corresponding EBA181945-1097 domain is circled in black. 
 
 
DISOPRED and IUPRED were used to study the likelihood of disorder of EBA-181.  
According to the disorder prediction shown in Figures 3.31 and 3.32, the EBA-181 protein 
shows two principal regions. The N-terminus part to around residue 650/700 is predicted as 
being ordered, the subsequent 250 residues becomes less ordered, and from roughly 
residue 900 to almost the end of the sequence, it becomes disordered once again. The 
EBA181945-1097 domain is located in this latter region. The ANCHOR server predicts the 
disordered regions which might fold and thus interact with a globular partner, as also 
shown in Figure 3.32. Interestingly, despite its disordered nature, the EBA181945-1097 
domain is predicted as being a putative binding region. 
EBA181945-1097 
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Figure 3.31: Disorder prediction of the full-length EBA-181 protein by DISOPRED server. 
The stippled line represents the disorder threshold to distinguish between ordered and 
disordered regions set by the program to 0.05. 
 
Figure 3.32: Disorder prediction of the full-length EBA-181 protein by IUPRED server and 
binding regions prediction using ANCHOR. The stippled line represents the disorder 
threshold set to 0.5 by the program. 
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3.5.1.2  Secondary structure and disorder predictions of EBA181945-1097 
According to the PSIPRED and I-TASSER secondary structure predictions, the 
EBA181945-1097 domain is predicted as being mainly disordered, but with some residual 
alpha-helices (residues in pink, Figure 3.33 for the PSIPRED server; Figure 3.34 for the 
I-TASSER prediction). In Figure 3.33 it is possible to have some doubt about the actual 
existence of the first helix with only four residues. Nevertheless, the predictions result in 
the fact that EBA181945-1097 is probably globally very weakly structured.  
 
 
 
 
Figure 3.33: Secondary structure map of the EBA181945-1097 domain given by the 
PSIPRED web-based server. 
 
 
Figure 3.34: The highest scoring predicted 3D model of the EBA181945-1097 domain using 
the I-TASSER server. Estimated accuracy: C-score= -3.95. 
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The DISOPRED and IUPRED disorder prediction servers gave a very clear result about 
the disordered state of EBA181945-1097 (Figure 3.35 and Figure 3.36), with the disorder 
tendency over the threshold for the whole sequence. Nevertheless, in the DISOPRED 
prediction, the probability fluctuations and in particular the four fragments with a disorder 
tendency close to the threshold could mean the presence of few residual structures 
(Figure 3.35). It is clearer in the IUPRED prediction where the disorder tendency is almost 
equal to 1 all along the sequence. Here there is no probability fluctuation as seen with the 
DISOPRED server and therefore no secondary structure predicted in the EBA181945-1097 
domain (Figure 3.36). The ANCHOR server predicts four disordered regions to interact 
with partners, as shown in Figure 3.36 and table 3.6; with almost the whole EBA181945-1097 
domain being predicted as a putative binding region. Moreover, the 4.1R10kDa binding 
region located between the residue 34 and 63 is situated in one of these predicted binding 
regions.  
 
 
 
Figure 3.35: Disorder prediction of the EBA181945-1097 domain by DISOPRED server. The 
stippled line represents the disorder threshold (equal to 0.05). 
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Figure 3.36: Disorder prediction of the EBA181945-1097 domain by IUPRED server and 
binding regions prediction using ANCHOR. The stippled line represents the disorder 
threshold (equal to 0.5). The binding region to 4.1R10kDa is represented by the blue box. 
 
 
 
 
 
 
 
 
 
Table 3.6: Predicted disordered binding regions of the EBA181945-1097 domain by 
ANCHOR server. 
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3.5.1.3  Secondary structure and disorder predictions of full-length 4.1R 
According to the secondary structure prediction servers PSIPRED and I-TASSER 
(respectively Figures 3.38 and 3.39), the full-length 4.1R protein is folded for the first half 
of its sequence from its N-terminus part until roughly residue 310 (corresponding to the 
30 kDa domain, see Figure 3.37, alpha helices and beta sheets based on the available X-ray 
structure, see Section 2.1.2). Then, the sequence becomes predicted as being mainly 
disordered, from residue 310 to 500 (corresponding to both the 16 kDa and the 10 kDa 
domains). As a reminder, the 4.1R10kDa domain includes residues from 404 to 471. In the 
I-TASSER prediction, it can be noticed that 4.1R10kDa is envisaged to have some residual 
alpha helices. Finally, the C-terminus part of the sequence is predicted as being folded 
again, with alpha helices and beta sheets. This region corresponds to the C-terminus 
22 kDa domain. 
 
 
 
 
 
Figure 3.37: Schematic of the domain organisation of the full-length 80 kDa 4.1R protein. 
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Figure 3.38: Secondary structure map of the full-length 4.1R protein given by PSIPRED 
server. 
 
 
 
 
Figure 3.39: The highest scoring predicted 3D model of the full-length 4.1R protein using 
the I-TASSER server. Estimated accuracy: C-score= -0.86, TM-score= 0.61 ± 0.14 Å and 
RMSD= 9.7 ± 4.2 Å. The corresponding 4.1R10kDa domain is encircled in black colour. 
 
 
4.1R10kDa 
4.1R10kDa 
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The DISOPRED and IUPRED disorder prediction servers (respectively Figures 3.40 and 
4.41) gave a very clear result about the folded state of the N-terminus 30 kDa domain of 
full-length 4.1R, since the X-ray structure of this domain is really compact. From roughly 
the residue 300 and so the 16 kDa domain, the disorder prediction rose and is above the 
0.05 threshold until the C-terminus end. Thus, the three 16 kDa, 10 kDa and 22 kDa 
domains are here predicted as being unfolded. Nevertheless, the presence of several 
oscillations of the disorder tendency and its range around the threshold for some regions 
might suggest the presence of residual secondary structures. This is particularly true for the 
IUPRED prediction of the 4.1R10kDa domain showed to be unfolded but with a disorder 
probability rather close to the threshold which might also suggest the possible presence of 
secondary structures. The ANCHOR server predicts seven disorder regions to interact with 
partners, as shown in Figure 3.41 and table 3.7. Three of these seven predicted binding 
regions are located in the 4.1R10kDa domain.  
 
 
Figure 3.40: Disorder prediction of the full-length 4.1R protein by DISOPRED server. The 
stippled line represents the disorder threshold (equal to 0.05). 
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Figure 3.41: Disorder prediction of the full-length 4.1R protein by IUPRED server and 
binding regions prediction using ANCHOR. The stippled line represents the disorder 
threshold (equal to 0.5). The 4.1R10kDa domain binding to EBA181945-1097 is represented by 
the blue box. 
 
 
 
 
 
 
 
 
 
Table 3.7: Predicted disordered binding regions of the full-length 4.1R protein by 
ANCHOR server. 
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3.5.1.4  Secondary structure and disorder predictions of 4.1R10kDa 
The PSIPRED and I-TASSER servers (Figures 3.42 and 3.43) predicts 4.1R10kDa to have 
three dominant alpha-helix domains, separated by coiled regions. In addition, the 
PSIPRED server predicted five residues to be in a beta sheet conformation. 
  
 
 
 
Figure 3.42: Secondary structure map of the 4.1R10kDa domain given by PSIPRED server. 
 
 
 
 
Figure 3.43: The highest scoring predicted 3D model of the 4.1R10kDa domain using the 
I-TASSER server. Estimated accuracy: C-score= -2.99, TM-score= 0.38 ± 0.13 Å and 
RMSD= 9.6 ± 4.6 Å. 
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The DISOPRED and IUPRED servers (Figures 3.44 and 3.45) predicted 4.1R10kDa to be 
disordered but with a disorder tendency around the threshold. This might mean that the 
domain is not fully disordered and might have some structure. Nevertheless, in the 
DISOPRED prediction, the disorder tendency for the N-terminus and the C-terminus ends, 
with respectively the 10 first and the last 5 amino acids is really high and might signify that 
these regions are clearly disordered. In conclusion and from these two disorder prediction 
servers, 4.1R10kDa is neither totally unfolded nor fully ordered; and the protein could for 
example be very flexible. Finally, the ANCHOR server (Figure 3.45 and Table 3.12) 
predicts two putative binding sites, respectively from residues 12 to 22, and 37 to 46, 
corresponding to the two folded and helical domains predicted by DISOPRED and 
I-TASSER. 
 
 
 
Figure 3.44: Disorder prediction of the 4.1R10kDa domain by DISOPRED server. The 
stippled line represents the disorder threshold (equal to 0.05). 
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Figure 3.45: Disorder prediction of the 4.1R10kDa domain by IUPRED server and binding 
regions prediction using ANCHOR. The stippled line represents the disorder threshold 
(equal to 0.5). 
 
Predicted disordered binding regions 
 
From To Length 
1 12 22 11 
2 37 46 10 
     
Table 3.12: Predicted disordered binding regions of the 4.1R10kDa domain by ANCHOR 
server. 
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3.5.2 1D NMR assessment of EBA181945-1097, 4.1R10kDa and the complex  
One dimensional NMR (1D NMR) was carried out to check the conformational state of the 
two individual untagged proteins and of the complex. 200 μl of protein was used at a 
minimum concentration of 100 μM on a 600 MHz NMR spectrometer equipped with a 
cryo-probe. 10 % of D2O was added to the sample in order to allow the calibration of the 
magnetic field. Experiments were finally carried out at different temperatures, from 4°C to 
40°C. 
 
3.5.2.1  Protein EBA181945-1097 
In contrast to folded proteins that show a very broad spectrum and signals above 8.5 ppm 
and below 0.5 ppm, no signal could be seen in this folded region. This indicates that 
EBA181945-1097 is unfolded at 5°C, 25°C and 40°C (Figure 3.46).  
 
Figure 3.46: 1H-NMR experiments on EBA181945-1097. Temperatures: 5°C (red curve), 
25°C (blue curve) and 40°C (green curve). 
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3.5.2.2  Protein 4.1R10kDa 
Similarly, the 
1
H-NMR spectrum of 4.1R10kDa (Figure 3.47) showed no signal in the 
chemical shift ranges of structured region. However, in contrast to EBA181945-1097 more 
intense and sharper signals were observed around 7 p.p.m. These signals are attributable to 
phenylalanine and would indicate a mobility of side chains compared to the protein 
backbone. Thus, it is possible that amide protons from the backbone were in an exchange 
state and so invisible to NMR. Therefore aromatic signals appear more intense because of 
the loss of the N-H signals from the backbone. Another possibility is the combination of 
the phenomenon explained earlier with the low compactness/fold of the protein. It was 
impossible to conclude with certitude the degree of folding of 4.1R10kDa, it was therefore 
decided to continue the studies using other techniques. 
 
 
 
 
Figure 3.47: 1H-NMR experiment on 4.1R10kDa at 4°C. 
  
122 
 
3.5.2.3  EBA181945-1097 / 4.1R10kDa protein complex 
In order to check for conformational changes when the two EBA181945-1097 and 4.1R10kDa 
proteins are in complex, 
1
H-NMR experiments were also carried out on the complex. 
However, no signal is observed in the folded region of the NMR spectra when 4.1R10kDa 
and EBA181945-1097 are in complex (Figure 3.48). This suggests that there is not a 
significant change in folding state of the proteins upon binding. 
 
 
 
 
 
Figure 3.48: 1H-NMR experiment on the 4.1R10kDa / EBA181945-1097 complex at 4°C. 
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3.5.3 Circular dichroism (CD) measurements 
After cleavage of their respective tags, both protein domains were analysed using circular 
dichroism. Circular dichroism measurements were carried out by recording a spectrum in 
far UV (from 190 to 260 nm). Each experiment was recorded three times at both 4°C and 
20°C. The blank sample was made with dialysis buffer of each individual protein.  
 
 
3.5.3.1 Protein EBA181945-1097       
Circular dichroism measurements on EBA181945-1097 (Figure 3.49) show a slightly dipped 
plateau between 250 nm and 215 nm and only one minimum around 200-205 nm. This 
curve is interpretable as a curve typical of random coil conformation and disordered 
protein (Figure 3.49, blue calculated curve as estimation of secondary structures from the 
experimental curve), implying that EBA181945-1097 is in an unfolded state. 
 
 
  
124 
 
           
 
Figure 3.49: Comparison between experimental curve and estimated content in 
secondary structure (calculated curve) using the far-UV CD spectrum of EBA181945-1097. 
Green curve: experimental curve. 
Blue curve: calculated curve used to determine the secondary structure content. 
Red curve: residual curve after subtraction of experimental and calculated curves.  
 
 
3.5.3.2  Protein 4.1R10kDa 
In contrast to the circular dichroism spectra of EBA181945-1097, the same experiment 
performed on 4.1R10kDa (Figure 3.50) shows two very specific minima at 208 nm and 
222 nm. This curve is typical of alpha-helix content in molecules. Modelling by the 
JASCO software Spectra Manager II (Figure 3.50, blue calculated curve) estimated 
4.1R10kDa to be composed of 35 % of alpha helices, 20 % of turn and 45 % of random coil. 
 
Experimental 
Calculated 
Residue 
  
125 
 
         
 
Figure 3.50: Comparison between experimental curve and estimated content in 
secondary structure (calculated curve) using the far-UV CD spectrum of 4.1R10kDa. 
Green curve: experimental curve. 
Blue curve: calculated curve used to determine the secondary structure content. 
Red curve: residual curve after subtraction of experimental and calculated curves.  
 
 
3.5.4 Thermal shift assay (TSA) measurements 
Thermal shift assays were carried out to obtain stability information on both proteins and 
in particular to define the best buffer conditions for protein purification and storage. Each 
assay experiment was replicated three times. The assays were realised in 96 well plates 
Experimental 
Calculated 
Residue 
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(Stratagene) using a pre-defined range of 48 buffers with pH varying from 5.0 to 9.0, and 
with two different concentrations of salt (100 and 500 mM NaCl). 
 
3.5.4.1  Protein EBA181945-1097 
From the assay result performed on EBA181945-1097, it was impossible to determine the Tm 
for any of the buffer and salt conditions for EBA181945-1097. There was no significant shift 
of the fluorescence of the probe whilst increasing the temperature, meaning that the protein 
was already unfolded at 25°C (Figure 3.51). The fluorescence shifts only when the probe 
binds in exposed hydrophobic regions following the protein melting. 
 
Moreover, the measured fluorescence started at very high levels (between 10 000 and 
40 000 depending the buffers) even at 25°C, meaning that the probe was already bound to 
hydrophobic regions even at low temperatures. 
 
Even if the results of the TSA on EBA181945-1097 did not permit the best buffer conditions 
to be defined for protein stability, the absence of a hydrophobic core is further evidence for 
the unfolded nature of the protein.  
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Figure 3.51: Thermal shift assay on EBA181945-1097 from pH 5.0 to pH 9.0. Left: 
experiment at 100 mM NaCl. Right: experiment at 500 mM NaCl. 
 
 
3.5.4.2  Protein 4.1R10kDa 
For 4.1R10kDa protein, the highest Tm was determined to be 57°C at pH=6.0 and 100 mM 
NaCl concentration (Figure 3.52, left, orange curve). Nevertheless, the TSA results had 
similar overall fluorescence behaviour to EBA181945-1097: a high starting fluorescence point 
and no shift of the probe fluorescence with increasing the temperature. These results meant 
that the protein was at least partially unfolded or very flexible. 
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Figure 3.52: Thermal shift assay on 4.1R10kDa from pH 5.0 to pH 9.0. Left: experiment at 
100 mM NaCl. Right: experiment at 500 mM NaCl. 
 
 
3.5.4.3  Protein GST-4.1R10kDa 
For GST-4.1R10kDa protein, a clear Tm was obtained, demonstrating protein folding (most 
likely due to the GST tag). The highest Tm was determined to be 53°C between pH 7.0 and 
8.5, and 100 mM NaCl concentration (Figure 3.53, left).  
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Figure 3.53: Thermal shift assay on GST-4.1R10kDa from pH 5.0 to pH 9.0. Left: 
experiment at 100 mM NaCl. Right: experiment at 500 mM NaCl. 
 
 
3.5.5 Multi-angle laser light scattering coupled to size exclusion 
chromatography and refractive index (SEC-MALLS-RI) for determination 
of oligomeric state and molar mass calculation 
 
SEC-MALLS-RI experiments were performed to analyse the oligomeric state of each 
individual protein in solution and to check the molarity of the complex. The column and 
device were equilibrated overnight in the corresponding dialysis buffer at a flow of 
0.5 ml/min, and 50 µl of each purified and concentrated protein were then injected. Finally 
the data were analysed using the ASTRA software (WYATT Technology). 
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3.5.5.1  Protein EBA181945-1097 
According to the SEC-MALLS-RI data (Figures 3.54 and 3.55), EBA181945-1097 is 
monomeric in solution, with a measured size of 17.4 kDa ± 3 % (0.5 kDa), which 
corresponds to the expected size of 17 kDa given by the amino-acid sequence. 
 
 
 
Figure 3.54: SEC-MALLS-RI analysis of EBA181945-1097 using a size-exclusion 
chromatography SuperdexTM 200 column. 
 
0,00E+00
1,00E-05
2,00E-05
3,00E-05
4,00E-05
5,00E-05
6,00E-05
7,00E-05
10 12 14 16 18
D
if
fe
r
en
ti
a
l 
r
ef
ra
ct
iv
e 
in
d
ex
 (
R
IU
) 
Volume (ml) 
7  e
-5
 
6  e
-5
 
5  e
-5
 
4  e
-5
 
3  e
-5
 
2  e
-5
 
1  e
-5
 
0 
  
131 
 
 
 
 
Figure 3.55: Molar mass calculation using the SEC-MALLS-RI analysis of EBA181945-1097. 
 
 
3.5.5.2  Protein 4.1R10kDa 
Regarding its relative small size, two different size-chromatography columns were used to 
analyse the 4.1R10kDa protein by MALLS (Superdex
TM
 200 and Superdex
TM
 75 columns). 
 
According to the MALLS result using the S200 column (Figure 3.56 and Figure 3.57), 
4.1R10kDa is monomeric in solution, with a measured size of 10.8 kDa ± 36 % (3.9 kDa), 
which corresponds to the expected size of 8.5 kDa, given by the amino-acid sequence. 
Nevertheless, the accuracy of the measure was low. This result could be caused by the 
S200 size-exclusion chromatography resolution which was not sufficient for a low 
molecular weight protein.  
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Figure 3.56: SEC-MALLS-RI analysis of 4.1R10kDa on the size-exclusion chromatography 
SuperdexTM 200 column.  
 
 
 
 
 
Figure 3.57: Molar mass calculation using the SEC-MALLS-RI analysis of 4.1R10kDa on 
the S200 column. 
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Regarding the high error range given by the S200 size-exclusion column, it was decided to 
use a S75 column to cross-check and improve the previous MALLS result. Using the S75 
size-exclusion chromatography column, it was possible to improve the quality of the 
results (Figure 3.58) and thus, the accuracy of the measured size was higher (Figure 3.59).  
The resulting data also showed 4.1R10kDa to be a monomer in solution, with a measured 
size of 8.8 kDa ± 9% (0.8 kDa). 
 
 
 
 
 
Figure 3.58: SEC-MALLS-RI analysis of 4.1R10kDa on the size-exclusion chromatography 
SuperdexTM 75 column.  
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Figure 3.59: Molar mass calculation using the SEC-MALLS-RI analysis of 4.1R10kDa on 
the S75 column. 
 
 
3.5.5.3  EBA181945-1097 / 4.1R10kDa protein complex 
Using the SEC-MALLS-RI method it was possible to determine the molarity of the 
EBA181945-1097 / 4.1R10kDa complex (Figure 3.60). The measured size was equal to 24 kDa 
± 0.9 % (0.2 kDa). The theoretical sizes of EBA181945-1097 and 4.1R10kDa are respectively 
17 kDa and 8.5 kDa for a complex of 24.5 kDa, close to the resulting weight from the 
SEC-MALLS-RI and indicating a 1:1 molar ratio in the complex. 
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Figure 3.60: SEC-MALLS-RI analysis of the EBA181945-1097 / 4.1R10kDa complex on TSKgel 
G3000SWxl size-exclusion chromatography column. Green: refractometry. 
 
 
3.5.6 Dynamic light scattering (DLS) measurements 
Dynamic light scattering was used to check the quality of the samples after the final step of 
purification and to determine the hydrodynamic radius (Rh) of 4.1R10kDa and 
EBA181945-1097 (see Figure 3.61). Dynamic light scattering measurements were performed 
on 25 to 45 µl of protein sample in a concentration range between 0.5 and 5 mg/ml in a 
three windows quartz cuvette (Hellma) on a Zetasizer (Malvern) device set at 4°C. In order 
to characterise the effect of buffer composition and pH on their respective sizes, further 
DLS hydrodynamic radius measurements were carried out on the two proteins purified in 
four different buffers: Tris pH 8.0, PBS pH 7.4, sodium phosphate pH 7.0 and sodium 
phosphate  pH 6.0 (Figures 3.61, 3.62 and 3.63; buffer compositions shown in 
Appendix A.2). 
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3.5.6.1  Protein EBA181945-1097  
The hydrodynamic radius of EBA181945-1097 was measured for each of the four pH 
conditions (Figure 3.61) with the smallest Rh equal to 2.95 nm at pH=6.0. The results were 
similar for the tagged His-EBA181945-1097 construct (data not shown). This experiment 
defined the best condition (buffer/pH) for EBA181945-1097: sodium phosphate (NaP) buffer 
at pH 6.0; and gave its physical size (Rh) of 2.95 nm. 
 
Tris pH=8.0: 
 
Rh = 3.4 nm 
 
Sodium phosphate pH=7.0: 
 
Rh = 3.5 nm 
PBS pH=7.4: 
 
Rh = 3.2 nm 
 
Sodium phosphate pH=6.0: 
 
Rh = 2.95 nm 
 
Figure 3.61: DLS measurements of hydrodynamic radius (Rh) of EBA181945-1097 in four 
different pH buffers (Tris pH=8.0, PBS pH=7.4, sodium phosphate pH=7.0 and sodium 
phosphate pH=6.0). The smallest Rh is underlined. 
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3.5.6.2  Protein 4.1R10kDa 
Hydrodynamic radius of 4.1R10kDa was measured for each of the four pH conditions 
(Figure 3.62) with the minimum Rh equal to 2.0 nm at pH=6.0. This experiment defined the 
best buffer/pH for 4.1R10kDa: sodium phosphate buffer at pH 6.0; and gave its physical size 
(Rh) of 2.0 nm. 
 
Tris pH=8.0: 
 
Rh = 2.5 nm 
 
PBS pH=7.4: 
 
Rh = 3.9 nm 
 
 
Sodium phosphate pH=7.0: 
 
Rh = 3.9 nm 
 
Sodium phosphate pH=6.0: 
 
Rh = 2.0 nm
 
 
Figure 3.62: DLS measurements of hydrodynamic radius (Rh) of 4.1R10kDa in four different 
pH buffers (Tris pH=8.0, PBS pH=7.4, sodium phosphate pH=7.0 and sodium phosphate 
pH=6.0). The smallest Rh is underlined. 
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3.5.6.3  EBA181945-1097 / 4.1R10kDa  protein complex 
The hydrodynamic radius of the complex was measured for three pH conditions 
(Figure 3.63) with the best (minimum) Rh equal to 4.4 nm at pH=6. In addition to defining 
the best buffer/pH for the complex (sodium phosphate buffer at pH 6.0) and the calculation 
of its physical size (Rh=4.4 nm), the DLS measurement added evidence for the complex 
interaction by showing an increase of the observed size over the individual proteins. 
 
Tris pH=8.0: 
 
Rh = 4.6 nm 
 
PBS pH=7.4: 
 
Rh = 4.9 nm  
+ 18.5 nm (slight aggregation) 
 
Sodium phosphate pH=6.0: 
 
Rh = 4.4 nm 
 
Figure 3.63: DLS measurements of hydrodynamic radius (Rh) of the complex formed 
between EBA181945-1097 and 4.1R10kDa in three different pH buffers (Tris pH=8.0, 
PBS pH=7.4 and NaP pH=6.0). The smallest Rh is underlined. 
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These different Rh measurements from the DLS experiments (Tables 3.13) could also 
provide additional information when compared to the Rh of globular proteins, so called 
Rmin (Table 3.14). Rmin is therefore the minimal radius of a sphere that could contain the 
given mass of protein. With an Rh of 2.0 nm, 4.1R10kDa and its 10 kDa size (calculated from 
amino acid composition) is comparable to a globular protein of at least 30 kDa. This shows 
that 4.1R10kDa is neither globular nor even compact. EBA181945-1097 has a Rh equal to 
2.95 nm and is therefore comparable to a globular protein of approximately 90 kDa. 
Regarding its size of 18 kDa, this shows that EBA181945-1097 is very likely to be unfolded. 
The same behaviour is noticeable with the complex between EBA181945-1097 and 4.1R10kDa, 
and its Rh of 4.4 nm. This would be the size of a 350 kDa globular protein, thus showing 
the disordered/unfolded character of this complex. 
 
 
  4.1R10kDa EBA181945-1097 
 
Complex 
Rh 
 
2.0 nm 
Sodium phosphate 
pH=6.0 
 
 
2.95 nm 
Sodium phosphate 
pH=6.0 
 
 
 
4.4 nm 
Sodium phosphate 
pH=6.0 
 
 
Table 3.13: Summary of the smallest hydrodynamic radius measured by DLS 
for EBA181945-1097, 4.1R10kDa and the complex. 
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Table 3.14: Comparison of the hydrodynamic radius measured by DLS of EBA181945-1097, 
4.1R10kDa, and the complex to Rmin and corresponding weights (from Erickson, 2009). 
 
 
3.5.7 Isothermal titration calorimetry (ITC) studies of the complex 
ITC was used to characterise the thermodynamics of the complex formation. For these ITC 
measurements, tagged GST-4.1R10kDa and untagged EBA181945-1097 were used. The 
reservoir of the ITC machine used has a minimum volume of 2 ml and was filled with 
GST-4.1R10kDa protein concentrated at 2 mg/ml. Regarding the amount of material needed 
to fill the reservoir, it was not possible to use untagged 4.1R10kDa protein (since its 
production yield is very low). The EBA181945-1097 partner concentrated at 40 mg/ml was 
injected through a syringe filled with 300 μl. Both proteins were in phosphate buffered 
saline. 
 
Prior to the ITC on the complex, three negative controls were performed (curves not 
shown): PBS buffer injected in PBS buffer, PBS buffer injected in GST-4.1R10kDa and 
EBA181945-1097 
4.1R10kDa 
 
Complex 
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EBA181945-1097 injected in the PBS buffer. For all three controls, as would be expected 
with no interaction (i.e no heat released) between the reservoir and injected solutions, the 
calorimetry curve stayed flat.  
 
Unfortunately, it was not possible to obtain an interpretable ITC curve for the complex 
formation from any of the subsequent tests performed. Aggregation of GST-4.1R10kDa in 
the reservoir was noticed (Figure 3.64), even in varying the temperature from 4°C to 40°C 
or using different concentration of both proteins. This behaviour masked any changes of 
heat during the titration of GST-4.1R10kDa with EBA181945-1097. It was therefore decided to 
use another method, micro-scale thermophoresis, to define the Kd of the interaction 
between the two proteins. 
 
 
 
Figure 3.64: Unintrepretable ITC measurement recorded by titration of GST-4.1R10kDa with 
EBA181945-1097. 
0 100 200 300   -20 
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3.5.8 Micro-scale thermophoresis (MST) studies of the complex 
Since the ITC failed, micro-scale thermophoresis was used in order to determine the Kd of 
the complex between EBA181945-1097 and 4.1R10kDa. In contrast to ITC, the amount of 
material required for MST is low; it was therefore possible to use untagged 4.1R10kDa. 
Moreover, since the GST-tag is cleaved, the Kd obtained could be considered to be more 
relevant. 
 
The Monolith NT
TM
 Protein Labelling Kit RED-NHS from NanoTemper Technologies was 
used to label the EBA181945-1097 protein, and 4.1R10kDa was kept as the non-labelled 
partner. The NT-647-NHS reactive dye contains N-hydroxysuccinimide esters and forms 
highly stable crosslinks with proteins by reacting with protein primary amines. Thus since 
buffers that contain primary amines (Tris buffer for example) would significantly reduce 
protein labelling, a first step of buffer exchange was required using the labelling buffer 
from the kit. In a second step, the solid NT-647-HNS fluorescent dye was solubilised using 
DMSO, mixed with the EBA181945-1097 protein in a 1 to 1 molar ratio and incubated for 
30 minutes in the dark. The main interest of this kit comes from the optimisation for 
elimination of unreacted free dye. To achieve this, the last step was the purification of the 
dye using a small desalting column equilibrated in the buffer chosen for the MST analysis 
(50 mM sodium phosphate pH 6.0, 50 mM NaCl and 5 mM βME). Finally, the ratio 
protein to dye was checked (both were approximately equal to 10 μM) and aliquots of 
labelled EBA181945-1097 were kept at -80°C. 
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To prepare the MST experiment, the concentration of EBA181945-1097 was kept constant 
(2 μM) while its partner 4.1R10kDa was diluted 16 times (from 100 μM to 2 nM) by serial 
dilution assay method. 10 μl of each diluted 4.1R10kDa was mixed with 10 μl of labelled 
EBA181945-1097 for a total of 16 capillaries. The experiment was carried out in triplicate at 
room temperature on the NanoTemper Monolith NT.115 Instrument and finally gave a Kd 
close to 0.3 μM (Figure 3.65). 
 
 
 
Figure 3.65: MST measurement of 4.1R10kDa with labelled EBA181945-1097. 
 
 
3.5.9 Crystallisation trials 
As a matter of course, crystallisation trials were carried out on all of the protein systems 
studied in this thesis work. These included both the 4.1R10kDa and EBA181945-1097 proteins 
with and without their respective tags. Complexes between 4.1R10kDa and EBA181945-1097, 
and between GST-4.1R10kDa and the Pf30 peptide were also submitted to crystallisation 
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trials. The high-throughput crystallisation robot from the ‘High Throughput Crystallisation 
Platform’ of the EMBL was used, and manual crystallisation attempts were also carried out. 
Unfortunately these trials were unsuccessful.   
 
3.5.9.1  Pre-crystallisation 
The ‘PCT Pre-Crystallisation Test kit’ (Hampton Research) was used in order to establish 
the protein concentration range suitable for first crystallisation screenings. The results were 
5 mg/ml for 4.1R10kDa and 20 mg/ml for EBA181945-1097. 
 
3.5.9.2  High-throughput and manual screenings 
Screening for initial crystallisation was initially made with the use of the EMBL High 
Throughput Crystallisation robot. Sitting drop vapour diffusion at 4°C was made across 576 
different standard conditions of various buffers, pH, salts and precipitants. Then, manual 
drops (gradients pH vs precipitant concentration) were set according to the best conditions 
from the crystallisation robot. The following trials were performed: 
 
Individual proteins: 
For His-EBA181945-1097 and EBA181945-1097, crystallisation attempts were carried out at 
protein concentrations of 20 mg/ml, 50 mg/ml and 90 mg/ml (the protein solubility limit of 
the protein). 
 
For the GST-4.1R10kDa construct, trials were carried out using a variety of buffer 
conditions, with protein concentrations of 4 mg/ml and 8 mg/ml (solubility limit). Some 
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crystals were obtained using Tris and HEPES buffer conditions, but diffraction tests at the 
ESRF showed them to be salt. For the 4.1R10kDa domain, crystallisation trials were also 
performed, using two concentrations: 2.5 mg/ml and 5 mg/ml (solubility limit). 
 
Construct Protein concentration 
His-EBA181945-1097 
 20 mg/ml 
 50 mg/ml 
 90 mg/ml (solubility limit) 
EBA181945-1097 
 20 mg/ml 
 50 mg/ml 
 90 mg/ml (solubility limit) 
GST-4.1R10kDa 
 4 mg/ml 
 8 mg/ml (solubility limit) 
4.1R10kDa 
 2.5 mg/ml 
 5 mg/ml (solubility limit) 
 
Table 3.15: Crystallisation trials of the individual tagged or untagged EBA181945-1097 and 
4.1R10kDa proteins. 
 
 
Complex: 
Crystallisation trials of various forms of the complex were also carried out: 
EBA181945-1097 / 4.1R10kDa (at 3 mg/ml and 4.5 mg/ml, the latter being the solubility limit) 
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and EBA181945-1097 / GST-4.1R10kDa (at 3 mg/ml, 5 mg/ml, 7 mg/ml).  No crystals were 
observed. 
 
For Pf30 / GST-4.1R10kDa crystallisation trials at 4 mg/ml and 8 mg/ml were carried out. 
(8 mg/ml was the solubility limit of the protein). Crystals were obtained from the 8 mg/ml 
trial of the Pf30 / GST-4.1R10kDa system in a variety of conditions (phosphate buffer and 
HEPES buffers). The crystals were reproduced by manual screening but X-ray diffraction 
tests at ESRF also showed them to be salt crystals. 
 
 
Construct Protein concentration 
EBA181945-1097 / 4.1R10kDa 
 3 mg/ml 
 4.5 mg/ml (solubility limit) 
EBA181945-1097 / GST-4.1R10kDa 
 3 mg/ml 
 5 mg/ml 
 7 mg/ml 
Pf30 / GST-4.1R10kDa 
 4 mg/ml 
 8 mg/ml (solubility limit) 
 
Table 3.16: Crystallisation trials of the EBA181945-1097 / 4.1R10kDa complex. 
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3.6 Discussion and conclusions 
 
The EBA-181 protein sequence from the residue 945 to the residue 1097 and 
encompassing the binding region to the 4.1R protein was expressed, purified and 
intensively studied using biophysical and biochemical techniques. From the purification 
procedure, which includes size-exclusion chromatography, it was found that the 
EBA181945-1097 protein  eluted in a long series of fractions and not as a sharp peak, with the 
beginning of the elution appearing earlier than for a globular protein of this weight 
(18 kDa), although MALLS data showed the protein to be monomeric in solution. This 
characterisation was the first of a series of observations that suggested the protein to be 
unfolded.  1D NMR experiments yielded a narrow 
1
H spectrum, typical of unfolded 
protein. CD analysis also resulted in spectra that are typically associated with a random 
coil conformation. Moreover, TSA analysis showed the protein to not have a defined 
hydrophobic core, something that is characteristic of unfolded proteins. DLS 
measurements showed the protein to have a size (Rh) of at least 2.95 nm, corresponding to 
a 90 kDa globular protein. All other aspects of the protein characterisation were consistent 
with EBA181945-1097 existing in a disordered state – one that was very unlikely to 
crystallise. Hence it seems that the EBA181945-1097 domain is an intrinsically disordered 
protein, consistent with the information given by the structural and disorder predictions on 
the full-length protein and to all the biophysical characterisation performed on the 
EBA181945-1097 domain. According to the bioinformatics predictions on the full-length 
protein, the N-terminus part (which includes the transmembrane domain) appears to be 
structurally folded. Nevertheless, at least half of its sequence, after the N-terminus and 
almost until the C-terminus, is predicted be disordered. Moreover, and very interestingly, 
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the binding region to the 4.1R protein as well as all other predicted and putative binding 
regions can only be found in this unfolded region.  
 
For the 4.1R10kDa protein, the results were rather different. Following expression and 
purification, CD analysis showed a typical curve of helical content, which could be 
estimated as followed: 35 % of alpha helices, 20 % of turns and 45 % of random coil. DLS 
measurements showed a minimum size (Rh) of 2.0 nm, comparable to a globular protein of 
at least 30 kDa and showing the relatively low compactness of 4.1R10kDa. 1D NMR showed 
a narrow spectrum, typical of disordered proteins or dynamic alpha helices. This last 
possibility of a dynamic behaviour including the appearance of alpha helices, is likely to be 
the biological relevant conformation, when comparing to the other characterisation. The 
consensus of all the biophysical characterisation performed shows that 4.1R10kDa is neither 
globular nor even compact, but has some 3D structure with an estimation of 35 % of alpha 
helices. The protein as a whole is well known to be digested by proteases (Leto et al., 
1984) as four well-defined domains of 30 kDa, 16 kDa, 10 kDa and 22 kDa; the 10 kDa 
one interacting with the EBA-181 protein. The 30 kDa domain is the only one with a 
known 3D structure, but the three other domains are very likely to have some secondary 
structures too, as shown by the trypsin digestion experiment and the structure and disorder 
predictions carried out.  
 
The complex between EBA181945-1097 and 4.1R10kDa was also thoroughly characterised. 
The micro pull-down procedure, allowing the use of very small amounts of sample and the 
characterisation of a range of different conditions in parallel, confirmed the complex 
formation and showed that the complex formed independently of the presence or the 
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absence of the His or GST tag, carried respectively by the EBA181945-1097 or 4.1R10kDa 
proteins. Moreover, the complex also formed during size exclusion chromatography 
(tagged proteins); or using native polyacrylamide gel electrophoresis (untagged proteins) 
with the appearance of a novel band after co-migration of the two proteins. Further pull-
down analysis demonstrated the complex to be stable in various pH (from at least pH 5.0 to 
9.0), in the presence of high salt concentration (up to 2 M NaCl), or even when in 
competition with shorter EBA peptides encompassing the 4.1R binding sequence. 
Quantification in gel filtration studies and in MALLS experiments provided new insights 
on the stoichiometry of the interaction, demonstrating that the EBA-4.1R complex is 
formed as a 1 to 1 complex. Interestingly, 1D NMR spectra did not show any folding upon 
binding, as it was also suggested by the DLS data (Rh of minimum 4.4 nm, corresponding 
to the size of a 350 kDa globular protein). Finally, MST analysis gave the Kd of the 
biological relevant complex between untagged EBA181945-1097 and 4.1R10kDa to be close to 
0.3 μM, showing medium affinity of the two partners. 
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His-EBA181945-1097   EBA181945-1097 GST-4.1R10kDa   4.1R10kDa 
Plasmid  
and tag 
pET15b (Kan
R
) with 
His tag 
pET15b (Kan
R
) with 
His tag 
pGEX-4T-2 (Kan
R
) 
with GST tag 
pGEX-4T-2 (Kan
R
) 
with GST tag 
Expression  
yield 
~ 5 mg/l of culture                                                                   
in E.coli Rosetta2 
(DE3) Cam
R
 
~ 5 mg/l of culture                                                                   
in E.coli Rosetta2 
(DE3) Cam
R
 
~ 2 mg/l of culture                                           
in E.coli Rosetta2 
(DE3) Cam
R
 
~ 0.5 mg/l 
 of culture                                                                    
in E.coli Rosetta2 
(DE3) Cam
R
 
1D NMR 
Data suggest protein 
is not folded 
Protein not folded 
 Protein not folded 
(or alpha helices 
invisible) 
Circular 
Dichroism 
Protein not folded                                                                                        
(4°C and 25°C) 
Protein not folded                                                                
(4°C and 25°C) 
Protein ~70% 
folded
(30 % helices and 
40 % beta) 
Protein weakly 
folded                                            
(~35% of helices, 
20% of turn and 
45% of random coil)                                                 
Thermal Shift 
Assay 
Protein not folded                                                                              Protein not folded                                                               
Protein folded,                                                                             
success in defining 
the best stability 
condition 
Very flexible 
Gel filtration                            
and MALLS 
Protein not  
globular                                                                                 
 
=> Monomer 
Protein not 
globular                                                    
 
=> Monomer 
 
Protein not 
globular                                                                                 
 
=> Monomer 
DLS 
Protein solution 
monodisperse,  
not globular                                        
(3.0 nm, size of a 
100 kDa globular 
protein) 
Protein solution 
monodisperse,  
not globular                                        
(2.95 nm, size of a 
100 kDa globular 
protein) 
 
Protein solution 
monodisperse,  
not globular                                        
(2.0 nm, size of a 
30 kDa globular 
protein) 
Crystallisation 
trials 
No crystal 
 
20 mg/ml                                                                           
50 mg/ml                                                                          
90 mg/ml 
No crystal 
 
20 mg/ml                                              
50 mg/ml                                              
90 mg/ml 
Salt crystals 
 
4 mg/ml                                    
8 mg/ml                           
 
No crystal 
 
2.5 mg/ml                                                                                               
5 mg/ml
 
 
Table 3.17: Summary of the main results on individual tagged or untagged EBA181945-1097 
and 4.1R10kDa proteins. 
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Complex 
Gel filtration                            
and MALLS 
Evidence of 1 to 1 stoichiometry 
EBA-181 / 4.1R: 
measured MW of 24 kDa 
Quantification 
on gel 
Evidence of 1 to 1 stoichiometry 
EBA-181 / 4.1R 
Native gel 
Appearance of a band consistent 
with complex formation 
DLS Hydrodynamic radius Rh = 4.4 nm 
1D NMR 
No evidence of folding  
upon binding 
ITC Failed 
MST Kd = 0.3 μM 
Crystallisation 
trials 
EBA181945-1097 / 4.1R10kDa 
(3 mg/ml and 4.5 mg/ml) 
=> no crystal 
 
EBA181945-1097 / GST-4.1R10kDa 
(3 mg/ml, 5 mg/ml, 7 mg/ml) 
=> no crystal 
 
Pf30 / GST-4.1R10kDa 
(4 mg/ml and 8 mg/ml) 
=> salt crystals 
 
Table 3.18: Summary of the main results on the EBA181945-1097 / 4.1R10kDa complex. 
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4. SAXS AND SANS CHARACTERISATION OF 
EBA181945-1097, 4.1R10kDa AND THEIR COMPLEX. 
 
 
Abstract 
 
The main goal of the work described in this chapter was to carry out solution structural 
studies of the individual proteins EBA181945-1097 and 4.1R10kDa, (tagged and untagged) as 
well as of the complex formed between them. The overall strategy was to apply 
complementary small-angle X-ray and neutron scattering techniques (SAXS and SANS 
respectively) in a way that provided low resolution information on the solution structures 
of the two proteins and of the complex. 
 
The SAXS experiments demonstrated that both proteins are elongated and non-globular, 
consistent with the disordered structures as described in Chapter 3. SANS measurements 
on the complex were also carried out. Here full use of deuteration was exploited by making 
samples of the complex in which the EBA-181 protein was deuterated, and the 4.1R protein 
hydrogenated. This allowed H2O/D2O-based solvent contrast variation to be used in 
distinguishing and imaging the two parts of the intact complex. This also permitted a direct 
comparison of the complex structure with that derived from SAXS experiments on both 
labelled and unlabelled analogues of the EBA-181 / 4.1R system. These results show that 
(I) the SAXS and the SANS analyses provide good agreement in terms of the solution state 
modelling of the complex, (II) the EBA181945-1097 / 4.1R10kDa complex adopts a ‘T-shaped’ 
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structure in which the 4.1R10kDa molecule protrudes from the central region of the 
elongated EBA181945-1097 molecule, and (III) the EBA181945-1097 and the 4.1R10kDa protein 
structures, at the resolution of the SAS analysis, appear to be relatively unchanged 
following complex formation, with their respective radius of gyration and Dmax parameters 
remaining very similar between the uncomplexed and complexed forms of both proteins. 
 
 
4.1 Introduction 
 
As described in previous chapters, a clear interaction has been identified between the 
EBA181945-1097 and 4.1R10kDa domains. The studies described in Chapter 3 have 
demonstrated that the EBA181945-1097 protein is intrinsically disordered and that the 
4.1R10kDa protein is also disordered to a large degree. One major consequence of this 
characterisation work is that neither the components of the complex nor the complex itself 
are likely to be amenable to traditional crystallography. In the circumstances, the only 
options remaining for structural information are solution state studies using small-angle 
X-ray scattering (SAXS), small-angle neutron scattering (SANS) or nuclear magnetic 
resonance (NMR). 
 
This chapter focuses on solution scattering work carried out on this system using both 
SAXS and SANS. The project exploited the optimised expression system described in 
Chapter 3 as well as facilities of the PSB in Grenoble, including SAXS beamlines of the 
ESRF and the SANS instrument of the ILL. Both approaches are strongly complementary 
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in the information they provide, and in both cases ab-initio modelling can be applied to 
image the proteins or protein components under study. In the case of the SANS work, it 
was necessary to label the EBA-181 protein with deuterium so that solvent contrast 
variation could be used to distinguish between the two components of the complex. 
 
Section 4.2 describes the material and methods used to perform the scattering experiments, 
including sample preparation for SAXS/SANS and the unique deuteration methods used in 
SANS for contrast variation (see Chapter 2 for further technical details). Section 4.3 
describes the structural characterisation results using small-angle X-ray scattering on the 
individual proteins as well as the complex. Section 4.4 presents the small-angle neutron 
scattering structural characterisation on the complex using deuteration and contrast 
variation. Finally, Section 4.5 summarises the combined SAXS and SANS analyses in the 
context of the other information that has been gathered on the EBA-181/4.1R interaction. 
 
 
4.2 Material and methods 
 
This study required the large scale production of both EBA181945-1097 and 4.1R10kDa 
proteins (tagged and untagged) for SAXS. In the case of SANS, an additional requirement 
was the production of deuterium-labelled EBA181945-1097. The following sections describe 
how these proteins were produced and characterised prior to the small-angle scattering 
experiments. 
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4.2.1 Sample production for small-angle X-ray scattering 
The large-scale expression and the different purification steps of the individual proteins 
were performed as previously described in Chapter 3. The tagged complex 
(His-EBA181945-1097 / GST-4.1R10kDa) was formed as described in Chapter 3, whereas the 
untagged complex (EBA181945-1097 / 4.1R10kDa) was formed by mixing the individual 
untagged proteins in a 1 to 1 molar ratio, as shown by the MALLS analysis (Chapter 3). In 
order to optimise the quality of the final SAXS experiment a variety of buffers were 
evaluated following the final purification steps using gel filtration, DLS and preliminary 
SAXS measurements. These measurements were designed to detect specific issues of 
importance for the analysis of the small-angle scattering data, in particular aggregation 
issues. The buffers used in this evaluation were: Tris buffer at pH 8.0, PBS buffer at 
pH 7.4, sodium phosphate (NaP) at pH 7.0 and NaP buffer at pH 6.0. The NaCl 
concentration was another variable parameter, as well as the final protein concentration in 
each sample (Figure 4.2). Typical DLS measurements on the proteins and their complex 
are shown in Figure 4.1. 
 
      
 
Figure 4.1: DLS measurements showing the individual 4.1R10kDa and EBA181945-1097 
proteins and the complex to be monodisperse after the final step of purification (in NaP 
buffer at pH 6.0 + 50 mM NaCl). 
4.1R10kDa 
 
EBA181945-1097 Complex 
 
Rh (nm) 
 
Rh (nm) 
 
Rh (nm) 
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4.2.2 Sample production for small-angle neutron scattering 
As described in Chapter 2, small-angle neutron scattering is a powerful technique whereby 
solution contrast can be used to distinguish between, and model, specific components of a 
biological macromolecular complex, especially if deuteration methods are deployed. In 
these SANS studies of the EBA181 / 4.1R protein complex, the EBA181945-1097 protein was 
deuterated at approximately 75 % in ‘non-exchangeable’ positions (as noted in Chapter 2, 
this level of deuteration was chosen so as to produce material that would be optimally 
matched out in pure D2O), and the 4.1R10kDa protein was kept hydrogenated. In principle 
either protein could have been deuterated, but in this case EBA-181 was chosen because of 
its high expression level, as opposed to the low expression of 4.1R10kDa (see Chapter 3).  
 
One of the important issues that arise in connection with the use of deuterated proteins and 
D2O based solvents is the fact that there is anecdotal evidence that deuteration increases 
aggregation problems when handling protein samples. Hence some care was needed in 
evaluating this potential problem prior to the SANS experiments. 
 
4.2.2.1 Bacterial adaptation to deuterium 
In order to be able to grow in deuterated medium and thus express the protein of interest to 
a sufficient level, bacteria need an adaptation process. To achieve this and express the 
deuterated EBA181945-1097 protein, 30 cycles of 10 ml bacterial cultures in 85 % deuterated 
Enfors medium with Kan + Cam antibiotics were performed as follows: the initial 10 ml 
culture was initiated using 1 ml of stationary phase LB culture of E. coli Rosetta
TM
 2 cells 
carrying the plasmid for the expression of the His-EBA181945-1097 protein (initiated from  
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Figure 4.2: Summary of the main steps of EBA181945-1097 and 4.1R10kDa purification 
protocol and sample preparation for the SAXS experiments. 
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the kanamycin resistant clone stored at - 80°C, see Chapter 3). The 29 subsequent cycles 
were initiated using 1 ml of the previous stationary phase culture and 9 ml of fresh Enfors 
medium. Each step required an O.N. growth at 30°C under agitation. 
 
The deuterium-adapted E. coli Rosetta
TM
 2 expressing the His-EBA181945-1097 protein was 
stored at -80°C. For this, the 30
th
 adaptation cycle (having reached the stationary phase) 
was used to make long-term storage stocks using sterile beads in a cryo-preservative 
solution (Technical Service Consultants Ltd). 
 
Table 4.1 A and B presents the composition of the bacterial growth media used for the 
expression of deuterated EBA181945-1097 protein (modified from Enfors et al., 2000). The 
powders were resuspended in 85% D2O, and the medium was sterilised by filtering through 
a 0.2 μm filter. 
 
Enfors medium Concentration 
 
(NH4)2SO4 anhydrous 
 
6.86 g/l 
KH2PO4 anhydrous 1.56 g/l 
Na2HPO4 anhydrous 6.48 g/l 
(NH4)2-H-citrate anhydrous 0.49 g/l 
100% hydrogenated glycerol 5 g/l 
MgSO4 1M 1 ml/l 
Metal salts* 1 ml/l 
 
Table 4.1 A: Enfors growth medium used for EBA181945-1097 protein deuteration. 
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*Metal salts (x1000) Concentration 
 
CaCl2.2H2O 
 
0.5 g/l 
FeCl3.6H2O 16.7 g/l 
ZnSO4.7H2O 0.18 g/l 
CuSO4.5H2O 0.16 g/l 
MnSO4.4H2O 0.15 g/l 
CoCl2.6H2O 0.18 g/l 
Na-EDTA anhydrous 20.1 g/l 
 
Table 4.1 B: Metal salts used to prepare the Enfors growth medium. 
 
 
4.2.2.2  Expression and solubility tests 
Since deuteration might have an impact on expression and solubility of proteins, it was 
necessary to perform new expression and solubility tests to determine the condition where 
the expression and solubility of the EBA181945-1097 protein was the highest (Figure 4.3).   
 
The results show that an overnight expression at 30°C gave the best expression and 
solubility when compared to the three other conditions tested (37°C for 3h, 37°C for 7h 
and 20°C for 48h). 
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Figure 4.3: SDS-PAGE of expression tests of His-EBA181945-1097 in 85 % D-Enfors 
medium. The sign “<” indicates the migration position of His-EBA181945-1097. 
 
 
 
4.2.2.3  Large-scale expression of deuterated EBA181945-1097 and hydrogenated 
4.1R10kDa proteins 
In order to express the hydrogenated 4.1R10kDa protein, E. coli Rosetta™ 2 (DE3) cells 
were transformed with the pGEX-4T-2 plasmid (protocol similar to Section 3.2.3) and 
plated on LB-plates (+ Kan and Cam antibiotics). The selected medium for the large-scale 
hydrogenated protein expression was the LB medium supplemented with 30 µg/ml of 
kanamycin and with 34 µg/ml of chloramphenicol. Firstly, precultures were inoculated 
from the LB plates (LB-Agar, Kan + Cam) from the transformation and incubated until 
reaching the stationary phase of growth (37°C, overnight under agitation). Further 
preculture steps were required to inoculate each of the 1 litre culture (1:50 dilution). The 
< 
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bacteria were grown at 37°C to an optical density of around 0.7 at 600 nm. Protein 
expression was induced with 1 mM IPTG over 3 hours as described in Chapter 3; and the 
bacteria were then lysed by sonication to release the proteins. The suspension was then 
centrifuged at 40 000 g for 1 h and at 4°C to separate the soluble material as showed in 
Figure 4.4. 
 
The selected medium for the large-scale expression of the 75 % deuterated EBA181945-1097 
was the Enfors medium in 85 % D2O, supplemented with 30 µg/ml of kanamycin and 
34 µg/ml of chloramphenicol. By using unlabelled glycerol as carbon source, the protein 
produced was approximately 75% deuterated in 85 % D2O medium. In order to express the 
deuterated EBA181945-1097 protein, the deuterium-adapted E. coli Rosetta™ 2 (DE3) cells 
expressing the His-EBA181945-1097 protein (pET15b) were used (from the -80°C long-term 
storage clone) and plated on a LB plate (LB-Agar, Kan + Cam). Precultures were 
inoculated from this Petri dish and incubated until reaching the stationary phase of growth 
(37°C, overnight under agitation). Finally, 1 litre of 85 % D-Enfors was inoculated with 
the last preculture (1:50 dilution) and split into two 3 litre flasks in order to maximise the 
aeration. The bacteria were grown at 30°C to an optical density of around 0.7 at 600 nm. 
Protein expression was induced with 1 mM IPTG overnight as previously defined in 
Figure 4.2, and the bacteria were lysed by sonication to release the proteins. The 
suspension was then centrifuged at 40 000 g for 1 h and at 4°C to separate the soluble 
material as showed in Figure 4.4. 
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Figure 4.4: Left: SDS-PAGE showing the expression of deuterated His-EBA181945-1097 
after adaptation and right: hydrogenated GST-4.1R10kDa. The sign “<” indicates the 
migration position of the respective proteins. 
MW: Molecular weight marker (PageRulerTM Plus Prestained SM181 from Fermentas). 
Not induced: Sample before induction with IPTG. 
Total: Insoluble and soluble protein after IPTG induction. 
Soluble: Soluble proteins after IPTG induction and centrifugation. 
 
 
Both deuterated EBA181945-1097 and hydrogenated 4.1R10kDa proteins were subsequently 
purified as described in Chapter 3 and the complex was formed by mixing the individual 
proteins in a 1 to 1 molar ratio. In order to allow the contrast variation experiment, the final 
< 
< 
His-EBA181945-1097 GST-4.1R10kDa 
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buffer (50 mM NaP buffer + 50 mM NaCl) was used either as 100 % hydrogenated (the 
solvent is pure H2O), or as respectively 40 % and 100 % deuterated. To achieve this, the 
deuteration of the inorganic materials was achieved by flash evaporation: the hydrogenated 
NaP buffer was evaporated at 60°C with the use of a rotary evaporator system and the 
resulting powder was resuspended in the minimal required volume of D2O. This process 
was performed three times in order to remove traces of H2O. Finally, the powder was 
resuspended in 40 % or 100 % D2O to prepare the two buffers required for the contrast 
variation experiment. SDS-PAGE and DLS measurements were performed on the purified 
deuterated EBA181945-1097 and hydrogenated 4.1R10kDa proteins to control the quality of the 
purification and check for aggregation. The deuterated EBA181945-1097 samples as well as 
the hydrogenated 4.1R10kDa samples were monodisperse in each of the 0 %, 40 % or 100 % 
D2O based NaP pH 6.0 buffers. Typical DLS measurements in 100 % D2O are shown in 
Figure 4.5. 
 
4.2.3 SAXS and SANS data collection 
4.2.3.1  BioSAXS 
Small-angle X-ray scattering measurements were performed at the BioSAXS beamlines of 
the European Synchrotron Radiation Facility (ESRF, Grenoble, France). Two similar 
SAXS beamlines were used: ID14-3 and BM29 (Pernot et al., 2013). Prior to the 
measurements each sample was centrifuged and filtered to remove aggregates. The 
scattering measurements were performed using the capillary pre-installed on the beamline 
(1 mm width) under temperature control (4°C and 20°C) using the sample changer robot 
(see Chapter 2) and recorded using a 2D sensitive pixel detector (Pilatus). The 
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sample-to-detector distance was 2.841 metres with an incident radiation wavelength (λ) of 
0.99 Å, providing an accessible q-range from 0.22 to 4 nm
-1
. 10 frames were recorded for 
each sample (1 second per frame under constant flow). Each single measurement was 
manually inspected for radiation damage and then averaged in order to maximise the 
signal/noise ratio. The different dialysis buffers corresponding to the samples were also 
measured (before and after every sample) to allow their background scattering to be 
subtracted from the sample measurements.  
 
        
 
 
 
 
Figure 4.5: DLS measurements showing the deuterated EBA181945-1097 (A) and 
hydrogenated 4.1R10kDa (B) proteins to be monodisperse after the final step of purification 
and in the 100 % D2O NaP pH 6.0 buffer. 
4.1R10kDa in 100 % D2O 
 
 
75% deuterated EBA181945-1097 in 100 % D2O 
B) 
A) 
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Sample-detector distance 2.841 metres 
Wavelength 0.99 Å 
q-range 0.22 to 4 nm
-1
 
Exposure time 10 x 1 second frames 
Sample temperature 4°C and 20°C 
Sample concentration 
4.1R10kDa: 0.4 to 3 mg/ml 
GST-4.1R10kDa: 3 mg/ml 
 
EBA181945-1097: 5 to 30 mg/ml 
His-EBA181945-1097: 10 to 30 mg/ml 
 
4.1R10kDa / EBA181945-1097 complex: 5 mg/ml 
 
Table 4.2: Summary of the main parameters of the SAXS experiments. 
 
 
4.2.3.2  SANS 
The small-angle neutron scattering measurements presented here were performed on the 
D22 instrument of the Institut Laue Langevin (ILL, Grenoble, France) as described in 
Chapter 2.  
 
The samples were placed in quartz cuvettes and set in the sample holder which allows 
temperature control. During the experiments carried out on D22, the instrument was set up 
to work at a wavelength of 8 Å with sample-detector distances of either 2.0 metres, 
5.6 metres or 17 metres; and the temperature control set to 4°C (as a reminder, in standard 
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conditions D22 covers a total q-range of 4 x 10
-4
 to 0.44 Å
-1
 no detector offset, or 0.85 Å
-1
 
with detector offset). The data were collected via the two dimensional 
3
He multidetector, 
before being integrated to obtain the final intensity vs diffusion angle curve.  
 
Sample-detector distance 2.0 metres / 5.6 metres / 17 metres 
Wavelength 8 Å 
q-range 4 x 10
-4
 to 0.44 Å
-1
 or 4 x 10
-4
 to 0.85 Å
-1
 
Exposure time 30 minutes 
Sample temperature 4°C 
Sample concentration 
4.1R10kDa / EBA181945-1097 complex: 2 mg/ml 
(for the three solvent contrasts chosen: 0 %, 40 % and 
100 % D2O) 
 
Table 4.3: Summary of the main parameters of the SANS experiment. 
 
 
4.2.4 Data treatment 
For each SAXS sample the 10 recorded frames and the two buffer measurements were 
automatically averaged using the beamline software AUTOSUB (beamline software 
BsxCuBE and ATSAS package – EMBL) in order to obtained one averaged sample 
scattering curve and one averaged buffer scattering curve. The data were then analysed 
manually using the PRIMUS (Konarev et al., 2003) software for buffer subtraction, data 
reduction, as well as curve merging for the different sample concentrations and the Guinier 
(low q) / Porod (high q) analysis.  
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The SANS data were analysed using a range of software (from R. Ghosh, ILL): RNILP was 
used to list the transmission and scattering data, RNILS to calculate the radial distribution 
function, DETCI to adjust the position of the centre of the detector (as a function of its 
distance) in order to mask it using the RMSK program. SPOLLY was then used in order to 
analyse further the data by means of three different including cadmium and empty cell 
scattering measurements as well as the transmission from a H2O sample. Following this, 
each sample was corrected for the scattering from their respective buffer. 
 
For both SAXS and SANS data, GNOM (Svergun et al., 1992) was then used to define the 
Dmax and the P(r) function. The modelling of each individual analysed curve was carried 
out using the DAMMIF (Franke et al., 2009) software (set in slow mode) in order to create 
an ensemble of models. The averaging of these different models coming from DAMMIF 
was carried out using the DAMAVER program (Volkov et al., 2003). 
 
 
4.3 Structural characterisation using small-angle X-ray scattering 
 
In order to optimise the SAXS data and perform a complete characterisation, both tagged 
and untagged versions of the EBA181945-1097 and 4.1R10kDa proteins were analysed. For this 
a wide range of buffers, pH, NaCl and sample concentrations was tested to find the most 
suitable conditions for SAXS measurements. The main results on the individual proteins 
are presented below in two sections (Sections 4.3.1 and 4.3.2) and the corresponding tables 
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(Tables 4.4 and 4.5). The results presented in bold in the tables correspond to the 
conditions that gave the highest quality SAXS measurements in terms of aggregation and 
signal/noise ratio and which were chosen thereafter to perform the structural 
characterisation and the ab-initio modelling.  
 
The complex formed between the two EBA181945-1097 and 4.1R10kDa proteins was also 
characterised using a similar approach. The different conditions tested and scattering 
results are presented in Section 4.3.3 with the summary shown in Table 4.6. Finally, the 
untagged complex displaying the best scattering quality measurement was chosen and used 
in order to perform the structural analysis and the ab-initio modelling. 
 
 
4.3.1 SAXS characterisation of tagged GST-4.1R10kDa and  
His-EBA181945-1097 proteins 
 
Protein samples of GST-4.1R10kDa and His-EBA181945-1097 were analysed by SAXS using 
several conditions and optimisation in order to reach the highest quality possible and 
obtain a reliable structural characterisation of both proteins. The results are summarised in 
Table 4.4. 
 
The GST-4.1R10kDa protein was kept in the PBS buffer at pH 7.4 since its higher 
iso-electric point strongly constrains the possible range of pH that can be used (the 
theoretical pI of GST-4.1R10kDa is 6.6) and thus the use of the dialysis conditions presented 
in Figure 4.2 and especially the buffers with a pH close to its iso-electric point could lead 
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to its precipitation. This makes the use of buffers with a pH below 7 impossible. Two NaCl 
concentrations were used, 137 mM and 1 M. The scattering from the centrifuged sample in 
PBS in 1 M NaCl was nearly identical to the scattering of its buffer indicating protein 
precipitation and gave unusual results with a nonsensical Rg. Facing the difficulty to 
concentrate GST-4.1R10kDa to more than 3-4 mg/ml, only two sample concentrations were 
tested: 1 and 3 mg/ml. In 137 mM NaCl they both show a similar scattering profile 
(Table 4.4), thus the data from the sample concentrated to 3 mg/ml and presenting a 
slightly better signal to noise ratio was kept for the ab-initio modelling. The radius of 
gyration of GST-4.1R10kDa (molecular weight = 35 kDa) is close to 4 nm (Rg results are 
equal to 4.17 nm at very low scattering angles q in the Guinier analysis, and 4.14 nm at 
higher q in the Porod region), with a calculated Porod volume of 187 nm
3
. The P(r) 
function analysis gave a slightly smaller Rg, at 3.71 nm, and a Dmax equal to 12 nm. These 
results suggest that the protein is not globular and quite elongated since the theoretical Rg 
of a 35 kDa globular protein would be close to 2.0 nm (Bernado et al., 2009, see 
calculation below). 
 
For globular proteins: Rg (Å) ~ 6.25 x M
1/3
 (M in kDa) 
For unfolded proteins: Rg (Å) ~ 8.05 x M
0.522
 (M in kDa) 
 
It is also interesting to compare the results of GST-4.1R10kDa with the SAXS measurements 
performed on the GST tag alone, giving a Rg of approximately 2.5 nm and a Dmax of 
6.6 nm (molecular weight = 26 kDa). The addition of the 4.1R10kDa protein to the GST tag 
adds only 9 kDa, but the measured Rg drastically increases, from approximately 2.5 nm to 
4.2 nm. The same behaviour can be noticed when comparing the Dmax between the GST tag 
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alone and the GST-4.1R10kDa construct, with a rise from 6.6 nm to 12 nm. These results 
clearly demonstrate the non-globular and elongated state of the 4.1R10kDa protein which 
dominates the hydrodynamic radius compared to its molecular weight. 
 
For the His-EBA181945-1097 protein two different buffers and pH were chosen according to 
DLS results displaying the lowest aggregation (data not shown): Tris pH 8.0 and NaP 
pH 6.0. The scattering results from the sample in sodium phosphate buffer at pH 6.0 gave 
the highest quality results as expected after the different biophysical characterisations 
performed (Chapter 3). The scattering quality of this experiment was sufficient to perform 
ab-initio modelling, and thus no further conditions were tested. The measurement 
performed in Tris buffer at pH 8.0, with His-EBA181945-1097 concentrated at 14 mg/ml, 
gave a result almost as good as in NaP pH 6.0. The increase of protein concentration to 
20 mg/ml resulted in dramatic aggregation during the SAXS irradiation as highlighted by 
the Guinier analysis, with a Rg almost doubled to 4.21 nm. The radius of gyration of 
His-EBA181945-1097 (measured in NaP pH 6.0) was determined from the 15 mg/ml 
experiment in the range from 2.31 nm (Porod region) to 2.91 nm (P(r) function), with the 
Guinier analysis giving a Rg of 2.40 nm. The Dmax is equal to 9.1 nm which is very wide 
for an 18 kDa protein, highlighting the very elongated state of the protein; the theoretical 
Rg of a globular protein of the same mass would be close to 1.6 nm.  
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Sample Buffer 
NaCl 
concentration 
Sample 
concentration 
(mg/ml) 
Guinier region Porod region P(r) function 
Rg 
(nm) 
MM 
(kDa) 
Rg 
(nm) 
Vp 
(nm3) 
Rg 
(nm) 
Dmax 
(nm) 
GST-4.1R10kDa 
PBS pH 7.4 137 mM 1 3.98 45 4.02 182 4.16 13.9 
PBS pH 7.4 137 mM 3 4.17 41 4.14 187 3.71 12.0 
PBS pH 7.4 1 M 3 0.28 2 N.D. N.D. N.D. N.D. 
 
  
       
GST tag alone PBS pH 7.4 137 mM 5 2.60 22 2.58 99 2.41 6.6 
 
  
       
His-
EBA181945-1097 
Tris pH 8.0 100 mM 14 2.40 14 2.31 11 2.90 9.3 
Tris pH 8.0 100 mM 20 4.21 40 4.24 24 2.51 9.0 
NaP pH 6.0 100 mM 15 2.40 21 2.31 15 2.91 9.1 
 
Table 4.4: Summary of the experimentally determined structural SAXS parameters and 
results of tagged His-EBA181945-1097 and GST-4.1R10kDa proteins. The data sets shown in 
bold were chosen thereafter to perform structural characterisation and ab-initio modelling. 
N.D.: non-determined values due to insufficiently good data. 
 
 
The small-angle X-ray scattering curve of GST-4.1R10kDa, after subtraction of the 
scattering data from the buffer alone and reduction of the data in the range from 0.4 nm
-1
 to 
2.1 nm
-1
, is displayed on the left hand side of Figure 4.6 A. The associated paired vector 
distribution function P(r) which shows the histogram of all inter-atomic distance vectors, 
was calculated and is displayed in Figure 4.6 B.  
 
The small-angle X-ray scattering curve of His-EBA181945-1097 after subtraction of the data 
recorded from the buffer alone and reduction of the data in the range from 0.3 nm
-1
 to 
3 nm
-1
 is displayed on the right hand side of Figure 4.8 A. The associated P(r) was 
calculated and is displayed on the right hand side of Figure 4.8 A. 
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Figure 4.6: Left: GST-4.1R10kDa and Right: His-EBA181945-1097 with (A) buffer corrected 
SAXS curves and (B) associated calculated P(r).  
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Ab-initio modelling was performed on both GST-4.1R10kDa and His-EBA181945-1097 
proteins, and ten models were created as respectively shown in Figures 4.7 A and 4.8 A. 
The final models after averaging the 10 different 3D models for each of the tagged proteins 
using DAMAVER are presented in Figures 4.7 B and 4.8 B. The SAXS ab-initio models of 
GST-4.1R10kDa and His-EBA181945-1097 are consistent with the biophysical characterisation 
results (DLS, CD and structural predictions). His-EBA181945-1097 appears to be a very 
elongated protein in contrast to GST-4.1R10kDa which has a more compact core and 
structural elements due to the GST tag. In order to validate the models, the back-calculated 
scattering curves of His-EBA181945-1097 and GST-4.1R10kDa from the models were 
calculated and are shown in green on the experimental red scattering curve and show a 
very good match (Figures 4.8 B and 4.9 B, right hand side). 
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Figure 4.7: Tagged GST-4.1R10kDa with (A) ab-initio 3D models using DAMMIF 
(10 models) and (B) averaged ab-initio 3D model using DAMAVER and displayed as 
spheres (left) and fit of the simulated scattering curve in green versus the experimental 
data in red (right). 
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Figure 4.8: Tagged His-EBA181945-1097 with (A) ab-initio 3D models using DAMMIF 
(10 models) and (B) averaged ab-initio 3D model using DAMAVER and displayed as 
spheres (left) and fit of the simulated scattering curve in green versus the experimental 
data in red (right). 
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The disordered state of a biological macromolecule can be qualitatively assessed by means 
of a Kratky plot (Kratky et al., 1955), when the scattering intensities for macromolecules 
which behave as random coils would plateau in a q
2
 x I(q) vs q plot. Thus, both His-
EBA181945-1097 and GST-4.1R10kDa as well as the GST tag alone scattering measurements 
were plotted as a Kratky plot (Figure 4.9). The Kratky plot analysis confirms the 
disordered state of the His-EBA181945-1097 protein with the characteristic plateau displayed 
by the blue scattering curve in Figure 4.6. In contrast, the GST tag alone and the GST-
4.1R10kDa scattering curves do not display this plateau, demonstrating their more largely 
non-disordered state (red and green curves in Figure 4.9), as would be expected. 
 
 
 
 
Figure 4.9: Kratky plot of tagged His-EBA181945-1097 (blue), GST-4.1R10kDa (green) and the 
GST tag alone (red). 
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Figure 4.10 shows the 3D ab-initio model of the GST-4.1R10kDa protein. The GST protein 
tag ab-initio model resulting from the SAXS measurement is also displayed on the right 
hand side to allow a direct comparison with the ab-initio model of tagged GST-4.1R10kDa 
protein, as well as the X-ray crystal structure of human GST from the PDB (ref. 9GSS, 
resolution = 1.97 Å). The SAXS measurement of the GST tag alone and with the X-ray 
crystal structure allowed its probable location to be found in the 3D model of 
GST-4.1R10kDa, as displayed in Figure 4.10. The GST tag appears to be globular in 
solution, as would be expected, while the 4.1R10kDa protein is more elongated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Ab-initio 3D models displayed as spheres of left: the tagged GST-4.1R10kDa 
protein and right: the GST tag alone from SAXS (top) and crystal structure of the GST 
protein from Schistosoma japonicum (bottom, pdb 1M9A, resolution 2.1 Å). 
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4.3.2 SAXS characterisation of untagged 4.1R10kDa and EBA181945-1097 proteins 
Protein samples of untagged 4.1R10kDa and EBA181945-1097 were analysed by SAXS using a 
wide range of conditions and optimisation, including buffer type, pH variation or NaCl and 
sample concentrations (Table 4.5) in order to optimise the SAXS. 
 
The 4.1R10kDa and EBA181945-1097 protein samples were dialysed in three different types of 
buffer: Tris, PBS and NaP; allowing a pH range from 8.0 to 6.0 to be analysed. Several 
samples were tested and studied for each of these conditions in order to optimise the data 
quality, particularly at low and high scattering angle values; and to prevent sample 
aggregation, radiation damage and optimise the signal/noise ratio. 
 
The 4.1R10kDa scattering results in Tris buffer at pH 8.0 display similar values of Rg for all 
of the conditions tested, with values approximately equal to 2 nm. The Dmax measured is 
between 6.2 nm and 9.3 nm. It should be noted that the increase of the NaCl concentration 
seems to increase the apparent Dmax of the protein, with the highest values found at 
250 mM and 1M NaCl. This means that the addition of ions and charges tend to stretch the 
protein making it even more elongated, but with no change in the calculated Rg. The 
highest sample concentration (3 mg/ml) resulted in precipitation of the protein, with a Rg 
value measured to be almost null. This shows once again the difficulties to obtain 
concentrated samples of untagged 4.1R10kDa. All of the trials in PBS at pH 7.4 and NaP at 
pH 7.0 also resulted in precipitation of the protein, with Rg values almost null. These two 
buffers were thus eliminated in the optimisation process. The two measurements performed 
at pH 6.0 in the NaP buffer gave the highest quality results; the data from measurements on 
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the sample with protein concentration of 1.5 mg/ml were used for further analysis and the 
ab-initio modelling process. 
 
The EBA181945-1097 scattering experiments performed at pH 8.0 in the Tris buffer gave all 
similar results. In 100 mM NaCl the Rg is comprised between 1.7 nm and 3.0 nm (Guinier, 
Porod and P(r) analysis) and the Dmax between 6.2 nm and 7.2 nm. When the NaCl 
concentration is increased to 250 mM or 1 M, the Rg slightly increases and the Dmax 
reaches 9.7 nm, showing an effect of the charges on the EBA181945-1097 protein. As 
observed for 4.1R10kDa, the addition of ions and charges tend to stretch the protein making 
it more elongated (slight increases of the Dmax and Rg). The scattering results performed in 
PBS at pH 7.4 and acetic acid at pH 3.5 were unsuccessful, with precipitation of the 
protein. The trials in NaP at pH 7.0 gave similar results to those in Tris at pH 8.0. The best 
scattering results were obtained with a lower pH at 6.0, with a Rg equal to 2.35 nm, 
2.30 nm or 1.75 nm when calculated respectively using the Guinier approximation, the 
Porod law or the P(r) function. The Dmax was measured to be equal to 7.9 nm which, in 
addition to the very small calculated value for the Porod volume, indicates a very 
elongated shape for the EBA181945-1097 protein. 
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Sample Buffer 
NaCl 
concentration 
Sample 
concentration 
(mg/ml) 
Guinier region Porod region P(r) function 
Rg 
(nm) 
MM 
(kDa) 
Rg 
(nm) 
Vp 
(nm3) 
Rg 
(nm) 
Dmax 
(nm) 
4.1R10kDa 
Tris pH 8.0 100 mM 0.4 2.05 11 1.93 1.5 1.89 6.2 
Tris pH 8.0 100 mM 0.8 2.04 11 1.95 1.3 2.07 7.5 
Tris pH 8.0 100 mM 1 2.06 16 2.03 3.2 2.18 7.4 
Tris pH 8.0 250 mM 
Combination 
of 0.4 + 0.8 + 
1.6 + 3.2 
2.02 11 1.93 3.4 2.15 6.2 
Tris pH 8.0 250 mM 1.5 2.36 15 2.35 4.1 2.56 8.3 
Tris pH 8.0 250 mM 3 0.67 2 N.D. N.D. N.D. N.D. 
Tris pH 8.0 1 M 2.5 2.02 47 2.06 3.5 3.19 9.3 
PBS pH 7.4 133 mM 1.5 0.76 0.6 N.D. N.D. N.D. N.D. 
PBS pH 7.4 133 mM 3 0.87 2 N.D. N.D. N.D. N.D. 
PBS pH 7.4 1 M 2.5 0.89 2 N.D. N.D. N.D. N.D. 
NaP pH 7.0 100 mM 1.5 0.39 0.5 N.D. N.D. N.D. N.D. 
NaP pH 7.0 100 mM 3 0.94 1 N.D. N.D. N.D. N.D. 
NaP pH 6.0 100 mM 1.5 2.02 10 1.90 3 1.89 6.0 
NaP pH 6.0 100 mM 3 2.16 15 2.1 5 2.03 6.3 
 
   
      
EBA181945-
1097 
Tris pH 8.0 100 mM 10 2.33 21 2.04 6 1.69 6.2 
Tris pH 8.0 100 mM 30 2.96 26 3.03 9 2.14 7.2 
Tris pH 8.0 250 Mm 5 3.23 26 3.22 11 2.82 9.1 
Tris pH 8.0 250 Mm 10 3.26 29 3.15 11 2.80 9.1 
Tris pH 8.0 1 M 8 3.25 30 3.12 11 2.95 9.7 
PBS pH 7.4 133 mM 5 0.47 2 N.D. N.D. N.D. N.D. 
PBS pH 7.4 133 mM 10 0.62 2 N.D. N.D. N.D. N.D. 
PBS pH 7.4 1 M 10 0.65 2 N.D. N.D. N.D. N.D. 
NaP pH 7.0 100 mM 5 3.12 34 3.35 12 3.08 7.6 
NaP pH 7.0 100 mM 10 3.15 34 3.36 12 3.09 7.5 
NaP pH 6.0 100 mM 5 2.32 20 2.32 12 1.69 6.3 
NaP pH 6.0 100 mM 10 2.35 21 2.30 15 1.75 7.9 
Acetic Acid 
pH 3.5 
250 Mm 2 0.20 2 N.D. N.D. N.D. N.D. 
 
Table 4.5: Summary of the experimentally determined structural SAXS parameters of the 
untagged EBA181945-1097 and 4.1R10kDa proteins. The data sets highlighted in bold were 
chosen to perform the structural characterisation and the ab-initio modelling. N.D.: non-
determined values due to insufficiently good data. 
 
 
 
  
181 
 
The small-angle X-ray scattering curve of untagged 4.1R10kDa, after subtraction of the 
scattering data from the buffer alone and reduction of the data to the range 0.4 nm
-1
 to 
2.8 nm
-1
, is displayed on the left hand side of Figure 4.11 A. The associated P(r) was 
calculated and is shown in Figure 4.11 B. After subtraction of the data recorded from the 
buffer alone and reduction of the data to the range 0.05 nm
-1
 to 4.2 nm
-1
 to keep a good 
signal/noise ratio, the small-angle X-ray scattering curve of untagged EBA181945-1097 is 
displayed on the right hand side of Figure 4.11 A. The calculated associated P(r) is 
displayed in Figure 4.11 B.  
 
 
  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Untagged 4.1R10kDa (left) and EBA181945-1097 (right) with (A) buffer corrected 
SAXS curves and (B) associated calculated P(r).  
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Ab-initio modelling was performed using the data from both untagged 4.1R10kDa and 
EBA181945-1097 proteins and ten models were created as shown in Figures 4.12 A and 
4.13 A respectively. For each of the two proteins the ten models were averaged using 
DAMAVER (Figures 4.12 B and 4.13 B). In order to validate them, the respective back-
calculated scattering curves from the different averaged models were also calculated and 
are shown in green on each experimental red scattering curve. The experimental and 
calculated curves show a very good match (Figures 4.12 B and 4.13 B, right hand side). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Untagged 4.1R10kDa with (A) ab-initio 3D models using DAMMIF (10 models) 
and (B) averaged ab-initio 3D model using DAMAVER and displayed as spheres (left) 
and fit of the simulated scattering curve in green versus the experimental data in red 
(right). 
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Figure 4.13: Untagged EBA181945-1097 with (A) ab-initio 3D models using DAMMIF 
(10 models) and (B) averaged ab-initio 3D model using DAMAVER and displayed as 
spheres (left) and fit of the simulated scattering curve in green versus the experimental 
data in red (right). 
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The disordered/ordered state of the untagged EBA181945-1097 and 4.1R10kDa proteins have 
been assessed by the mean of Kratky plot (expressed as q
2
I(q) as a function of q). 
 
The Kratky plot analysis of the EBA181945-1097 protein (Figure 4.14, yellow curve) 
confirmed its disordered state, as already demonstrated with the analysis on tagged 
His-EBA181945-1097. The Kratky curve on the 4.1R10kDa protein shows the presence of a 
plateau followed by a slow descent (Figure 4.14, green curve) revealing the protein to be 
partially unfolded. This is in agreement with the biophysical characterisation performed 
previously, and particularly the CD analysis showing around 35 % of folding (Chapter 3). 
 
 
 
 
Figure 4.14: Kratky plot of untagged EBA181945-1097 (yellow) and 4.1R10kDa (green). 
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4.3.3 SAXS characterisation of the EBA181945-1097 / 4.1R10kDa protein complex 
The protein complex between the EBA181945-1097 and 4.1R10kDa proteins was analysed by 
SAXS using a wide set of conditions, optimisation and protein types as listed in Table 4.6. 
This analysis included the main goal of this study, namely the complex between 4.1R10kDa 
and EBA181945-1097 as untagged proteins. Other constructs were also analysed: the complex 
between 4.1R10kDa and His-EBA181945-1097, between GST-4.1R10kDa and 
His-EBA181945-1097, and between GST-4.1R10kDa or 4.1R10kDa and the two peptides used in 
Chapter 3 for the biochemical pull-down assays (Pf30, the 30 amino acid peptide 
encompassing the binding region to 4.1R10kDa; and Pr30, its homologous region from the 
Plasmodium reichenowi parasite). 
 
The 4.1R10kDa / EBA181945-1097 and the 4.1R10kDa / His-EBA181945-1097 complexes were 
analysed in the different conditions as previously defined for the individual proteins, using 
a variety of buffers and pH from pH 8.0 to 6.0. The GST-4.1R10kDa / EBA181945-1097 
complex was only measured in the PBS buffer, because of the isoelectric point of the 
GST-4.1R10kDa protein, as already mentioned. Due to the low expression level and the 
difficulties to concentrate the 4.1R10kDa protein, the concentrations of the different samples 
were kept in the range 1 to 4 mg/ml. As firstly demonstrated in Chapter 3 and then 
confirmed with the SAXS measurements on the individual proteins, the measurements 
performed on the complex gave the best results at pH 6.0, where the least sample 
aggregation was observed and for which the smallest radius of gyration was calculated. 
The Rg was equal to 3.53 nm and the Dmax to 10.4 nm, showing an increase compared to 
the respective values for the individual 4.1R10kDa or EBA181945-1097 proteins. All of the 
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different conditions SAXS measurements were analysed but only the most relevant result 
on the untagged complex is described here-after. The scattering curve of the run at pH 6.0 
was used for ab-initio modelling.  
 
Complex Buffer 
NaCl 
concentration 
Sample 
concentration 
(mg/ml) 
Guinier region Porod region P(r) function 
Rg 
(nm) 
MM 
(kDa) 
Rg 
(nm) 
Vp 
(nm3) 
Rg 
(nm) 
Dmax 
(nm) 
EBA181945-1097 / 
4.1R10kDa 
 
Tris pH 8.0 100 mM 2 3.81 29 3.84 13.1 3.70 10.8 
Tris pH 8.0 1M 1.5 3.80 32 3.85 13.0 3.72 10.9 
PBS pH 7.4 133 mM 2 3.94 30 3.98 14.1 3.94 11.1 
PBS pH 7.4 133 mM 3 3.93 29 3.88 14.2 3.93 11.2 
NaP pH 7.0 100 mM 2 3.82 28 3.84 13.7 3.81 10.7 
NaP pH 7.0 100 mM 4 3.83 28 3.90 13.8 3.79 10.7 
NaP pH 6.0 100 mM 2 3.70 26 3.72 12.9 3.56 10.4 
NaP pH 6.0 50 mM 2 3.54 26 3.54 12.8 3.53 10.4 
   
 
      
His-EBA181945-1097 
/ 4.1R10kDa 
Tris pH 8.0 100 mM 2 3.98 72 3.99 13.1 4.02 13.13 
Tris pH 8.0 1M 1.5 3.96 73 3.94 13.0 4.07 13.26 
PBS pH 7.4 133 mM 2 0.55 2 N.D. N.D. N.D. N.D. 
PBS pH 7.4 133 mM 3 4.05 77 4.06 13.2 4.16 13.58 
NaP pH 7.0 100 mM 2 0.52 1 N.D. N.D. N.D. N.D. 
NaP pH 7.0 100 mM 4 0.45 1 N.D. N.D. N.D. N.D. 
NaP pH 6.0 100 mM 2 3.88 32 3.92 13.1 3.79 10.8 
NaP pH 6.0 50 mM 4 3.89 32 3.81 13.1 3.69 10.9 
   
 
      
His-EBA181945-1097  
/ GST-4.1R10kDa 
PBS pH 7.4 133 mM 1 4.09 89 4.12 
 
4.27 14.32 
   
 
      
Pf30 / GST-4.1R10kDa PBS pH 7.4 133 mM 1 0.57 3 N.D. N.D. N.D. N.D. 
Pf30 / 4.1R10kDa 
Tris pH 8.0 250 mM 2 2.62 2 2.68 
 
2.45 7.38 
PBS pH 7.4 133 mM 3 4.49 42 4.57 
 
3.91 13.69 
   
 
      
Pr30 / GST-4.1R10kDa PBS pH 7.4 133 mM 1 5.13 86 5.21  
4.4 14.1 
Pr30 / 4.1R10kDa 
Tris pH 8.0 250 mM 2 2.0 8 2.21 
 
2.1 7 
PBS pH 7.4 133 mM 3 2.24 10 2.32 
 
2.31 7.84 
 
 
Table 4.6: Summary of the experimentally determined SAXS parameters obtained on the 
tagged and untagged EBA181945-1097 / 4.1R10kDa complex, the 4.1R10kDa / Pf30 complex and 
the 4.1R10kDa / Pr30 complex. The data set highlighted in bold was chosen to perform the 
structural characterisation and the ab-initio modelling. N.D.: non-determined values due to 
insufficiently good data. 
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The small-angle X-ray scattering curve of the untagged EBA181945-1097 / 4.1R10kDa 
complex, after subtraction of the SAXS background of the buffer alone and reduction of 
the data to the range 0.05 nm
-1
 to 4.5 nm
-1
, is shown in Figure 4.15 A. The associated P(r) 
was then calculated (Figure 4.15 B) and ab-initio modelling was performed: ten models 
were created using DAMMIF, as shown in Figure 4.15 C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: (A) Buffer subtracted SAXS curves of the untagged EBA181945-1097 / 
4.1R10kDa protein complex and (B) associated calculated P(r) and (C) ab-initio 3D models 
using DAMMIF (10 models). 
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The ten models of the EBA181945-1097 / 4.1R10kDa complex were averaged using 
DAMAVER (Figure 4.18). In order to validate them, the back-calculated scattering curve 
from the modelling was also calculated and is displayed in green on the experimental red 
scattering curve and shows a good match (right hand side). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Averaged ab-initio 3D model of the untagged EBA181945-1097 / 4.1R10kDa 
protein complex using DAMAVER and displayed as spheres (left) and fit of the simulated 
scattering curve in green versus the experimental data in red (right). 
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The disordered state of the untagged EBA181945-1097 and 4.1R10kDa protein complex has 
also been assessed by the means of a Kratky plot. The Kratky plot analysis showing the 
presence of a typical plateau reveals the complex to be unfolded (Figure 4.17). It is 
particularly interesting to mention here that, at the SAXS resolution, there is no apparent 
folding resulting from the binding of the two protein partners, as it is often observed for 
other intrinsically disordered protein complexes (Sugase et. al, 2007). 
 
 
 
 
 
Figure 4.17: Kratky plot of the untagged EBA181945-1097 / 4.1R10kDa protein complex. 
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4.4 Structural characterisation of the EBA-181 / 4.1R complex 
using small-angle neutron scattering 
 
The complex formed between EBA181945-1097 and 4.1R10kDa was analysed by small-angle 
neutron scattering. The untagged version of the EBA181945-1097 and 4.1R10kDa protein 
complex, more biologically relevant than the tagged complex, was chosen and further 
analysed in this section. To achieve this, the use of protein deuteration was exploited: the 
EBA181945-1097 protein was expressed as 75% deuterated and the 4.1R10kDa protein as 
100 % hydrogenated. The H2O/D2O based buffers enabled to fully exploit the contrast 
variation approach by using three different D2O percentages (Figure 4.19). In the 0 % D2O 
buffer (NaP pD 6.0), the whole complex is visible (A). In the 40 % D2O buffer, the 
hydrogenated protein is matched out and only the deuterated one is visible. Thus, the 
4.1R10kDa protein is matched out and the EBA181945-1097 protein remains visible (B). In the 
100 % D2O buffer, the opposite occurs, with the deuterated EBA181945-1097 protein 
matched out and the hydrogenated 4.1R10kDa remaining visible (C). 
 
     
 
Figure 4.19: Principle of the SANS experiment on the EBA181945-1097 / 4.1R10kDa complex 
using contrast variation (as a reminder). The colours used for the representation of the 
different protein domains are kept for the next figures and analyses. 
C) B) A) 
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The best scattering results were obtained with a distance sample-to-detector of 2 metres 
and a wavelength of 8Å and are thus presented here-after. The ones performed at 
5.6 metres and 17 metres are not shown. 
 
4.4.1 SANS characterisation of the EBA181945-1097 / 4.1R10kDa protein complex 
in 0 % D2O 
The protein complex between EBA181945-1097 and 4.1R10kDa was firstly analysed in 
0% D2O, in the NaP buffer at pD 6.0. This condition is the same as that used during the 
SAXS experiments and previously described in this chapter. As already mentioned, 
in 0 % D2O none of the hydrogenated 4.1R10kDa or the deuterated EBA181945-1097 is 
matched out, therefore the whole complex is visible under these conditions. The scattering 
of the background was firstly subtracted from the scattering curve (calibration including 
the adjustment of the position of the centre of the detector and the background correction 
factors calculated with the scattering measurements of cadmium alone, H2O alone and one 
empty cell). The resulting subtracted curve is shown in Figure 4.20. 
 
Following this, this scattering curve of the EBA181945-1097 and 4.1R10kDa complex sample 
was subtracted with the scattering curve of its respective buffer (NaP buffer at pH 6.0 in 
0 % D2O), with the result shown in Figure 4.21. For the whole complex the Guinier 
analysis gives a radius of gyration equal to 3.95 nm (Figure 4.22), a Dmax of 10.8 nm 
(Figure 4.23) and a Porod volume of 44.1 nm
3
. 
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Figure 4.20: Background subtracted SANS curve of the complex in 0 % D2O buffer. 
 
 
 
 
 
Figure 4.21: Buffer subtracted SANS curve of the complex in 0 % D2O NaP buffer. 
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Figure 4.22: Guinier region of the buffer subtracted SANS curve of the complex in 0 % 
D2O NaP buffer. 
 
 
The P(r) function associated to the buffer subtracted SANS curve of the complex in 0 % 
D2O was calculated and 10 ab-initio 3D models were generated using DAMMIF 
(Figure 4.23). From these 10 models, an averaged 3D model was generated using 
DAMAVER as shown in Figure 4.24. 
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Figure 4.23: (A) Calculated P(r) from the buffer subtracted SANS curves of the untagged 
EBA181945-1097 / 4.1R10kDa complex in 0 % D2O and (B) ab-initio modelling using DAMMIF 
(10 models). 
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Figure 4.24: Averaged ab-initio 3D model of the untagged EBA181945-1097 / 4.1R10kDa 
complex in 0 % D2O using DAMAVER. Displayed respectively as spheres (left) and 
scattering curves (right). Red: experimental, green: back calculated from the model. 
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4.4.2 SANS characterisation of the EBA181945-1097 / 4.1R10kDa protein complex 
in 40 % D2O 
In the second experiment, the EBA181945-1097 and 4.1R10kDa protein complex was analysed 
in 40 % D2O. In this case, the hydrogenated 4.1R10kDa protein is matched out, thus the 
75 % deuterated EBA181945-1097 protein should be the only one visible in the complex.  
 
As for the in 0 % D2O analysis, the scattering of the background was firstly subtracted 
from the scattering curve. The resulting subtracted curve is shown in Figure 4.25. 
 
 
 
 
 
Figure 4.25: Background subtracted SANS curve of the complex in the 40 % D2O buffer. 
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Following this step, the scattering curve of the EBA181945-1097 and 4.1R10kDa complex was 
subtracted with the scattering curve of its respective buffer (NaP buffer at pH 6.0 in 40 % 
D2O), with the result shown in Figure 4.26. The resulting scattering curve shows high 
noise above 0.12 Å
-1
. This can be explained by the low protein concentration used here 
(2 mg/ml) and can be explained by the low intensity of the neutron flux in comparison to 
the X-ray flux of a synchrotron that allows to study proteins at very low concentrations. 
The Guinier analysis gives for the EBA181945-1097 molecule in the complex a Rg equal to 
4.14 nm (Figure 4.27) and a Dmax of 11.1 nm (Figure 4.28). These results are close to those 
obtained in 0% D2O (10.8 nm) meaning that the EBA181945-1097 protein is, due to its 
disordered state and with regard to the size, the main object in the complex, with little 
apparent contribution from 4.1R10kDa. 
 
The P(r) function was calculated using the buffer subtracted SANS curve of the complex in 
40 % D2O and 10 ab-initio 3D models were generated using DAMMIF (Figure 4.28). 
From these 10 models, an averaged 3D model was generated using DAMAVER, as shown 
in Figure 4.29. 
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Figure 4.26: Buffer subtracted SANS curve of the complex in the 40 % D2O buffer. 
 
 
 
 
Figure 4.27: Guinier region of the buffer subtracted SANS curve of the complex in the 
40 % D2O buffer. 
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Figure 4.28: (A) Calculated P(r) from the buffer subtracted SANS curves of the untagged 
EBA181945-1097 / 4.1R10kDa complex in 40 % D2O and (B) ab-initio modelling using DAMMIF 
(10 models). 
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Figure 4.29: Averaged ab-initio 3D model of the untagged EBA181945-1097 / 4.1R10kDa 
complex in 40 % D2O using DAMAVER. Displayed respectively as spheres (left) and 
scattering curves (right). Red: experimental, green: back calculated from the model. 
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4.4.3 SANS characterisation of the EBA181945-1097 / 4.1R10kDa protein complex 
in 100 % D2O 
In the final SANS experiment, the EBA181945-1097 and 4.1R10kDa protein complex was 
analysed in 100 % D2O. In this case the 75 % deuterated EBA181945-1097 protein is matched 
out and the hydrogenated 4.1R10kDa protein remains visible. As performed and presented 
before, the scattering of the background was firstly subtracted from the scattering curve, 
with the resulting subtracted curve shown in Figure 4.30. 
 
 
 
Figure 4.30: Background subtracted SANS curve of the complex in 100 % D2O NaP 
buffer. 
 
 
Following this step, the scattering curve of the EBA181945-1097 / 4.1R10kDa complex was 
subtracted with the scattering curve of its respective buffer (NaP buffer at pH 6.0 in 100 % 
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D2O) as shown in Figure 4.31. The Guinier analysis gives for the 4.1R10kDa molecule in the 
complex a radius of gyration equal to 1.78 nm (Figure 4.32) and a Dmax of 6.0 nm 
(Figure 4.33). These results are consistent with those measured in SAXS for the 4.1R10kDa 
protein alone, with a Rg of 2.02 nm and a Dmax of 6.0 nm. 
 
The P(r) function associated with the buffer subtracted SANS curve of the complex in 
100 % D2O was calculated and 10 ab-initio 3D models were generated using DAMMIF in 
slow mode (Figure 4.33). From these 10 models, an averaged 3D model was generated 
using DAMAVER, as shown in Figure 4.34. 
 
 
 
 
Figure 4.31: Buffer subtracted SANS curve of the complex in 100 % D2O NaP buffer. 
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Figure 4.32: Guinier region of the buffer subtracted SANS curve of the complex in 100 % 
D2O NaP buffer. 
 
 
 
 
 
 
 
 
 
Figure 4.33: (A) Buffer subtracted SANS curves of the untagged EBA181945-1097 / 
4.1R10kDa complex in 100 % D2O; (B) associated calculated P(r) and (C) ab-initio modelling 
using DAMMIF (10 models). 
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Figure 4.34: Averaged ab-initio 3D model of the untagged EBA181945-1097 / 4.1R10kDa 
complex in 100 % D2O using DAMAVER. Displayed respectively as spheres (left) and 
scattering curves (right). Red: experimental, green: back calculated from the model. 
 
 
4.4.4 Validation of the data 
It is possible to monitor the quality of a contrast variation experiment by calculating the 
following parameter √
𝑰𝟎
𝑪.𝑻.𝒆
  (Ibel et al., 1975) which is proportionally linear with the D2O 
percentage in a theoretically perfect experiment. I0 is the zero intensity, C the sample 
concentration in mg/ml, T the transmission and e the path-length in cm, and the result can 
have a positive or a negative sign. The contrast variation results are presented in Table 4.7 
and Figure 4.35. 
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As shown in Figure 4.35, the √
𝑰𝟎
𝑪.𝑻.𝒆
 parameter results in a linear curve in function of the 
percentage of D2O when applied to the three contrasts chosen for the SANS: 0 %, 40 % 
and 100 % D2O. This validates the SANS experiment using deuterium-based contrast 
variation. 
 
  0 % D2O 40 % D2O 100 % D2O 
√
𝑰𝟎
𝑪. 𝑻. 𝒆
 (±) 1.08 (±) 0.64 (±) 0.28 
 
Table 4.7: Contrast variation experiment of the untagged EBA181945-1097 / 4.1R10kDa 
complex. 
 
 
 
Figure 4.35: Validation of the neutron contrast variation experiment performed on the 
untagged EBA181945-1097 / 4.1R10kDa protein complex. 
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4.5 Discussion and conclusions: SAXS and SANS consensus 
 
A summary of the main structural parameters derived from the SAXS and SANS data is 
given in Table 4.8.  
 
 
Individual proteins 
 
His-EBA181945-1097 EBA181945-1097 GST-4.1R10kDa 4.1R10kDa 
Rg 2.40 nm 2.35 nm 4.17 nm 2.02 nm 
Dmax 9.1 nm 7.9 nm 12.0 nm 6.0 nm 
 
 
  EBA181945-1097 / 4.1R10kDa complex 
  SAXS SANS 0 % D2O SANS 40 % D2O SANS 100 % D2O 
Rg 3.53 nm 3.95 nm 4.14 nm 1.78 nm 
Dmax 10.4 nm 10.8 nm 11.1 nm 6.0 nm 
 
Table 4.8: Structural parameters (Rg and Dmax) derived from (A) SAXS measurements on 
tagged and untagged EBA181945-1097 and 4.1R10kDa proteins and (B) SAXS and SANS 
measurements in the three solvent contrasts on the untagged EBA181945-1097 / 4.1R10kDa 
protein complex. 
 
B) 
A) 
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Firstly, the analysis of the SAXS data recorded from the tagged constructs of the 
His-EBA181945-1097 and GST-4.1R10kDa proteins has provided their structural parameters in 
solution (Table 4.8, A). In order to further characterise their structures a Kratky plot 
analysis was performed (Figure 4.9), re-emphasising the disordered state of the tagged 
His-EBA181945-1097 protein, as described following the biophysical characterisation 
performed and described in Chapter 3. Ab-initio modelling was performed (Figure 4.7 and 
Figure 4.8) on both tagged His-EBA181945-1097 and GST-4.1R10kDa proteins. 
His-EBA181945-1097 is an elongated shape whereas GST-4.1R10kDa appears to be mostly 
folded, as expected given that approximately two-thirds of the protein constitutes the GST 
tag. Moreover, a comparison of the 3D models for the GST tag alone, and that derived 
from the GST-4.1R10kDa protein provides a useful insight into the location and structure of 
the tag within the protein (Figure 4.10). The GST tag has a globular shape, as expected by 
comparison with its crystal structure, whilst the 10 kDa domain of the 4.1R protein appears 
substantially more elongated.  
 
Secondly, the analysis of the SAXS data for the untagged constructs of the proteins 
(EBA181945-1097 and 4.1R10kDa) yielded their structural parameters (Table 4.8, A), with 
respectively their Rg measured at 2.35 nm and 2.02 nm, and their Dmax equal to 7.9 nm and 
6.0 nm. A Kratky plot analysis for these proteins (Figure 4.17) shows EBA181945-1097 to be 
disordered and 4.1R10kDa to be partially folded. These results are again in agreement with 
the biophysical characterisation performed (Chapter 3) which includes CD, 1D NMR and 
the measurement of their respective sizes (Rh) using DLS, leading to values corresponding 
to folded proteins with a four times higher molecular mass. In addition, the averaged 
ab-initio models show elongated shapes for both EBA181945-1097 and 4.1R10kDa. Finally in 
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order to validate the data, the simulated scattering curves from the models were calculated 
and provide a good fit to the experimental data (Figures 4.12 and 4.13). 
 
The final SAXS data analysis was performed on the complex formed by the untagged 
EBA181945-1097 and 4.1R10kDa proteins, with the resulting structural parameters summarised 
in Table 4.8, B. Interestingly, the Kratky plot analysis suggests that the complex is 
disordered, implying there is no significant protein structural ordering upon binding and 
complex formation. Ab-initio modelling reveals that the complex adopts a ‘T-shaped’ 
structure with the 4.1R10kDa protein which protrudes from the central region of the 
elongated EBA181945-1097 (Figure 4.16). 
 
SANS studies add a powerful complement to the SAXS results in that they allow (i) the 
identification of the location of the protein partners within the complex, and (ii) by 
comparison with individual protein forms they allow conformation changes in each protein 
(if any) before and after binding to be studied and imaged. This SANS study of the 
untagged EBA181945-1097 / 4.1R10kDa protein complex used solvent contrast variation with 
varying amount of D2O to match out, in turn, each of the proteins involved in the complex. 
 
At 0 % D2O (corresponding to schematic A in Figure 4.19) both molecules are visible, 
providing the structural parameters of the whole complex in solution (Table 4.8) and 
enabling the complex of the deuterated EBA181945-1097 with the hydrogenated 4.1R10kDa 
protein to be modelled (Figures 4.24). The ab-initio models derived from the SAXS and 
SANS data give a very similar T-shaped structure (Figure 4.36, C) and close structural 
parameters. The corresponding Rg and Dmax values on the complex are respectively 
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3.95 nm and 10.8 nm for the SAXS measurement, 3.53 nm and 10.4 nm for the SANS 
measurement in 0 % D2O.  
 
For the experiment at 40 % D2O experiment (corresponding to schematic B in 
Figure 4.19), in principle the hydrogenated 4.1R10kDa protein is matched out and thus only 
the deuterated EBA181945-1097 is visible in the complex (Figure 4.29). The structural 
parameters calculated from these SANS data for the deuterated EBA181945-1097 in its 
complexed form are higher than those obtained from SAXS for the individual 
EBA181945-1097 protein (Table 4.8), with a measured Rg of 4.14 nm by SANS compared 
with 2.35 nm by SAXS; and a Dmax of respectively 11.1 nm by SANS for 7.9 nm by 
SAXS. This may mean that the EBA181945-1097 is stretched when in complex with 
4.1R10kDa. Nevertheless, it should be noted that the SANS data measured in 40 % D2O have 
a low signal/noise ratio and thus the derived structural parameters need to be taken with 
caution. It could also be caused by the 4.1R10kDa protein not being completely matched out 
and thus contributing to the measured size. Indeed, the 40 % contrast value of D2O is only 
theoretical and the experimental contrast to completely match out the 4.1R10kDa protein 
might thus be slightly different. However, the comparison between the ab-initio models 
from the SAXS and SANS experiments shows a good agreement in their overall elongated 
shapes, although their relative sizes are different (Figure 4.36, B). 
 
For the SANS experiment performed in 100 % D2O (corresponding to schematic C in 
Figure 4.19), the deuterated EBA181945-1097 is matched out, with the hydrogenated 
4.1R10kDa staying visible and thus being modelled in its complexed form (Figure 4.34). The 
Rg and Dmax obtained were in good agreement with the values obtained by SAXS for the 
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4.1R10kDa protein in its uncomplexed form (Table 4.8), with a Rg of 1.78 nm (2.02 nm in 
SAXS) and a Dmax of 6.0 nm (also 6.0 nm in SAXS). The comparison between the SANS 
and SAXS data shows similar 3D ab-initio models and the only difference comes from the 
conformation slightly more closed of 4.1R10kDa when in complex, with measurement of its 
internal angle decreasing to 120°, instead of 140° when in the free form (Figure 4.36, A). 
 
This work highlights key aspects of importance for small-angle solution scattering studies 
of biological macromolecules. A successful solution scattering study requires 
monodisperse protein solutions, free of both insoluble and soluble aggregates. This is an 
essential prerequisite in every scattering experiment and a crucial point for structural 
modelling. Since the scattering of a particle is related to the square of its scattering length, 
aggregates contribute disproportionally to the signal, resulting in interpretation difficulties. 
A mixture of different oligomeric forms also leads to an interpretation problem, 
highlighting the necessity of performing extensive biochemical and biophysical analysis on 
the samples as a prerequisite of every SAS experiment, as presented in Chapter 3. In the 
case of this work, aggregation issues were addressed by working at low temperature during 
the whole purification process, using freshly purified samples for every scattering 
experiment, and lastly, by performing a high speed centrifugation of the samples just 
before the scattering measurements. Hence, the proteins used were pure and monodisperse 
(as assessed by DLS) after the final step of optimisation and purification.  
 
In conclusion, the SAXS and the SANS analyses provide good agreement in terms of the 
solution state modelling, including the 3D models of the individual proteins as well as the 
complex formed between them (Figure 4.36, A, B and C). 
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Figure 4.36: Comparison of the final SAXS and SANS 3D models of (A) uncomplexed 
form of 4.1R10kDa (left) and complexed form of 4.1R10kDa (right), (B) uncomplexed 
EBA181945-1097 (left) and complexed EBA181945-1097 (right), and (C) the final 3D models of 
the full complex by SAXS (left) and SANS (right). 
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5. SOLUTION STATE NMR STUDIES OF EBA181945-1097, 
4.1R10kDA AND THEIR COMPLEX 
 
 
Abstract 
 
This chapter describes NMR solution state studies that were carried out on the 
EBA181945-1097 and 4.1R10kDa proteins, and on the complex formed between the two. The 
motivation for this work derived from the nature of the results described in Chapter 3 and 
Chapter 4 where a wide body of evidence demonstrated that the EBA181945-1097 protein 
was itself intrinsically disordered and that the 4.1R10kDa was only partially folded. Despite 
this, there was clear evidence of complex formation between the two proteins (Chapters 3 
and 4). Hence one of the major goals of this NMR work was to further assess the nature of 
the individual proteins and their complex. This study is also of interest since intrinsically 
disordered proteins are of emerging importance, given that they are implicated in a wide 
range of interactions where a specific structure is only formed upon binding with a 
particular protein partner. 
 
A detailed structural and dynamic characterisation of the protein is presented here, using 
NMR spectroscopy. The experiments confirmed the unstructured nature of EBA181945-1097, 
providing detailed insight on its dynamic and structural behaviour. EBA181945-1097 is 
predominantly a random coil molecule containing several turn motifs. It does not contain 
transiently populated secondary structures as it occurs in numerous intrinsically 
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disordered proteins that fold via specific, pre-formed molecular recognition elements. 
Experiments carried out on the GST tagged 4.1R10kDa demonstrated partial folding. 
Titration studies of the complex were carried out and showed evidence of complex 
formation. 
 
5.1 Introduction 
 
Applications of nuclear magnetic resonance can be very broad: characterisation of soluble 
biomolecules, interfaces and complexes, determination of protein structure or 
thermodynamic parameters. The samples have to be concentrated (> 0.1 mM) and their 
molecular weight can be a limiting factor: 30-40 kDa is often taken as a maximum for 
protein structure determination. NMR spectra of proteins are complex, due to their large 
molecular weight and number of atoms present. Deuterium labelling is often used to 
overcome molecular weight limitations by minimising the effect of proton dipolar 
coupling. 
15
N 
13
C isotope labelling are often used to allow backbone and residue 
assignment respectively. 
 
Results from the previous chapters have clearly demonstrated the EBA181945-1097 protein to 
belong to the family of intrinsically disordered proteins. The intrinsic disorder of EBA-181 
and the lack of structure of 4.1R10kDa clearly limit the applicability of conventional 
structure determination methods. The data shown in Chapter 3 provide abundant evidence 
of the unstructured nature of EBA181945-1097 from CD, 1D-NMR and TSA. Similar 
measurements on 4.1R10kDa suggest approximately 35% alpha-helical content. Despite 
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clear evidence of complex formation from biochemical and biophysical studies, the 
complex itself appears to be substantially disordered and the attempts to crystallise the 
individual proteins and the complex were unsuccessful. The NMR studies were based on 
the use of selective 
15
N and 
13
C labelling such that the individual proteins could be studied 
and their complex formation assessed in a number of titration experiments, firstly where 
unlabelled 4.1R10kDa was titrated into double labelled EBA181945-1097, and secondly where 
unlabelled EBA181945-1097 was titrated into double labelled GST-4.1R10kDa. 
 
In recent years, intrinsically disordered proteins have emerged as an important class of 
proteins which lack significant amounts of secondary and tertiary structure but play active 
roles in many biological processes (Dunker et al., 2001; Dunker et al., 2008; Tompa et al., 
2012). This chapter focuses on the structural and dynamic characterisation of Plasmodium 
falciparum EBA181945-1097 and human 4.1R10kDa domains using solution state NMR to 
supplement the structural studies presented in the previous chapters. This work was carried 
out in collaboration with the NMR group of the ‘Institut de Biologie Structural’ (IBS) in 
Grenoble. Section 5.2 describes the material and methods used to perform the NMR 
spectroscopy experiments, including sample preparation and 
15
N / 
15
N
13
C labelling. 
Section 5.3 describes the spectroscopy results obtained using single- and double-labelled 
EBA181945-1097 protein, including 
1
H-
15
N and 
13
C-
15
N heteronuclear single quantum 
coherence (HSQC) spectra, complete spectral assignment of double labelled 
EBA181945-1097, chemical shifts, backbone dynamics, structural ensemble descriptions and 
residual dipolar coupling measurements. Section 5.4 presents the initial results obtained on 
double labelled GST-4.1R10kDa protein as well as when in complex with EBA181945-1097. 
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Finally, Section 5.5 summarises and concludes the chapter with a summary of the results 
obtained and suggestions for future work. 
 
 
5.2 Material and methods 
 
5.2.1 Sample production and labelling for NMR solution studies 
5.2.1.1  Large-scale protein expression 
As described in Chapters 3 and 4, the E. coli Rosetta™ 2 (DE3) bacterial cells expressing 
either the His-EBA181945-1097 or the GST-4.1R10kDa proteins and stored at -80°C were used 
here to initiate the bacterial cultures in minimum medium (‘Ross’ medium). The Ross 
minimum medium (Ross et al., 2004) was slightly modified and used to express single- and 
double-labelled (
15
N and 
13
C/
15
N) His-EBA181945-1097 and GST-4.1R10kDa proteins 
(Tables 5.1 and 5.2). After preliminary expression tests (not shown), the 
His-EBA181945-1097 and the GST-4.1R10kDa proteins were expressed by inducing the 
bacterial cultures with 1 mM IPTG during 16 hours at 30°C. 
 
5.2.1.2 Protein purification 
As previously described in Chapter 3, the EBA181945-1097 and GST-4.1R10kDa proteins were 
firstly purified by affinity chromatography (IMAC) using respectively a nickel or a GST 
resin. Their  tags  were  cleaved  using  thrombin  protease  (followed  by  a second affinity 
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Modified Ross medium pH 6.8 Concentration 
 
Glucose monohydrate 
(
12
C / 
13
C-labelled) 
 
 
 3.41    g/l 
 
Magnesium sulphate 1.2    g/l 
Potassium dihydrogen phosphate 8.7    g/l 
85% phosphoric acid 7.38    g/l 
Ammonium chloride (
15
N labelled) 1.94    g/l 
6 M sodium hydroxide 6.67  ml/l 
Thiamine hydrochloride 
 
Trace elements* 
9 mg/l 
 
1 ml/l 
 
Table 5.1: Modified Ross medium preparation used to label the proteins (initially from 
Ross et al., 2004). 
 
*trace elements (x1000) Concentration 
 
Fe2(SO4)3.H2O 
 
82.3   g/l 
CoSO4.7H2O        4.7   g/l 
MnSO4.H2O 20.1   g/l 
CuSO4.5H2O 3.4   g/l 
H3BO3 4.7   g/l 
Na2MoO4.2H2O 4.7   g/l  
ZnSO4.7H2O 
EDTA 
Concentrated sulphuric acid (18M) 
53.0   g/l 
14.1   g/l 
4 ml/l 
 
Table 5.2: Trace element preparation required for the bacterial expression medium.  
 
 
purification step for the EBA181945-1097 protein in order to remove the cleaved his tag). 
Finally, the proteins were purified on a size exclusion chromatography column 
(Superdex
TM
 75). The two proteins were analysed in the following buffer conditions: 
50 mM NaH2PO4 / Na2HPO4 at pH 6.0 + 50 mM NaCl. 
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5.2.2 Solution-state NMR experiments 
5.2.2.1  Spectrometers 
NMR experiments were performed on Varian/Agilent VNMRS 600 MHz and 800 MHz 
spectrometers using room temperature as well as cryogenically cooled triple-resonance 
HCN probes. Both of these spectrometers are located at the Instititut de Biologie 
Structurale (IBS) located on the EPN campus. These NMR systems were used to carry out 
HSQC experiments on the samples made for this study (see more details in Section 2.2.4). 
 
5.2.2.2  NMR spectroscopy 
The NMR spectral assignment was obtained using a series of BEST-type triple resonance 
experiments: HNCO, intra-residue HN(CA)CO, HN(CO)CA, intra-residue HNCA, 
HNCOCACB and intra-residue HNCACB. The spectra were processed in NMRPipe 
(Delaglio et al., 1995), analysed using the program SPARKY (T. D. Goddard and D. G. 
Kneller, SPARKY 3, University of California, San Francisco) and automatic assignment of 
spin systems was achieved using MARS (Jung et al., 2004), followed by manual 
verification. Secondary chemical shifts were calculated using the random coil values from 
RefDB (Zhang et al., 2003). Site specific 
15
N R1, R2 and {
1
H}-
15
N heteronuclear nOes 
were measured using pulse sequences. The heteronuclear nuclear Overhauser effect (nOes) 
were obtained as the ratio between the two spectra acquired with and without initial proton 
saturation. The experiment was repeated twice and the values of the nOes were taken as the 
average between these two measurements. Residual dipolar couplings (RDCs) were 
measured in a liquid crystal composed of poly-ethylene glycol and 1-hexanol. 
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5.2.2.3  Structural ensemble selections on the basis of experimental NMR data 
Ensemble selections of EBA181945-1097 were carried out by generating a large pool of 
statistical coil conformers (10000 structures) using Flexible-Meccano (Ozenne et al., 
2012). From this pool, five representative ensembles of 200 conformers each were selected 
using ASTEROIDS (Salmon et al., 2010) on the basis of the experimental chemical shifts. 
The backbone dihedral angles were extracted from the five representative ensembles 
giving 1000 / pairs for each residue. These dihedral angle distributions were used to 
generate a new pool of conformers of EBA181945-1097 from which a new round of 
selections of five ensembles was carried out. This procedure was repeated five times (five 
iterations) until convergence with respect to the experimental data was achieved.  
 
The five ensembles obtained at the end of the fifth iteration were analysed in terms of site-
specific populations in four distinct regions of Ramachandran space defined as: L { > 
0°}; R { < 0, -120° < ψ < 50°}; P {-100° <  < 0°, ψ > 50° or ψ < -120°}; S {-180° < 
 < -100°, ψ > 50° or ψ < -120°}. The populations of these quadrants are respectively 
denoted p(L), p(R), p(P) and p(S). 
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5.3 NMR solution spectroscopy measurements from EBA181945-1097  
 
5.3.1 Structural and dynamic characterisation of EBA181945-1097 
An analysis of the amino acid composition of RIII-V domains of the EBL proteins 
(Figure 5.1, A) reveals an abundance of charged amino acids (lysines, glutamic and 
aspartic acids), as well as hydrophilic residues (threonine and serine). Moreover, the EBL 
proteins are depleted in hydrophobic amino acids necessary for forming stable 
hydrophobic cores in folded proteins. A comparison with the amino acid composition of 
the DisProt database (http://www.disprot.org/) reveals that the disordered regions of the 
EBL proteins are richer in asparagines, serines and glutamic acids, while lacking alanines 
that normally represent one of the most common amino acid types in intrinsically 
disordered proteins (Figure 5.1, B). The functional role of RIII-V remains to be elucidated; 
however, they may function as interaction platforms for different cellular partners (see 
Chapter 3, prediction of interaction sites carried out using the server ANCHOR). 
 
5.3.1.1 1H-15N HSQC and 13C-15N HSQC NMR spectra of labelled EBA181945-1097 
Functionally disordered proteins often possess transiently populated secondary structures 
used by other proteins as molecular recognition elements. Once bound to their protein 
partners, these molecular recognition elements usually undergo folding into specific 
conformations. This pre-formation of secondary structure may facilitate the binding 
process by lowering the entropic cost of folding from a completely unfolded chain. In 
order to obtain information about transiently populated secondary structures, 
  
221 
 
EBA181945-1097 was labelled (
15
N and 
15
N-
13
C) and characterised at near atomic resolution 
using NMR spectroscopy.  
 
 
 
 
 
 
Figure 5.1: (A) Domain organisation of the three erythrocyte binding-like proteins 
EBA-175, EBA-140 and EBA-181. The blue and green colour indicates the folded regions 
(homology compared to the crystal structures of regions II and RVI available for EBA-175) 
and the positions of the transmembrane regions are indicated in red. The red box 
indicates the location of the EBA181945-1097 domain. (B) Amino acid composition within the 
RIII-V regions of the EBL proteins EBA-140 (blue), EBA-175 (red) and EBA-181 (green) 
compared to the composition of the DisProt database release 6.02 (orange). 
 
 
B) 
EBA181945-1097 
A) 
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Determination of the oligomeric state is a prerequisite required for the analysis of the NMR 
experiments. It was showed using size exclusion chromatography combined with detection 
by multi-angle laser light scattering and refractometry that EBA181945-1097 is monomeric in 
solution (Chapter 3). The far-UV circular dichroism spectrum of the protein displayed a 
typical signature of random coil conformations with a minimum around 202 nm, and the 
initial 1D NMR spectrum carried out also showed the unfolded state of EBA181945-1097 
(Chapter 3).  In order to increase the resolution of the initial 1D-NMR spectrum presented 
in Chapter 3, and to ensure the feasibility of the next NMR solution experiments involving 
labelling using 
13
C and 
15
N isotopes, the first NMR experiment was carried out on single 
labelled 
1
H-
15
N EBA181945-1097. Thus, the disordered state of the EBA181945-1097 protein 
was demonstrated with certitude as shown by the HSQC spectrum and its limited signal 
dispersion in the 
1
H dimension, characteristic of an intrinsically disordered protein 
(Figure 5.2, A). 
 
In  order to assign each amino acid to the different peak of the 
1
H-
15
N HSQC spectrum, 
and to be able to carry out the full set of solution state NMR experiments, the 
EBA181945-1097 protein was produced as double labelled (
13
C and 
15
N). Figure 5.2 A 
displays the 
1
H-
15
N HSQC spectrum on single 
15
N labelled EBA181945-1097 protein. The 
13
C-
15
N HSQC spectrum on double 
15
N-
13
C labelled EBA181945-1097 protein was also 
acquired but is not shown here. The complete spectral assignment of the 
1
H
N
, 
15
N, 
13
C, 
13C’ and 13C nuclei of the protein was carried out using a set of standard triple resonance 
experiments (Appendix C, Table C.1) and the final HSQC spectrum with the complete 
attribution is presented in Figure 5.2 B. 
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Figure 5.2: A: 1H-15N HSQC on single labelled EBA181945-1097 (298 K) and B: 
1H-15N 
HSQC spectrum of EBA181945-1097 (298K) showing the spectral assignment of the NMR 
resonances.  
 
 
5.3.1.2  Characterisation of the structure and dynamics of EBA181945-1097 
In order to characterise further the transient structure and dynamics of the EBA181945-1097 
protein, chemical shifts were measured. As shown in Figure 5.3 A, the secondary C 
chemical shifts, which are the difference between the experimental C chemical shifts and 
the chemical shifts expected for a random coil chain, showed the protein to be intrinsically 
disordered without significantly populated secondary structure elements. These results are 
A) B) 
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in agreement with the results from Chapters 3 and 4. The backbone dynamics of the protein 
were characterised (pico- to nano-second time scale) through the measurements of 
15
N spin 
relaxation. With values close to zero at a 
1
H frequency of 600 MHz, the {
1
H}-
15
N 
heteronuclear nOes (Figure 5.3 B) displayed a profile characteristic of a disordered protein, 
in agreement with the previous results. The strong decrease of the nOes values from 
residues 1088 showed increased dynamics towards the C-terminus of the protein. On the 
contrary, the region encompassing residues 980-1025 shows on average larger 
heteronuclear nOes, with two short stretches having positive values (residues 986-988 and 
1016-1020) corresponding to a rigidification of these parts of the protein compared to the 
remainder of the chain. The 
15
N transverse and longitudinal spin relaxation rates 
(Figure 5.3 C and D) followed a similar pattern to 
15
N R2 rates, enhanced in the regions 
also showing positive heteronuclear nOes.  
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Figure 5.3: Characterisation of the structure and dynamics of EBA181945-1097. (A) 
Secondary C chemical shifts of EBA181945-1097. (B) {
1H}-15N heteronuclear nOes. (C) 15N 
R2 spin relaxation rates. (D) 
15N R1 spin relaxation rates. All relaxation data were obtained 
at a 1H frequency of 600 MHz and at 298 K. 
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5.3.2 Structural ensemble description of EBA181945-1097 from experimental 
chemical shifts 
In order to obtain more details about the local conformational sampling of EBA181945-1097, 
ensemble selections of the protein were carried out based on the experimental chemical 
shifts. Thus, 10000 structures were generated using the statistical coil generator 
Flexible-Meccano to create a large pool of random coil conformers of the EBA181945-1097 
protein. The genetic algorithm ASTEROIDS was finally used to select representative sub-
ensembles of EBA181945-1097 based on the measured chemical shifts (200 conformers). 
Excellent agreement was obtained between the experimental chemical shifts and those 
back-calculated from the ASTEROIDS ensembles (Figure 5.4).  
 
Following this, a detailed analysis of the site-specific conformational sampling in these 
selected ASTEROIDS ensembles revealed around 15 % depletion of the -strand region 
of Ramachandran space compared to statistical coil sampling, as well as an increase in the 
poly-proline II (P) populations in several regions of the protein. The increase reached 
20% additional sampling in the P region compared to statistical coil populations for some 
of the proline regions in the sequence, for example around P945, P949, P1003, P1039, 
P1040 and P1044 (Figure 5.5). In other regions, poly-proline II sampling was also 
enhanced but independently of the presence of proline residues (for example for the 
C-terminal residues 1085-1092). 
 
Further analysis of the conformational sampling of EBA181945-1097 showed an increase of 
the alpha-helical population in four different regions of the protein: residues 979-982, 
  
227 
 
986-988, 1006-1009 and 1016-1019, corresponding to the region displaying the largest 
heteronuclear nOes and transverse spin relaxation rates as previously described. These 
regions could adopt turn motifs or short -helices with populations of around 15-20 %, 
leading to a rigidification of the protein. This behaviour is also displayed by the calculation 
of the secondary structure propensity (SSP, Kragelj et al., 2013), a combined analysis of 
Cα and Cβ chemical shifts. The SSP is equal to 1 for 100 % α-helices and to -1 for 100 % 
β-sheets. As shown in Figure 5.6, the propensity to form secondary structure is very low, in 
the order of 10 to 20 %. Thus, the EBA181945-1097 protein is essentially intrinsically 
disordered, with a weak helical propensity (up to 20%) distributed all over the sequence. 
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Figure 5.4: Generation of representative structural ensembles of EBA181945-1097 on the 
basis of experimental chemical shift values. Comparison of experimental secondary 
chemical shifts (red) and back-calculated values from a selected ASTEROIDS ensemble 
comprising 200 conformers (blue). From top to bottom: C, C, C’, N and HN secondary 
chemical shifts.  
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Figure 5.5: Site-specific populations of EBA181945-1097 in four distinct regions of 
Ramachandran space derived from ASTEROIDS ensembles selected on the basis of 
experimental chemical shift. Red bars indicate populations derived from the experimental 
chemical shifts, while blue lines correspond to statistical coil populations.  
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Figure 5.6: EBA181945-1097 secondary structure propensity (SSP), combined analysis of 
Cα and Cβ chemical shifts. SSP: +1 for 100 % α-helices and -1 for 100 % β-sheets. 
 
 
5.3.3 Validation of structural ensembles by experimental residual dipolar 
couplings 
To confirm the previously selected structural ensembles, 
1
DNH residual dipolar couplings 
were measured on EBA181945-1097 in a liquid crystal composed of poly-ethylene glycol and 
1-hexanol. Helical elements or turn motifs gives rise to a sign inversion of the RDCs 
compared to random coil conformations; residual dipolar couplings are thus a powerful 
tool to sample the backbone conformation of disordered proteins. As expected for a 
disordered protein which mainly samples random coil conformations, the experimental 
1
DNH RDCs were negative, except for four short stretches encompassing the residues 
987-988, 998, 1006-1007 and 1016-1019, for which the RDCs were positive (Figure 5.7). 
The experimental RDCs matched reasonably well with those predicted from a statistical 
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coil ensemble generated using Flexible-Meccano (Figure 5.7 A). The reproduction of the 
experimental RDCs using the conformational sampling of EBA181945-1097 from the 
experimental chemical shifts gave a slight improvement of the results (Figure 5.7 B). The 
biggest improvement in the reproduction of the RDCs was observed within the turn or 
short helical motifs identified by the experimental chemical shifts and leading to positive 
back-calculated RDCs. Moreover, other improvements were observed in the poly-proline II 
regions of the protein (towards the N- and C-termini of the protein as well as around 
P1039-P1044). The improvement in the reproduction of the RDCs compared to a standard 
statistical coil ensemble provides an independent verification of the validity of the 
ASTEROIDS ensembles and testifies to the predictive nature of these ensembles.  
 
 
 
Figure 5.7: Validation of selected ASTEROIDS ensembles of EBA181945-1097 using 
1DNH 
residual dipolar couplings. (A) Comparison of experimental (red) and predicted (green) 
1DNH RDCs from a statistical coil ensemble. (B) Comparison of experimental (red) and 
predicted (blue) 1DNH RDCs from the representative ensembles of EBA181945-1097 derived 
on the basis of experimental chemical shifts only.  
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5.4 NMR solution spectroscopy results of the complex  
 
Titration NMR spectroscopy was used to study the structure and binding properties of the 
EBA181945-1097 and 4.1R10kDa complex. The titration experiments were performed in both 
directions, firstly with 4.1R10kDa as the titrant being added to 
15
N/
13
C EBA181945-1097 and 
secondly, with EBA181945-1097 as the titrant being added to 
15
N/
13
C GST-4.1R10kDa. Tagged 
4.1R10kDa domain (GST-4.1R10kDa) was used in order to maximise the final quantity of the 
protein because of the already low expression yield coupled to the expensive materials 
used for labelling. 
 
In the first titration experiment, the HSQC spectrum of labelled 
15
N/
13
C EBA181945-1097 
was acquired (Figure 5.8, signals in red). Then, a 7.5 fold excess of non-labelled 4.1R10kDa 
was added. A second spectrum was acquired (Figure 5.8, blue signals) aiming to follow the 
spatial displacement of the signals of labelled EBA181945-1097 on the 
1
H-
15
N HSQC 
spectrum. No chemical shift changes nor modulation of the intensities were observed 
(Figure 5.8). Two explanations can be put forwards: either 1) the complex between 
EBA181 and 4.1R was not formed, or 2) there was no change in the chemical environment 
of EBA181945-1097 when bound to 4.1R10kDa which is however unlikely to happen. This 
experiment was performed twice, with the same result. 
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Figure 5.8: 13C-15N HSQC spectrum. Titration of double labelled EBA181945-1097 with 
unlabelled 4.1R10kDa. Superposition of the spectra of EBA181945-1097 without 4.1R10kDa (red) 
and with 7.5 fold excess of 4.1R10kDa (blue).  
 
 
In the second titration experiment, the HSQC spectrum of double labelled 
15
N/
13
C GST-
4.1R10kDa was first acquired (Figure 5.9, signals in red). Following this, EBA181945-1097 was 
added up to a 1 to 1 molar ratio (Figure 5.9, blue signals) and then in a 4 to 1 ratio to reach 
an excess of EBA181945-1097. In this experiment changes of chemical shifts and modulation 
of intensities were noticed (Figure 5.10), indicating that this time the interaction between 
EBA181945-1097 and GST-4.1R10kDa is observed. Unfortunately these variations were too 
low in magnitude to continue further the characterisation. 
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Figure 5.9: HSQC spectrum. Titration of labelled GST-4.1R10kDa with unlabelled 
EBA181945-1097. Red: 4.1R10kDa without EBA181945-1097, blue: 4.1R10kDa and EBA181945-1097 
in 1:1 ratio, green: 4.1R10kDa and EBA181945-1097 in 1:4 ratio. 
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Figure 5.10: HSQC spectra (zoom in two regions). Titration of labelled GST-4.1R10kDa with 
unlabelled EBA181945-1097. Red: 4.1R10kDa without EBA181945-1097, blue: 4.1R10kDa and 
EBA181945-1097 in 1:1 ratio, green: 4.1R10kDa and EBA181945-1097 in 1:4 ratio. 
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5.5 Discussion and conclusions 
 
In the relatively recent past, intrinsically disordered proteins (IDPs) have appeared as a 
new class of proteins which challenge the classical structure-function paradigm. They do 
not adopt well-defined folded structures, and sample different conformations in solution. 
This is tremendously important for their structural and dynamic characterisation. One of 
the most significant characteristics of IDPs is their ability to interact with multiple partner 
proteins. 
 
In addition to chapter 3, a specific bioinformatics analysis of the EBL proteins using a 
database on disordered proteins was carried out and revealed the intrinsically disordered 
nature of the RIII-V regions, encompassing multiple predicted interaction sites. Only a few 
interaction partners to the EBL proteins have been identified so far, leaving the role that 
these regions play in the invasion process largely unknown. Considering the variable 
length of RIII-V within the three EBL proteins, it can be hypothesised that these disordered 
regions direct the EBL proteins towards different cellular functions by discriminating 
between different partner proteins. This theory is supported by the fact that the three 
proteins share very little sequence conservation within RIII-V, and this also provides a 
means of diversifying the invasion process across the EBL family. Thus, it can be 
imagined that RIII-V binds to proteins that are subsequently sequestered and inactivated, 
thereby enabling a simpler invasion. RIII-V regions could also cooperate with proteins that 
play a more direct role in the invasion process. For example, interactions with host 
erythrocyte proteins, such as protein 4.1R, could destabilise the membrane skeleton and 
may also weaken host membrane repair pathways. 
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In order to obtain more insight into the conformational state within the RIII-V of the 
EBA-181 protein, structural and dynamic characterisation of EBA181945-1097 was 
performed using NMR spectroscopy. The data demonstrated that EBA181945-1097 is 
essentially a random coil with a number of turns or short alpha-helical motifs. Three of the 
four motifs are located in the 30 amino acid binding zone with 4.1R (as identified by 
Lanzilotti et al. in 2005) and could function as molecular recognition elements and in that 
way play a role in the biological function of the protein. Nevertheless, this remains to be 
elucidated. The spectral assignment of the protein has provides a new basis for mapping 
and identifying interactions with different partner proteins in the future, and that at amino 
acid resolution. This could therefore provide valuable information on host-pathogen 
interactions during the invasion of erythrocytes. 
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6. DISCUSSION, CONCLUSIONS and FUTURE WORK 
 
The main results from this thesis work relate to the malarial parasite interaction with red 
blood cells either via the sialic acid dependent or independent pathways. Here, key 
interactions involve the EBA-175, EBA-140 and EBA-181 membrane receptors. Of these, 
both EBA-175 and EBA-140 bind to sialic acid and then to glycophorins A and C 
respectively, whilst EBA-181 binds to sialic acid and possibly to an unknown second 
receptor on the erythrocyte surface. Collectively, these interactions are likely to be 
important for the ability of P. falciparum to evade the immune system upon its entry to the 
erythrocyte. 
 
In this thesis work, the key objective was to bring a wide range of biochemical and 
biophysical techniques together to achieve a consensus view on the structure of the 
EBA181945-1097 and 4.1R10kDa proteins as well as the complex formed between them. The 
specific focus of the results summarised in Chapters 3, 4 and 5 is the interaction between 
the EBA-181 protein (located at the surface of the parasite in vivo) and the 4.1R protein 
(located within the red blood cell in vivo). This interaction, which was first identified using 
phage display, was confirmed during all of the major biochemical and biophysical 
experiments carried out during the project. One of the major challenges was, preliminary to 
the biochemical and biophysical characterisation, to optimise the quantities of proteins 
produced from the initial microgram scale to the milligram level required for structural 
work. Another point of importance was the production of labelled proteins (isotopes, 
including deuterium and 
15
N/
13
C labelling). Finally, the optimisation of protein conditions 
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(in particular buffers and aggregation states) as well as storage conditions was critical to 
the viability of the biophysical/biochemical characterisation.  
 
In Chapter 3, the biochemical studies and pull-down analyses confirmed the interaction 
between the two proteins, and enabled further characterisation of the complex under a wide 
range of conditions. The affinity between EBA-181 and 4.1R is in the micro-molar range 
and this interaction was proved to resist high salt concentration (tested up to 2 M NaCl), 
implying that it is likely to resist high local salt concentrations in the cell. The interaction 
is also resistant to pH variation (tested from pH 5.0 to 9.0), showing the capacity of the 
parasite to resist different stresses. In addition, none of the short EBA-based peptides used 
as competitors to the EBA-181 / 4.1R complex formation disrupt the interaction between 
EBA181945-1097 and 4.1R10kDa, even with a 100 fold excess of peptide. This is an important 
result and suggests that even if the shorter interacting sequence is sufficient to bind to the 
4.1R10kDa protein, the whole EBA181945-1097 sequence is important for the binding affinity. 
It would be interesting for future work to clone and express longer constructs of EBA-181 
in order to control the effects on affinity and binding to 4.1R10kDa, especially by comparing 
it to the EBA181945-1097 construct. 
 
The biophysical characterisation highlighted the intrinsically disordered state of 
EBA181945-1097, as well as the low level of folding in 4.1R10kDa, which contains some 
alpha-helical structure. Furthermore, the small-angle scattering studies described in 
Chapter 4, using both neutron and X-ray approaches, demonstrated again the interaction 
and characterised it in more detail, providing the respective sizes and molecular shapes of 
the individual proteins and the complex in solution (Table 6.1) and showing this complex 
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to be a 1 to 1 complex. Moreover, the results were consistent between the SAXS and 
SANS analyses and have provided good agreement and complementarity in terms of the 
solution state modelling of the individual proteins as well as the complex formed between 
them. It is also interesting to compare the resulting sizes of the EBA181945-1097 and 
4.1R10kDa proteins both from the SAXS analysis and the structural predictions performed 
by informatics. The structural prediction of EBA181945-1097 results in an apparent Rg of 
5.3 nm, for an Rg of only 2.35 nm from the SAXS experiment. This difference is due to the 
unstructured character of the protein which appears as a long, coiled and fully disordered 
sequence by bioinformatics, resulting in a bigger Rg. The prediction may have not taken 
into account the dynamics and the local secondary structures that could rigidify or impose 
some local conformations on the protein. Bioinformatics structural predictions have to be 
considered with caution since it is very difficult for these software to predict the behaviour 
and the molecular shape of intrinsically disordered proteins. It is different for 4.1R10kDa. Its 
structural prediction results in an Rg of 1.6 nm which is close to the value of 2.0 nm 
obtained from the SAXS data. The prediction of 4.1R10kDa is probably more relevant than 
that for EBA181945-1097 since the protein contains some secondary structure and it might 
thus be easier to predict its 3D structure. 
 
The nuclear magnetic resonance spectroscopy work performed on EBA181945-1097 and 
described in Chapter 5 enabled a detailed structural and dynamic characterisation of the 
protein at near atomic resolution and allowed preliminary work on the complex with 4.1R 
to be carried out. In this study, EBA181945-1097 was shown to be essentially a random coil, 
with the presence of short alpha-helical motifs. These structural motifs could function as 
molecular recognition elements and thereby play a role in the biological function of the 
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protein during erythrocyte invasion. Indeed, the majority of these short motifs appear in the 
EBA binding region for 4.1R identified by Lanzilotti et al. in 2005. It is interesting to note 
that the protein does not possess transiently populated secondary structures as commonly 
found for many intrinsically disordered proteins that fold via specific, pre-formed 
molecular recognition elements. Future work could include similar experiments on 
4.1R10kDa, complementing the CD analysis described in Chapter 3 and providing insight to 
the presence and localisation of structural elements or at least transiently populated 
secondary structures. The NMR results obtained for the complex were unfortunately 
insufficient to further characterise it, despite the fact that several experiments were 
performed, involving two complementary isotope labelling schemes with titrations of both 
proteins. Future work in this area is therefore highly desirable to resolve this situation.  
 
In terms of linking these observations to the wider context of the interaction between the 
two proteins in vivo, it is obviously hard to bridge the molecular to the microscopic and 
cellular lengthscales, and considerable caution needs to be exercised to avoid over-
interpretation.  
 
The results show both proteins to be disordered. It is now clear that IDPs are of 
fundamental importance in nature. IDPs have been found in bacteria, archaea and 
eukaryotes, and their presence in the literature is rising steadily (www.disprot.org, 
Sickmeier et al., 2007). To our knowledge, this is the first example of small-angle solution 
scattering experiments involving two intrinsically disordered proteins remaining disordered 
after the formation of their complex. Binding of an IDP to its protein partner is very often 
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Structural 
parameters 
4.1R10kDa 
SAXS 
EBA181945-1097  
SAXS 
Untagged complex 
SAXS SANS (0 % D2O) 
Buffer NaP pH 6.0 NaP pH 6.0 NaP pH 6.0 NaP pH 6.0 
Theoretical MM 8 kDa 17 kDa 25 kDa 25 kDa 
MM -  I(0) from 
Guinier analysis 
10 kDa 21 kDa 26 kDa 26 kDa 
Rg - from 
Guinier analysis 
2.02 nm 2.35 nm 3.54 nm 3.95 nm 
Dmax 6.0 nm 7.9 nm 10.4 nm 10.8 nm 
Rg - from P(r) 
analysis 
1.90 nm 2.30 nm 3.53 nm 3.90 nm 
 
 
 
Ab-initio 
modelling 
 
 
 
  
 
 
 
Table 6.1: Experimentally determined structural parameters of the best quality SAXS and 
SANS scattering curves used for ab-initio modelling of untagged EBA181945-1097 and 
4.1R10kDa proteins as well as the complex. 
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followed by a conformational change in which the disordered protein becomes folded as 
part of the complex. This does not seem to be the case for the 4.1R10kDa / EBA181945-1097 
complex. This type of structural disorder as the functional native state of proteins, and as a 
property of an IDP complex, is defined as fuzziness. This concept of fuzziness has only 
been recently established (Tompa et al., 2008) and it has become more and more clear that 
fuzzy complexes play a distinct role in a wide range of biological processes (Fuxreiter and 
Tompa, 2011). In these cases, even if high-resolution structural studies are not feasible, 
low-resolution methods coupled to biochemical approaches can provide valuable 
information, as emphasised during this work.  
 
One of the reasons that the two domains involved in the interaction are structurally 
disordered may be that the individual proteins have multiple binding partners under 
different functional contexts. This is plausible for the 10 kDa domain of the erythrocyte 
4.1R protein which interacts with a wide variety of cytoskeleton proteins. For the parasite 
EBA181945-1097, it is conceivable that its intrinsically disordered structure suppresses the 
formation of recognition elements that could then be recognised by the human immune 
system. Indeed, the disordered state of EBA-181 and other parasite proteins could be of 
fundamental biological importance for Plasmodium falciparum in escaping the immune 
system. For example, Uversky and colleagues showed in 2005 that the intrinsic 
immunogenicity of disordered protein sequences are lower than that of more conserved and 
ordered regions (Uversky et al., 2005). Moreover, this lack of secondary structure could 
also be an advantage in terms of the interaction with the 4.1R protein, which is set in a 
complex and dense cytoskeleton network. The intrinsically disordered state of EBA-181 
increases its flexibility and may well change its dynamics. IDPs have high specificity in 
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target selection, and a fast association/dissociation rate (Tompa, 2005), which is likely to 
be important for EBA-181 in its interaction with 4.1R and/or other human proteins.  
 
Given that the 4.1R protein is inside the erythrocyte, it is perhaps surprising that the 
parasite membrane protein EBA-181 interacts with human 4.1R. From the results 
described in this thesis, the following mechanism of action is speculatively proposed 
(Figure 6.1).  
 
Since the 4.1R protein is inside the red blood cell, the interaction between the two proteins 
cannot be immediately direct. After initial binding to the erythrocyte surface and 
reorientation, the parasite brings its apical end in contact with the red blood cell membrane 
(Gaur et al., 2004), signalling the secretion of the microneme and rhoptry proteins onto the 
parasite surface. From them, the DBL proteins (EBA-140, EBA-175 and EBA-181) are 
translocated onto the merozoite membrane through their C-terminal hydrophobic and 
transmembrane domains, with their DBL domains being free to interact with the 
erythrocyte receptors (Gilberger et al., 2003). A tight junction is thus established and 
ultimately connected to the actinomyosin motor which will drive the inwards motion inside 
the erythrocyte. Following this, the parasite will lose all its membrane receptors through 
the activity of proteases and becomes invisible to the immune system (Ejigiri et al., 2012). 
The disordered state of EBA-181 could be a helpful characteristic to favour its own release 
through the action the proteases during this process of removal of the parasite membrane 
receptors. Finally, the membranes seal once the tight junction reaches the posterior end of 
the parasite, concluding the invasion process. During or directly after this process, the 
EBA-181 protein could be secreted in the red blood cell in order to interact with 4.1R. 
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Figure 6.1: Putative mechanism for erythrocyte invasion by P. falciparum. (1) Adhesion. 
(2) Reorientation. (3) Tight junction formation. (4) Invasion. (5) Shedding of the surface 
(1) 
(5) 
(2) 
(6) 
(4) 
(7) 
(3) 
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coat and possible role of the disordered region of EBA-181 with protease cleavage. 
(6) Resealing of the erythrocyte and parasitophorous vacuole membranes. (7) Interaction 
between EBA-181 and 4.1R proteins. EBA-181 is released in the red blood cell and is 
thus free to interact with the 4.1R protein to disrupt/weaken the cytoskeleton and prevent 
the activation of the repair machinery. 
 
 
 
As previously described (Fowler et al., 1985; Pasternack et al., 1989 and Conboy et al., 
1993), the 10 kDa domain of 4.1R maintains the plasticity of the red blood cell by 
facilitating the interaction between spectrin and actin, and it is also known to bind and 
regulate myosin activity. This whole network is crucial to regulate the shape of the 
erythrocytes by an ATP-dependent process (Fowler et al., 1985). Since 4.1R is vital in 
stabilising the red blood cell structure and controlling the erythrocyte membrane integrity, 
disrupting the interaction between the 4.1R protein and the structural spectrin, actin and 
glycophorin C proteins will perturb the cytoskeleton of the cell, favouring the parasite 
exploitation of the human cell to its own advantage. This could be an important role of the 
EBA-181 protein, disturbing the erythrocyte conformation by interacting with 4.1R. The 
disordered nature of EBA-181 may also increase its flexibility and dynamics; this could be 
important for its mobility in the purpose of interacting with 4.1R, given that it is set in this 
dense cell network. Thus, measurement of the dynamics of EBA181945-1097 using neutrons 
for example, could lead to a better understanding of the behaviour of the protein.  
 
Additionally, EBA-181 may inhibit potential host membrane repair pathways subsequent 
to mechanical or chemical stress which damage the erythrocyte membrane. After 
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disruption of the skeletal network the cytosolic myosin is shifted to the erythrocyte bilayer, 
to form an actomyosin complex with the actin protofilaments and initiate the repair of the 
damaged zone (Cibert et al., 1999). In this sense, the damage caused by the invading 
parasites might initiate this actomyosin repair process and provide, with the restoration of 
the membrane, a barrier for the entry of other parasites. It is thus possible that the 
interaction between EBA-181 and 4.1R prior to/during the parasite entry is an evolutionary 
adaptation of P. falciparum to ensure its own survival, whereby EBA-181 would 
destabilise the linkages between 4.1R, spectrin, actin and myosin to prevent the activation 
of the actomyosin repair machinery and the restoration of the erythrocyte membrane. 
 
A recent study by Persson et al. has shown that the invasion-inhibitory activity of acquired 
antibodies from children exposed to malaria was significantly reduced when using 
P. falciparum parasites that did not express the EBA-181 protein, compared to unmodified 
parasites (Persson et al., 2013). The same phenomenon was as well noticed for the two 
other EBA-140 and EBA-175 homologous proteins. In a near future the EBA proteins 
could thus be valuable targets for the development of vaccines to malaria disease. 
Nevertheless, the diversity in term of expression and use of EBA proteins (as well as PfRh 
proteins) by the parasite clearly implies that any vaccine that targets these invasion 
proteins would require, to be effective, the inclusion of multiple antigens, and thus 
combine both the EBA and PfRh proteins. This might help to overcome the capacity of the 
parasite to evade the human immune system.  
 
In the context of this thesis and longer term perspectives, future work is needed to obtain 
further biophysical and structural information that would aim to permit the development of 
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novel therapeutic strategies for malaria prevention. A long term goal could be to express 
the full-length EBA-181 protein by overcoming the issues of expression and solubility of 
this membrane protein (for example using emerging cell free expression systems) in order 
to perform combined structural characterisation and understand the impact of the whole 
protein on binding to the 4.1R cellular skeletal protein. A further direction linking to the 
cellular / organism would be to take advantage of newly developed genome editing 
technology that have recently been demonstrated to be usable in Plasmodium genome 
(Ghorbal et al., 2014). Here, one could imagine making point mutations in the EBA gene 
and studying the outcome in function. Another angle would be to perform in vivo studies to 
follow the process of invasion and to determine if the putative pathway shown in Figure 
6.1 is correct. This could for example be achieved by GFP-labelling of the full-length 
protein and by performing invasion studies to follow its localisation in the cell, using high-
resolution fluorescence microscopy. Further to structural characterisation, high-throughput 
screening methods using mass spectrometry and fragment libraries can be used to explore 
molecules able to bind and disrupt the complex formation, generating leads for potential 
therapeutics. 
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APPENDIX A: ADDITIONAL MATERIAL 
 
A.1 Bacterial media 
 
Below are presented the composition of the bacterial growth media used for the expression 
of hydrogenated protein. 
 
LB broth medium 
The LB broth medium was developed by Giuseppe Bertani in 1951 (Bertani, 1951). The 
LB medium was used for both small and high scale cultures of proteins. 
 
For a final volume culture of 1 litre, 10 g of bacto-tryptone, 5 g of yeast extract and 10 g of 
NaCl are mixed together. Each flask are sterilised by autoclaving and stored at room 
temperature. 
 
LB-agar 
The LB-agar medium was used to make Petri dishes containing bacterial clones expressing 
the GST-4.1R10kDa and His-EBA181945-1097 proteins. 
 
15 g of agar powder was added to the previous LB medium. Each bottle of LB-agar were 
then sterilised by autoclaving (this process will also melt the agar), then left cool down to 
around 30 degrees prior adding the right antibiotics (30 µg/ml for kanamycin or 100 µg/ml
 
  
250 
 
for ampicillin, and 34 µg/ml for chloramphenicol). Finally 20 ml of LB agar was poured 
into each Petri dish and stored at 4°C prior to be used. 
 
Super optimal broth with catabolite repression 
The super optimal broth with catabolite repression (SOC medium) was developed by 
Douglas Hanahan in 1983 (Hanahan, 1983). This nutrient-rich bacterial growth medium is 
an adjusted version of the commonly used LB media.  
For a final culture of 1 litre, the SOC medium contains 2% w/v tryptone (20 g), 0.5% w/v 
Yeast extract (5 g), 10mM NaCl (0.584 g), 2.5mM KCl (0.186 g), 10mM MgCl2 
(anhydrous 0.952 g) or 10mM MgSO4 (heptahydrate 2.408 g) and 20mM glucose 
(3.603 g). 
 
pH adjustment 
For maximum effectiveness, SOB/SOC media should have its pH adjusted to 7.0 by adding 
concentrated sodium hydroxide. The original literature states that the pH of the final 
medium should be between 6.8 and 7.0. 
 
Sterilisation 
Every media are either autoclaved at 121 °C or filtered through a 0.22 µm filter to ensure 
sterility.  
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A.2 Composition of buffers  
 
Buffers used for protein purification and storage 
The composition of every buffers used to purify and characterise the different proteins is 
presented in Tables A.1 and A.2. 
 
 His-EBA181945-1097 EBA181945-1097 GST-4.1R10kDa 4.1R10kDa 
Lysis and 
loading 
 
20 mM Tris,  
pH 8.0 
 
+250 mM NaCl 
+5 mM βME 
+10 mM Imidazole 
+Complete antiprotease 
EDTA free (ROCHE®) 
 
 
20 mM Tris,  
pH 8.0 
 
+250 mM NaCl 
+5 mM βME 
+10 mM Imidazole 
+Complete 
antiprotease 
EDTA free 
(ROCHE®) 
 
 
Phosphate buffered 
saline, pH 7.4 
 
+5 mM βME 
+Complete 
antiprotease 
(ROCHE®) 
 
 
 
Phosphate buffered 
saline,  
pH 7.4 
 
+5 mM βME 
+Complete 
antiprotease 
(ROCHE®) 
 
 
Washing 
 
 
20 mM Tris,  
pH 8.0 
 
+1M NaCl 
+5 mM βME 
+15k mM Imidazole 
 
20 mM Tris,  
pH 8.0 
 
+1M NaCl 
+5 mM βME 
+15k mM Imidazole 
 
Phosphate buffered 
saline, 
pH 7.4 
 
+1M NaCl 
+5 mM βME 
 
Phosphate buffered 
saline, 
pH 7.4 
 
+1M NaCl 
+5 mM βME 
Elution 
 
 
20 mM Tris,  
pH 8.0 
 
+100 mM NaCl 
+5 mM βME 
+150 mM Imidazole 
 
20 mM Tris,  
pH 8.0 
 
+100 mM NaCl 
+5 mM βME 
+150 mM 
Imidazole 
 
20 mM Tris, 
pH 8.0 
 
+250 mM NaCl 
+5 mM βME 
+10 mM GSH 
 
 
20 mM Tris, 
pH 8.0 
 
+250 mM NaCl 
+5 mM βME 
+10 mM GSH 
 
Dialysis and size 
exclusion 
chromatography 
 
50 mM NaP,  
pH 6.0 
 
+50 mM NaCl 
+5 mM βME 
 
50 mM NaP,  
pH 6.0 
 
+50 mM NaCl 
+5 mM βME 
 
Phosphate buffered 
saline, 
pH 7.4 
 
+5 mM βME 
 
50 mM NaP, 
pH 6.0 
 
+50 mM NaCl 
+5 mM βME 
 
Table A.1: buffer composition for purification steps of tagged His-EBA181945-1097 and 
GST-4.1R10kDa or untagged EBA181945-1097 and 4.1R10kDa proteins. 
  
252 
 
Salts 
Concentration 
(mM) 
Concentration 
(g/l) 
NaCl 137 8.01 
KCl 2.7 0.20 
Na2HPO4 (2 H2O) 10 1.78 
KH2PO4 2.0 0.27 
pH 7.4 
   
Table A.2: Composition of phosphate buffered saline (PBS). 
 
 
Native polyacrylamide gel electrophoresis 
pH buffers: 
4x acetic acid gel buffer (200 mM acetic acid, pH 3.7 to 5.6) 
4x phosphate gel buffer (400 mM sodium phosphate, pH 5.8 to 8.0) 
4x tris gel buffer (200 mM Tris-Cl, pH 7.1 to 8.9)  
4x glycine gel buffer (200 mM glycine, pH 8.6 to 10.6)  
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pH range 3.7 to 5.6 
 
Stock solution 
Final 
acrylamide 
concentration 
in gel 
12.5 % 
30% 
acrylamide / 
0.8% 
bisacrylamide 
16.8 ml 
300 mM 
sodium 
sulphite 
0.4 ml 
4x acetic acid 
gel buffer 
10 ml 
H2O 12.48 ml 
10% (w/v) 
ammonium 
persulphate 
0.3 ml 
TEMED 0.02 ml 
 
 
pH range 7.1 to 8.9 
 
Stock solution 
Final 
acrylamide 
concentration 
in gel 
12.5 % 
30% 
acrylamide / 
0.8% 
bisacrylamide 
16.8 ml 
4x Tris gel 
buffer 
10 ml 
H2O 12.98 ml 
10% (w/v) 
ammonium 
persulphate 
0.2 ml 
TEMED 0.02 ml 
 
pH range 5.8 to 8.0 
 
Stock solution 
Final 
acrylamide 
concentration 
in gel 
12.5 % 
30% 
acrylamide / 
0.8% 
bisacrylamide 
16.8 ml 
4x phosphate 
gel buffer 
10 ml 
H2O 12.98 ml 
10% (w/v) 
ammonium 
persulphate 
0.2 ml 
TEMED 0.02 ml 
 
 
 
 
 
pH range 8.6 to 10.6 
 
Stock solution 
Final 
acrylamide 
concentration 
in gel 
12.5 % 
30%  
acrylamide / 
0.8% 
bisacrylamide 
16.8 ml 
4x glycine gel 
buffer 
10 ml 
H2O 12.98 ml 
10% (w/v) 
ammonium 
persulphate 
0.2 ml 
TEMED 0.02 ml 
 
 
Table A.3: Buffer conditions for the preparation of native polyacrylamide gels. 
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Samples: 
The protein samples to be analysed are solubilised using 5% (w/v) sucrose (using 2x stock 
solution at 10% (w/v) sucrose in the chosen gel buffer).  
 
Separation: 
The current is set to 15 mA and the run is performed at 8ºC. 
 
If the protein is negatively charged under the separation conditions, then the standard 
SDS-PAGE electrode polarity should be used (proteins will migrate to the anode as 
positive electrode). If the protein is positively charged, then the electrodes should be 
reversed at the power supply so the positively charged protein migrates to the negative 
cathode. 
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APPENDIX B: EBA-181 AND 4.1R PROTEINS 
 
B.1 The cloning strategy 
 
Protein EBA181945-1097 
The chosen DNA sequence for EBA-181 contains the coding sequence for the amino acids 
from 945 to 1097 (‘EBA181945-1097’, Figure B.1 A, blue rectangle) which contains the 4.1R 
binding sequence as demonstrated by our collaborators (Lanzilotti et al., 2005). The gene 
corresponding to this sequence has been cloned into a pET15b vector which adds an 
N-terminal polyhistidine (6x histidines) tag in order to facilitate the purification of the 
protein. 
 
The pET15b vector (Figure B.1 B) is a system for cloning and expressing recombinant 
proteins in E. coli. Protein expression is driven by a T7 promoter (T7 prom), which 
contains a downstream lac operator (lac o) sequence. The plasmid houses a multiple 
cloning site (MCS) where the gene for EBA181945-1097 was cloned with an N-terminal 
six-histidine tag which can be cleaved by the thrombin protease. The pET15b contains a 
T7 terminator sequence (T7 term), a lacI repressor sequence and an ampicillin resistance 
gene (Amp). The origin of replication (ori) is also indicated in the vector map. 
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Figure B.1: Schematic of A) the EBA-181 protein with its EBA181945-1097 domain and B) 
the map of the pET15b cloning vector adding the N-terminus histidine tag. 
 
 
 
Protein 4.1R10kDa 
The DNA sequence coding for the 10 kDa domain of 4.1R (amino acids from 405 to 471, 
Figure B.2 A, red rectangle) was cloned into a pGEX vector which add the glutathion-S-
transferase (GST) protein in fusion with the cloned protein. The GST has two interests: 
firstly to enhance the solubility of the fused protein (here the 10 kDa domain of 4.1R) and 
secondly to facilitate the purification. 
 
EBA181945-1097 
A) 
B) 
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Figure B.2: Schematic of A) the 4.1R protein with its 4.1R10kDa domain and B) the map of 
the pGEX-4T-2 cloning vector adding the N-terminus GST tag. 
 
 
 
The pGEX-4T-2 vector (Figure B.2 B) offers a tac promoter (tac prom) for chemically 
inducible, high level expression of recombinant proteins. A lac operator sequence (lac o) is 
situated downstream of the promoter followed by a region encoding the GST, before the 
multiple cloning site (MCS) where the gene for the 10 kDa domain of 4.1R was cloned. A 
thrombin site is located immediately after the GST region allowing the cleavage of the tag. 
The β-lactamase gene region (Amp), the lacI repressor region and the origin of plasmid 
replication (ori) are also indicated in Figure B.2 B. 
4.1R10kDa 
A) 
B) 
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As part of this thesis work, the antibiotic resistance of the expression vectors for both 
proteins was modified from ampicillin to kanamycin by the in-vitro transposition method. 
This method is based on a transposon containing the gene for kanamycin resistance and 
which is inserted randomly into the vector sequence. The clones into which the transposon 
is inserted in the ampicillin resistance sequence are selected and screened using different 
ampicillin or kanamycin agar plates. The commercial E. coli BL21 Rosetta
TM
 2 (DE3) 
bacteria from Novagen® were finally used in order to express the two proteins (Figure B.3 
and Table B.1). 
 
 
 
 
 
Figure B.3: Summary of the cloning strategies for EBA181945-1097 and 4.1R10kDa. 
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+ tag - tag 
MW pI MW pI 
EBA181945-1097 19 kDa 4.2 17 kDa 4.2 
4.1R(10kDa) 405-471 38 kDa 6.6 8 kDa 8.3 
 
 
Table B.1: Summary of the molecular weights and isoelectric points of the EBA181945-1097 
and 4.1R10kDa proteins with and without their respective tags.  
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B.2 EBA-181 / EBA-175 sequence alignment 
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Figure B.4: Sequence comparison of EBA-175 and EBA-181 proteins. 
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25% identical (red boxes) - 50% similar 
The EBA181945-1097 domain is highlighted in orange 
       : Interaction sequence with 4.1R10kDa 
 
 
 
 
Input parameters: 
 
Alignment Method:    slow 
Gap open:    10 
KTUP:    1 
Gap extend:    0.1 
Score:    percent 
DNA Weight Matrix:    iub 
Gap extend:    0.2 
Sequence type:    protein 
DNA Weight Matrix:    iub 
Gap distance:    5 
Iteration type:    none 
Pairgap:    3 
Protein Weight Matrix:    gonnet 
End gap:    false 
Top Diagonals:    5 
Number Iterations:    1 
Output order:    aligned 
Clustering:    NJ 
Protein Weight Matrix:    gonnet 
Gap open:    10 
Window:    5 
Program:    clustalw2 
Alignment format:    aln1 
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B.3 Protein EBA181945-1097 sequence and parameters 
 
        10         20         30         40         50         60  
GSCMHMPEVV PQETTSENGS SQDTKISSTE PNENSVVDRA TDSMNLDPEK VHNENMSDPN  
 
        70         80         90        100        110        120  
TNTEPDASLK DDKKEVDDAK KELQSTVSRI ESNEQDVQST PPEDTPTVEG KVGDKAEMLT  
 
       130        140        150  
SPHATDNSES ESGLNPTDDI KTTDGVVKEQ EILGGGESA  
 
Number of amino acids: 159 
 
Molecular weight: 17075.1 Da 
 
Theoretical pI: 4.15 
 
Amino acid composition:  
Ala (A)   6   3.8% 
Arg (R)   2   1.3% 
Asn (N)  11   6.9% 
Asp (D)  17  10.7% 
Cys (C)   1   0.6% 
Gln (Q)   6   3.8% 
Glu (E)  20  12.6% 
Gly (G)   9   5.7% 
His (H)   3   1.9% 
Ile (I)   4     2.5% 
Leu (L)   6   3.8% 
Lys (K)  11   6.9% 
Met (M)   5   3.1% 
Phe (F)   0   0.0% 
Pro (P)  11   6.9% 
Ser (S)  19  11.9% 
Thr (T)  16  10.1% 
Trp (W)   0   0.0% 
Tyr (Y)   0   0.0% 
Val (V)  12   7.5% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 37 
Total number of positively charged residues (Arg + Lys): 13 
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Atomic composition: 
 
Carbon      C        698 
Hydrogen    H       1127 
Nitrogen    N        199 
Oxygen      O        286 
Sulfur      S          6 
 
Formula: C698H1127N199O286S6 
Total number of atoms: 2316 
 
Extinction coefficients: 
 
This protein does not contain any Trp residues.  
 
 
 
 
B.4 Protein 4.1R10kDa sequence and parameters 
        10         20         30         40         50         60  
WKKKRERLDG ENIYIRHSNL MLEDLDKSQE EIKKHHASIS ELKKNFMESV PEPRPSEWDK  
 
 
RLSTHSP  
 
 
Number of amino acids: 67 
 
Molecular weight: 8084.1 Da 
 
Theoretical pI: 8.25 
 
Amino acid composition:  
Ala (A)   1   1.5% 
Arg (R)   5   7.5% 
Asn (N)   3   4.5% 
Asp (D)   4   6.0% 
Cys (C)   0   0.0% 
Gln (Q)   1   1.5% 
Glu (E)   9  13.4% 
Gly (G)   1   1.5% 
His (H)   4   6.0% 
Ile (I)   4   6.0% 
Leu (L)   6   9.0% 
Lys (K)   9  13.4% 
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Met (M)   2   3.0% 
Phe (F)   1   1.5% 
Pro (P)   4   6.0% 
Ser (S)   8  11.9% 
Thr (T)   1   1.5% 
Trp (W)   2   3.0% 
Tyr (Y)   1   1.5% 
Val (V)   1   1.5% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 13 
Total number of positively charged residues (Arg + Lys): 14 
 
Atomic composition: 
 
Carbon      C        354 
Hydrogen    H        565 
Nitrogen    N        105 
Oxygen      O        108 
Sulfur      S          2 
 
Formula: C354H565N105O108S2 
Total number of atoms: 1134 
 
Extinction coefficients: 
 
Extinction coefficients are in units of  M
-1
 cm
-1
, at 280 nm measured in water. 
 
Ext. coefficient    12490 
Abs 0.1% (=1 g/l)   1.545 
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APPENDIX C: NMR supplemental information 
 
C.1 Assigned chemical shifts of EBA181945-1097 
   Residue    HN     N    C    C    C’ 
 
945  P  -   -   63.154  31.964  176.632 
946  E  8.503  121.446  56.572  30.335  176.374 
947  V  8.204  122.210  62.182  32.539  175.882 
948  V  8.295  126.544  59.752  32.428  174.403 
949  P  -   -   63.177  32.059  176.838 
950  Q  8.466  121.035  55.791  29.730  176.042 
951  E  8.535  122.547  56.585  30.296  176.638 
952  T  8.327  115.803  61.851  69.678  174.705 
953  T  8.244  116.419  61.655  69.782  174.575 
954  S  8.381  117.990  58.292  63.346  174.689 
955  E  8.521  122.952  56.837  30.003  176.426 
956  N  8.444  119.387  53.375  38.783  175.874 
957  G  8.374  109.553  45.599  -   174.367 
958  S  8.236  115.534  58.246  63.411  174.878 
959  S  8.421  117.788  58.507  63.135  174.751 
960  Q  8.416  121.878  56.017  29.487  175.752 
961  D  8.314  121.381  54.480  40.960  176.521 
962  T  8.079  114.942  62.152  69.468  174.600 
963  K  8.307  124.066  56.362  32.645  176.527 
964  I  8.155  122.327  61.101  38.615  176.367 
965  S  8.414  120.087  58.097  63.289  174.520 
966  S  8.399  118.159  58.196  63.258  174.695 
967  T  8.206  115.531  61.743  69.557  174.397 
968  E  8.383  124.669  54.423  29.600  174.637 
969  P  -   -   63.383  31.946  176.730 
970  N  8.534  118.916  53.248  38.942  175.450 
971  E  8.490  121.613  56.983  29.964  176.294 
972  N  8.459  119.251  53.389  38.849  175.226 
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973  S  8.195  116.187  58.484  63.200  174.457 
974  V  8.122  122.084  62.535  32.413  176.258 
975  V  8.110  123.684  62.323  32.717  175.777 
976  D  8.359  124.237  54.327  41.106  176.059 
977  R  8.238  121.999  56.057  30.685  176.226 
978  A  8.395  125.123  52.888  18.982  178.353 
979  T  8.084  112.761  62.166  69.527  174.666 
980  D  8.272  122.493  54.616  40.931  176.589 
981  S  8.206  115.780  58.785  63.028  174.785 
982  M  8.280  121.396  55.795  32.641  175.898 
983  N  8.292  119.260  53.295  38.694  174.777 
984  L  8.130  122.503  54.899  42.436  176.740 
985  D  8.290  122.554  52.188  40.996  174.880 
986  P  -   -   63.872  32.017  177.613 
987  E  8.438  118.887  56.978  29.756  176.921 
988  K  7.960  120.999  56.332  32.790  176.564 
989  V  7.878  120.385  62.631  32.482  176.020 
990  H  8.526  122.407  55.397  29.339  174.277 
991  N  8.419  121.211  53.284  38.966  175.246 
992  E  8.660  121.720  57.037  29.973  176.235 
993  N  8.452  118.974  53.385  38.532  175.223 
994  M  8.255  120.840  55.563  32.736  176.167 
995  S  8.242  116.736  58.216  63.313  173.758 
996  D  8.310  123.666  52.167  41.225  174.941 
997  P  -   -   63.676  32.007  177.076 
998  N  8.559  117.924  53.605  38.662  175.571 
999  T  7.933  113.878  62.126  69.509  174.275 
1000  N  8.409  121.492  53.359  38.852  175.232 
1001  T  8.142  114.668  61.734  69.641  174.403 
1002  E  8.326  124.653  54.401  29.587  174.640 
1003  P  -   -   63.309  32.023  176.698 
1004  D  8.401  120.380  54.314  40.993  176.548 
1005  A  8.360  125.939  53.056  19.003  178.206 
1006  S  8.372  114.592  59.040  63.062  174.771 
1007  L  7.972  123.360  55.281  42.027  177.389 
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1008  K  8.097  121.727  56.298  32.932  176.212 
1009  D  8.279  121.673  54.335  41.183  175.916 
1010  D  8.281  121.511  54.435  40.978  176.337 
1011  K  8.207  121.222  56.439  32.390  176.644 
1012  K  8.198  122.222  56.446  32.889  176.674 
1013  E  8.418  122.051  56.691  30.019  176.716 
1014  V  8.147  120.795  62.456  32.745  176.030 
1015  D  8.373  123.975  54.493  41.084  176.453 
1016  D  8.348  121.952  54.932  40.931 1 76.686 
1017  A  8.184  123.553  53.262  18.706  178.471 
1018  K  8.089  119.189  56.689  32.314  177.102 
1019  K  8.056  121.867  56.884  32.785  176.972 
1020  E  8.344  121.284  56.730  29.977  176.728 
1021  L  8.187  122.911  55.473  42.208  177.630 
1022  Q  8.320  120.757  55.993  29.297  176.172 
1023  S  8.318  116.743  58.345  63.214  174.898 
1024  T  8.203  116.226  62.128  69.566  174.629 
1025  V  8.073  122.233  62.422  32.612  176.159 
1026  S  8.367  119.769  58.234  63.209  174.272 
1027  R  8.343  123.691  56.031  30.872  176.019 
1028  I  8.224  122.819  61.194  38.528  176.374 
1029  E  8.544  125.391  56.516  30.196  176.370 
1030  S  8.334  116.824  58.205  63.302  174.311 
1031  N  8.528  121.119  53.304  38.897  175.395 
1032  E  8.415  121.211  57.018  30.008  176.523 
1033  Q  8.329  120.220  55.989  29.514  175.744 
1034  D  8.329  121.634  54.416  40.953  176.259 
1035  V  8.044  120.348  62.392  32.541  176.294 
1036  Q  8.463  123.928  55.736  29.408  176.001 
1037  S  8.357  117.619  58.192  63.275  174.241 
1038  T  8.197  118.597  59.840  69.611  172.375 
1039  P  -   -   -   -   - 
1040  P  -   -   63.074  31.927  177.087 
1041  E  8.568  120.832  56.592  30.283  176.235 
1042  D  8.360  121.634  54.208  41.040  175.946 
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1043  T  8.088  117.181  59.960  69.690  172.774 
1044  P  -   -   63.261  32.122  177.089 
1045  T  8.324  115.802  61.975  69.678  174.619 
1046  V  8.223  122.914  62.224  32.722  176.053 
1047  E  8.512  124.936  56.764  30.237  176.881 
1048  G  8.418  110.321  45.302  -   173.866 
1049  K  8.168  121.203  55.977  33.004  176.690 
1050  V  8.249  122.038  62.607  32.597  176.760 
1051  G  8.499  112.693  45.247  -   173.912 
1052  D  8.209  120.809  54.483  41.227  176.512 
1053  K  8.283  121.577  56.375  32.696  176.500 
1054  A  8.281  124.838  52.810  18.909  177.975 
1055  E  8.352  119.848  56.710  30.146  176.542 
1056  M  8.291  121.130  55.575  32.758  176.160 
1057  L  8.254  123.321  55.340  42.262  177.511 
1058  T  8.054  114.315  61.577  69.760  174.285 
1059  S  8.259  119.181  56.301  62.811  172.737 
1060  P  -   -   63.388  32.017  176.738 
1061  H  8.436  118.559  55.199  29.365  174.382 
1062  A  8.354  125.786  52.777  19.003  177.946 
1063  T  8.211  112.927  61.679  69.661  174.316 
1064  D  8.301  122.560  54.301  41.084  175.996 
1065  N  8.454  119.661  53.356  38.827  175.539 
1066  S  8.390  116.418  59.154  63.105  174.989 
1067  E  8.462  122.457  56.881  29.926  176.819 
1068  S  8.227  116.115  58.571  63.296  174.870 
1069  E  8.413  122.856  56.807  29.953  176.794 
1070  S  8.325  116.503  58.747  63.253  175.221 
1071  G  8.373  110.745  45.410  -   173.971 
1072  L  7.986  121.055  55.015  42.467  176.931 
1073  N  8.522  120.629  51.331  38.752  173.346 
1074  P  -   -   63.620  32.058  177.317 
1075  T  8.166  113.079  61.881  69.560  174.500 
1076  D  8.181  122.226  54.512  41.132  175.839 
1077  D  8.237  120.671  54.309  41.013  176.081 
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1078  I  8.029  121.269  61.307  38.328  176.365 
1079  K  8.403  125.480  56.076  32.887  176.905 
1080  T  8.231  115.460  61.724  69.738  174.897 
1081  T  8.196  115.488  61.758  69.568  174.420 
1082  D  8.323  122.718  54.603  41.040  176.674 
1083  G  8.301  109.132  45.477  -   174.030 
1084  V  7.902  120.149  62.512  32.561  176.278 
1085  V  8.289  125.438  62.469  32.451  176.097 
1086  K  8.424  126.342  56.183  32.960  176.499 
1087  E  8.490  122.736  56.861  30.064  176.448 
1088  Q  8.405  121.040  55.980  29.603  175.893 
1089  E  8.419  122.861  56.653 30.216  176.285 
1090  I  8.238  122.760  61.073  38.411  176.329 
1091  L  8.389  127.040  55.207  42.229  177.936 
1092  G  8.455  110.223  45.393  -   174.777 
1093  G  8.354  108.876  45.356  -   174.831 
1094  G  8.348  108.894  45.210  -   174.259 
1095  E  8.414  120.578  56.640  30.223  176.607 
1096  S  8.361  117.093  58.120  63.477  173.263 
1097  A  7.986  131.633  53.864  19.911  176.082 
 
 
Table C.1:  Assigned chemical shifts (ppm) of EBA181945-1097 obtained at 298K. 
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